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Abstract 
 
The ileal pouch offers a unique opportunity to study the inter-relationships between the gut 
microbiota, barrier function and host immune responses. Intestinal dendritic cells (DC) are 
pivotal in the maintenance of gut immune homeostasis. Impaired barrier function due to 
altered cell to cell junctions, enables interactions between the microbiota and host immune 
responses prior to the onset of inflammation and epithelial damage. The role of innate immune 
factors in pouchitis remains unclear. 
 
 
We performed cross sectional and longitudinal studies of patients following restorative 
proctocolectomy and assessed DC and tight junction protein (TJP) characteristics in the ileal 
pouch. Increased expression of  the “pore-forming” claudin 2 was an early event in the 
development of pouch inflammation and aberrant DC expression of gut homing markers was 
characterised in the ileum and ileal pouch of ulcerative colitis patients without inflammation. 
DC phenotype in pouchitis suggested an activated innate immune response to microbial signals. 
 
 
Intestinal immune responses may be manipulated by modification of the gut microbiota. An 
emerging approach is transplantation of the entire “organ” of the gut microbiota. Effects of 
faecal microbiota transplantation (FMT) on recipient microbiota and immune responses in 
inflammatory bowel diseases are unknown. 
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A single nasogastrically delivered FMT from a healthy donor to patients with chronic pouchitis, 
resulted in some shift in the composition of the microbiota, with specific changes in the 
abundance of species suggestive of a “healthier” pouch microbiota. However, microbiota 
engraftment success varied greatly between recipients and regardless of engraftment success, 
FMT did not result in immunological response or clinical efficacy. 
 
 
In conclusion, aberrant DC and TJP characteristics are associated with inflammation of the ileal 
pouch. Manipulation of the microbiota by FMT may be one means of modifying DC and TJP 
expression in the ileal pouch. However, these factors were not influenced by a single 
nasogastrically delivered FMT. 
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Chapter 1. General Introduction 
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The human gut has evolved to interface with a diverse and dynamic community of 
microorganisms. Bacteria predominate, but eukaryotes, viruses and archaea are also present. 
Intestinal bacterial communities comprise up to 1000 different species constituting an 
incredibly diverse ecosystem (Duerkop et al., 2009). It is estimated that the human microbiota 
contains up to 1014 bacterial cells, an order of magnitude greater than the number of human 
cells in our body (Sekirov et al., 2010). This has given rise to the view of the microbiota as 
another organ and a perception of ourselves as ‘‘supraorganisms’’ whose genome is the sum of 
human and microbial genes (Peterson et al., 2008a). 
 
 
The co-evolution of the mammalian intestinal microbiota has primarily been driven by the 
metabolic advantages in enhancing host digestive capabilities. The complex community of 
bacteria which is rapidly adaptable and evolving, harbours a diversity of saccharolytic enzymes 
far beyond the limited repertoire encoded by the human genome alone. This association 
consequently enables flexible dietary changes and optimises efficiency of energy harvesting 
from our diet (Duerkop et al., 2009). 
 
 
Millions of years of co-evolution have led to an integral intertwining of host-microbial 
physiology. Much of our knowledge of gut microbiota function is derived from studies of germ 
free animals. These demonstrate the commensal microbiota to modulate nutrient absorption, 
mucosal barrier function, angiogenesis and intestinal maturation (Hooper et al., 2001). The 
intestinal microbiota plays a critical role in the development and maturation of the gut and 
systemic immune system. The mucosal immune system needs to be tolerant of the overlying 
20 
 
 
 
 
microbiota, and at the same time to control the gut microbiota to prevent its overgrowth and 
translocation to systemic sites and respond appropriately to pathogens. This has led to the 
development of a finely tuned homeostasis between the huge microbial load of the intestine 
and the host immune system. 
 
 
The intestinal microbiota is protective from invasion of pathogens. Gut microbiota provides a 
physical barrier to incoming pathogens by competitive exclusion, competitive consumption of 
nutrients, and stimulation of host production of antimicrobial substances (Lawley and Walker, 
2013). The commensal microbiota signals via TLR-MyD88 dependent pathways enhancing 
epithelial repair and cross-talk between components of the innate immune responses (Hooper 
et al., 2012). Commensal species have been shown to influence the make-up of T lymphocyte 
subsets with distinct effector functions both locally and systemically (Hooper et al., 2012). 
 
 
At the same time the intestinal immune system has developed strategies to preserve ignorance 
as well as tolerance of the commensal microbiota. The inner layer of mucus secreted by goblet 
cells is resistant to bacterial penetration whereas the outer layer is colonised with bacteria 
(Swidsinski et al., 2005). The epithelial layer bound together by tight junction proteins enables 
nutrient flux into tissues whilst preventing bacterial penetration. Epithelial cells also produce a 
number of antimicrobial peptides (Hooper et al., 2012). IgA producing B cells secrete bacteria 
specific IgA which is transcytosed to the apical layer of the epithelium, confining bacteria to the 
mucus layer (Peterson et al., 2008a). Symbiotic bacteria that do breach the mucosa are rapidly 
phagocytosed and killed by macrophages in contrast to pathogens that actively interfere with 
21 
 
 
 
 
macrophage function (Hooper et al., 2012). Dendritic cells sample penetrating and apical 
bacteria and interact with B and T cells to direct appropriate immune responses (Hooper et al., 
2012). Innate lymphoid cells that produce interleukin (IL)–22 are also essential for containment 
of lymphoid resident bacteria to the intestine, preventing their systemic translocation (Hooper 
et al., 2012). 
 
 
Despite huge advances in our understanding of the microbiota and host-microbiota 
relationships, much of the details of the structure and function of the microbiota are as yet 
unknown. Inflammatory bowel diseases (IBD) (Crohn’s disease, ulcerative colitis (UC) and 
pouchitis) are considered to be due to an inappropriate inter-relationship between the immune 
responses and intestinal microbiota (Sartor, 2009). Studies of the aetiology of these diseases 
are likely to enhance our knowledge of host-microbiota relationships. Genome wide association 
studies have identified genes contributing to susceptibility to Crohn’s disease and UC. The 
elucidation of these susceptibility loci highlight the role of the immune responses to microbial 
signalling and processing (Xavier and Podolsky, 2007) as well as epithelial barrier integrity 
(Anderson et al., 2011, Barrett et al., 2009). 
 
 
Animal studies of colitis demonstrate an immune driven dysbiosis (i.e. an alteration in the 
composition of the microbiota to one that is deleterious to host health) highlighting the control 
the immune system exerts on the structure of the intestinal microbiota (Garrett et al., 2007, 
Powell et al., 2012). Animal models of colitis also indicate the microbiota drives inflammation in 
genetically susceptible hosts (Sartor, 2008).  Knockout mouse models of colitis have also shown 
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a transferrable colitogenic microbiota to wild type mice (Garrett et al., 2007). Clinical evidence 
also points towards the microbiota driving inflammation. Faecal diversion is curative for Crohn’s 
disease whilst reintroduction of the ileal contents to the diverted bowel induces inflammation 
(D'Haens et al., 1998). However, the study of IBD in the clinical setting with human subjects is 
limited by the lack of a method that predicts and detects the exact onset of the disease during a 
first episode of inflammation or relapse. Consequently only clinical investigations in chronic 
stages of inflammation are possible in UC and Crohn’s disease. 
 
 
The ileal pouch and pouchitis however, offer a unique opportunity to study the inter- 
relationships between the gut microbiota, epithelial barrier and host immune responses from 
before the onset of disease. The ileal pouch provides a unique human model for studying IBD 
pathogenesis for the following reasons: a) the patients have a genetic predisposition to the 
intestinal inflammation, b) they are most likely to develop inflammation in their pouch in the 
first year after surgery, so following patients longitudinally from the time of pouch surgery 
enables access to samples from patients who develop inflammation and those who do not 
develop inflammation, c) the pouch is accessible with an endoscope and d) there is a human 
control group (FAP) who have a pouch without a predisposition to intestinal inflammation. For 
this reason the study of pouchitis could serve as a human model that significantly enhances our 
understanding of inflammatory bowel diseases in general. 
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1.1 Restorative proctocolectomy and ileal pouch-anal anastomosis 
 
 
Between 10 and 35% (Hendriksen et al., 1985, Langholz et al., 1992, Cottone et al., 2008, Hoie 
et al., 2007) of patients with ulcerative colitis (UC) eventually require surgery. For the majority 
of patients, restorative proctocolectomy with ileal pouch-anal anastomosis (RPC) is the 
operation of choice (Becker, 1999). It is also used for patients with Familial Adenomatous 
Polyposis (FAP). The procedure involves the removal of the colon and rectum and the 
construction of a reservoir created from 30-40cm of ileum, followed by ileo-anal anastomosis 
(Parks and Nicholls, 1978). This procedure avoids the need for a permanent stoma and allows 
good long term function and quality of life (Carmon et al., 2003, Fazio et al., 2013). Over 6000 
patients in the UK have undergone restorative proctocolectomy (Burns et al., 2011). 
1.1i Pouchitis 
 
 
Pouchitis is an idiopathic inflammatory condition that may occur in up to 60% of patients after 
RPC for ulcerative colitis. It is rarely seen in FAP patients after RPC. The cumulative risk of 
pouchitis increases with longer follow up, but is most frequently seen within the first two years 
of the pouch functioning. Up to 60% of patients may suffer a recurrence of pouchitis, but the 
prevalence of chronic pouchitis is only 5-19% (Simchuk and Thirlby, 2000, Stahlberg et al., 1996, 
Lohmuller et al., 1990, Salemans et al., 1992). 
 
 
The aetiology of pouchitis remains unclear. There are significant clinical (Gionchetti et al., 1999, 
Gionchetti et al., 2003, Mimura et al., 2004) and microbiological (Tannock et al., 2012, 
McLaughlin et al., 2010b) data implicating bacteria in the pathogenesis of pouchitis. Studies 
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suggest the microbiota stimulate mucosal immune responses in the ileal pouch (Bell, 2004, 
Pronio et al., 2008). However, the mechanisms by which the pouch microbiota interacts with 
the mucosal immune system are unclear and data regarding innate immune characteristics and 
epithelial barrier properties in pouchitis are sparse. 
1.1ii Clinical Characteristics of Pouchitis 
 
 
Clarity of the definition and diagnosis of pouchitis are critical in clinical and aetiological studies 
of pouchitis. The diagnosis of pouchitis requires the combination of clinical symptoms as well as 
endoscopic and histological findings. Clinical symptoms include increased stool frequency and 
liquidity, abdominal cramping, urgency and tenesmus and occasionally bleeding and fever. 
Endoscopic assessment and biopsy with flexible pouchoscopy (McLaughlin et al., 2009c) should 
be undertaken. Symptoms do not always correlate with endoscopic and histological findings. A 
number of pouchitis scoring systems are in use (Sandborn et al., 1994, Shen et al., 2003, 
Heuschen et al., 2002). The Pouch Disease Activity Index (PDAI) (Table 1.1) is most commonly 
used. This system attributes numbers to clinical, endoscopic (Figure 1.1) and histological 
features, which are combined to give a total score. A score ≥7 is diagnostic of pouchitis. 
However, a flaw of the PDAI is that the presence of acute histological inflammation is not 
required for a diagnosis of pouchitis. 
 
Pouchitis can be classified according to disease activity, duration, pattern and response to 
antibiotics. Acute pouchitis can be considered as less than 4 weeks duration, responding to a 
single antibiotic and occurring less than three times per year. Chronic pouchitis may be 
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considered to be chronic relapsing if there are three or more episodes per year responding to 
antibiotics or chronic antibiotic dependent if symptoms are only controlled while maintained on 
antibiotics. Chronic antibiotic refractory pouchitis is generally defined as pouchitis that no 
longer responds to a single antibiotic (McLaughlin et al., 2008b, Mahadevan and Sandborn, 
2003). 
1.1iii Differential Diagnoses 
 
 
Inflammation of the pouch can also occur for a number of other reasons that should be 
considered and excluded in the differential diagnosis of pouchitis. Pre-pouch ileitis is 
inflammation developing in the ileum immediately proximal to the pouch (Figure 1.2). It is 
usually concurrent with pouchitis, but can occur in isolation. Symptoms include those of 
pouchitis, but may also include those of intestinal obstruction (McLaughlin et al., 2008a, 
McLaughlin et al., 2009a). A number of treatments for pre-pouch ileitis have been described 
including steroids, antibiotics and 5-ASA medications (McLaughlin et al., 2008a). 
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Table 1.1 Pouch disease activity index 
 
Criteria Score 
Clinical 
Stool Frequency 
Usual postoperative stool frequency 0 
1-2 stools/day > postoperative usual 1 
≥3 stools/day > postoperative usual 2 
Rectal Bleeding 
None or rare 0 
Present daily 1 
Faecal Urgency or abdominal cramps 
None 0 
Occasional 1 
Usual 2 
Fever (temperature >37.8  ۫  C) 
Absent 0 
Present 1 
Endoscopic Inflammation 
Oedema 1 
Granularity 1 
Friability 1 
Loss of vascular pattern 1 
Mucous exudate 1 
Ulceration 1 
Acute histological inflammation 
Polymorphonuclear leucocyte 
Mild 1 
Moderate +crypt abscess 2 
Severe +crypt abscess 3 
Ulceration per lower power field 
<25% 1 
25-50% 2 
>50% 3 
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Figure 1.1 Endoscopic image of active chronic pouchitis 
 
 
 
 
 
 
Figure 1.2 Endoscopic image of pre-pouch ileitis 
 
 
 
 
 
Inflammation of the residual anorectal mucosa (cuffitis) can also be a cause of symptoms 
similar to pouchitis with endoscopic inflammation. There are a number of different surgical 
methods used to create the pouch-anal anastomosis. This can be hand-sewn or stapled. The 
stapled pouch-anal anastomosis leaves a variable length of anorectal mucosa in situ. Persisting 
proctitis of the residual anorectal mucosa may lead to bleeding, urgency, and frequency of 
small volume stool. This is less likely following hand-sewn anastomosis with mucosectomy. A 
high anastomosis can be distinguished clinically by digital examination as well as by contrast 
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enema and pouchoscopy. The presence of inflamed rectal mucosa can be confirmed on biopsy. 
Treatment is with 5-ASA or steroid suppositories or in severe persistent cases revision of the 
anastomosis may be undertaken (Shen et al., 2004, Tekkis et al., 2006, Tulchinsky et al., 2001, 
Wu et al., 2013). 
 
 
Two to three percent of patients diagnosed with ulcerative colitis preoperatively are 
subsequently found to have Crohn’s Disease (13). Crohn’s disease should be considered where 
there is fistulation or chronic unremitting pouchitis. Fistulas arising from the anastomosis 
suggest leak, whilst those arising from the pouch or the pre-pouch ileum usually indicate 
Crohn’s disease. Crohn’s disease is generally considered a contraindication to undertaking 
restorative proctocolectomy. However, a number of studies have assessed the outcomes of 
pouches performed for patients with Crohn’s disease. The majority of patients with Crohn’s 
disease who have undergone RPC were originally considered to have UC. In these patients, 
failure rates and poor pouch function are significantly greater compared with UC patients 
following RPC (Reese et al., 2007, Hahnloser et al., 2007). However, a recent study of patients 
where RPC was used intentionally for well-defined Crohn’s disease demonstrated no increase in 
pouch failure rates although there was an increased incidence of postoperative disease (Le et 
al., 2012). 
 
 
It is estimated that approximately 20-30% of patients diagnosed with chronic refractory 
pouchitis may have identifiable secondary causes of pouch inflammation (Navaneethan and 
Shen, 2010). Early or late pelvic sepsis are the most frequent cause of pouch failure (Tulchinsky 
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et al., 2003). Delayed pelvic sepsis may present with systemic illness and pouch dysfunction as 
well as focal inflammation of pouch mucosa. This should be considered particularly where early 
complications following ileostomy closure occurred. Cytomegalovirus and Clostridium difficile 
may cause pouch inflammation. Both are uncommon, but should be excluded in recurrent or 
refractory pouchitis (Munoz-Juarez et al., 1999, Moonka et al., 1998, McLaughlin et al., 2010a, 
Shen et al., 2008a). Pouch ischaemia can occur due to anatomical factors subsequent to the 
surgical procedure during restorative proctocolectomy where there may be vessel disruption or 
tension of the pouch-anal anastomosis. Non-steroidal medications can also contribute to 
inflammation and ulceration of the pouch and these should be withdrawn in patients with 
pouch inflammation or poor function. Furthermore, stasis due to poor pouch evacuatory 
function can lead to significant ulceration (Figure 1.3) and appropriate history and 
investigations should be undertaken to exclude this where suspected. 
 
 
Figure 1.3 Endoscopic image of pouch ulceration secondary to stasis 
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1.2 Risk factors for pouchitis 
 
 
Several risk factors for pouchitis have been reported, although they have not been 
demonstrated consistently. Extensive or severe UC (Fazio et al., 1995), backwash ileitis (Schmidt 
et al., 1998), extra-intestinal manifestations of UC (Lohmuller et al., 1990, Hata et al., 2003), 
pre-colectomy thrombocytosis (Okon et al., 2005, Lian et al., 2009), pANCA positivity (Fleshner 
et al., 2001, Fleshner et al., 2008), non-smoking status and NSAID use (Fleshner et al., 2007, 
Achkar et al., 2005, Shen et al., 2005b) have all been reported as risk factors for the 
development of pouchitis. Primary sclerosing cholangitis is associated with a two fold increase 
in risk of acute pouchitis (Zins et al., 1995, Penna et al., 1996) and is also associated with pre- 
pouch ileitis (Shen et al., 2011). Elevated serum IgG4 levels may be associated with a subset of 
chronic pouchitis patients (Navaneethan et al., 2011). Different risk factors may be associated 
with acute or chronic pouchitis, suggesting different pathogenic pathways in what may be two 
distinct diseases or different ends of a spectrum of inflammatory diseases (Fleshner et al., 2007, 
Achkar et al., 2005, Abdelrazeq et al., 2008). 
1.3 Pouch bacteriology and pouchitis 
 
 
The role of the gut microbiota is increasingly considered to be an important factor in the 
aetiology of inflammatory bowel diseases (Sartor, 2008, Tamboli et al., 2004). Clinical data 
implicate bacteria in the pathogenesis of pouchitis. Pouchitis only occurs following closure of 
the ileostomy when the pouch is exposed to significantly higher concentrations of bacteria. 
Antibiotics are the mainstay of treatment for acute and chronic pouchitis (Holubar et al., 2010, 
Gionchetti et al., 1999). Probiotics reduce the risk of disease onset (Gionchetti et al., 2003), 
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maintain disease remission (Gionchetti et al., 2000b, Mimura et al., 2004) and can induce 
disease remission (Gionchetti et al., 2007). 
 
 
The microbiota of the terminal ileum differs significantly from that of the colon with regard to 
bacterial cell concentration (Sekirov et al., 2010, Frank et al., 2007). In addition, there are 
significant differences in bacterial composition between the luminal and mucosal 
compartments of the gut (Swidsinski et al., 2005). Following closure of the ileostomy, the ileal 
mucosa in the pouch is exposed to faeces containing bacterial concentrations a million or more 
times greater than in the normal terminal ileum (Nicholls et al., 1981, Santavirta et al., 1991). 
 
 
In the normal ileum there are approximately 107 cells g-1 compared with 1012 cells g-1 in the 
distal colon (Sekirov et al., 2010). Differences in the diversity of bacterial groups present are 
also noted between ileal and colonic biopsies. Sequence analysis indicates that the wall of the 
distal small bowel is colonised by microbial populations that are not radically different from 
those of the large bowel. Both are dominated by bacteria of the phyla Bacteroidetes and 
Firmicutes, but do differ in the relative proportions in which subgroups of these phyla are 
present (Frank et al., 2007). Small intestine samples show increases in Streptococcaceae, 
Actinomycinaeae and Corynebacteriaceae compared with the colon, whilst fewer sequences of 
Bacteroidetes and Lachnospiraceae are found in small intestine samples compared with colonic 
samples (Frank et al., 2007). In addition, there are significant differences in bacterial 
composition between the luminal and mucosal compartments of the gut. Many bacterial 
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species present in the intestinal lumen do not access the mucus layer and epithelial crypts 
(Swidsinski et al., 2005). 
 
 
Many of the studies of the microbiota in the ileal pouch and pouchitis suffer from 
inconsistencies in the definition and diagnosis of pouchitis, prior to the widespread use of the 
pouch disease activity index (PDAI) in 1994 (Sandborn et al., 1994) as well as distinctions 
between acute and chronic pouchitis. Variability in the use of faecal or mucosal samples may 
also contribute to the inconsistencies in the findings between many of these studies. 
 
 
The majority of studies of pouch microbiota used culture methods. It is now known that 
approximately 60-80% of gut bacterial species cannot be cultured (Hayashi et al., 2002, 
Eckburg, 2005). Molecular techniques have developed to enable microbiota analysis of the 
entire microbiota without the limitations of culture methods. Various techniques are available, 
but all are based around the use of the 16S ribosomal RNA (rRNA) gene. The 16SrRNA gene is 
appropriately small (1.5 kb) and strikes a balance between high conservation and enough 
variability to distinguish between different species and strains, yet also enough similarity to 
identify members belonging to the same larger phylogenetic group (Sekirov et al., 2010). The 
16SrRNA genes are amplified by polymerase chain reaction (PCR). 16S rRNA sequences are 
“binned” into operational taxonomic units (OTUs) based on their percent sequence identity 
(%ID). Specific percentages of identifications are widely accepted as indicators of various tiers 
of taxonomic resolution. OTUs containing sequences with 99% pairwise sequence similarity 
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indicate “strain-level” taxa, while 97% designates “species,” 95% “genus,” and 90% “family” 
(Sekirov et al., 2010). 
 
1.3i Changes in the pouch microbiota following closure of the ileostomy 
 
 
Santavirta et al. (Santavirta et al., 1991) studied faecal samples from 30 UC RPC patients and  
ten with a conventional ileostomy. Nine patients had a history of pouchitis, although only three 
patients were symptomatic at the time of the study. The total bacterial count, the numbers of 
anaerobes and the anaerobe to aerobe ratios were all increased in samples from pouch patients 
compared  with  those  of  patients  with  a  conventional  ileostomy.  Nasmyth  et    al.              
(Nasmyth et al., 1989) also compared faecal samples of pouch patients with those with a 
conventional ileostomy for UC. They again found an increased anaerobe to aerobe ratio and an 
increase in Bacteroides and Bifidobacteria in the samples of pouch patients compared to those 
with a conventional ileostomy. Two studies have assessed the temporal changes in the pouch 
microbiota using molecular techniques following ileostomy closure. Over the first year following 
ileostomy closure, the overall composition of the pouch microbiota showed similarities with the 
colonic microbiota (Falk et al., 2007, Kohyama et al., 2009). 
1.3ii Differences in bacterial cultures between UC and FAP pouches 
 
 
A number of studies have assessed differences between the microbiota in UC patients and FAP 
patients with healthy pouches and conventional ileostomies. Using culture of faecal samples 
Duffy et al. (Duffy et al., 2002) studied 25 patients (10 UC RPC, 7 FAP RPC and 8 UC ileostomy). 
None had a previous history of pouchitis. Eighty percent of the UC RPC samples contained 
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sulphate reducing bacteria whereas none were found in the samples from the FAP RPC or UC 
ileostomy patients. There were no significant differences between counts for Lactobacilli, 
Clostridium Perfringens, Bacteroides, Bifidobacterium or Enterococi and Coliform in UC and FAP 
pouches. Smith et al. (Smith et al., 2005) cultured faecal samples from nine UC RPC, five FAP 
RPC and seven UC ileostomy patients. Sulphate reducing bacteria were exclusively found in 
samples from the UC RPC patients. 
1.3iii Differences in bacterial cultures between the healthy pouch and pouchitis 
 
 
Several studies have assessed the microbiota of the inflamed and non-inflamed UC and FAP 
pouch. O’Connell et al. (O'Connell et al., 1986) studied 20 UC RPC patients, eight with good 
function (<6 stools/day) and no pouchitis, six with poor function (>6 stools/day) and no 
pouchitis and six with pouchitis. Stool culture showed an increased bacterial count in all 
pouches with no differences between pouchitis or non-pouchitis patients with good or poor 
function. Onderdonk et al. (Onderdonk et al., 1992) cultured mucosal samples from RPC 
patients with and without pouchitis and samples from conventional ileostomies. Differences 
between obligate and facultative anaerobe counts were shown between pouchitis and non 
pouchitis patients with facultative anaerobe counts 50 to 500 times higher than those in non- 
pouchitis patients. Kmiot et al. (Kmiot et al., 1993) studied bacterial counts of stool samples 
from six non-pouchitis and six pouchitis patients before and following metronidazole. Higher 
aerobic counts and lower anaerobic counts were associated with pouchitis although these were 
not significant. Ruseler-van Embden et al. (Ruseler-van Embden et al., 1994) studied faecal 
samples of fourteen pouch patients (12 UC; 2FAP), five with pouchitis and nine classified as 
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non-pouchitis. There were no differences in the total numbers of bacteria between pouchitis 
and non-pouchitis patients, but patients with pouchitis had an increased number of aerobes, a 
decreased ratio anaerobes to aerobes, less Bifidobacteria and anaerobic Lactobacilli, more 
Clostridium perfringens, and several species such as fungi, that were not found in non-pouchitis 
patients. 
 
 
Mcleod et al. (McLeod et al., 1994) studied mucosal biopsies from 23 patients with normal 
pouches, twelve patients with pouchitis, fourteen patients who had either endoscopic or 
histologic evidence of inflammation but not both, twenty patients with conventional 
ileostomies, and nine patients without ileostomies from whom biopsy samples of normal ileum 
were obtained. The total aerobic facultative counts in the biopsy samples from the pouchitis 
patients were significantly higher when compared with biopsy samples from ileostomy or 
normal ileum. Intramural bacteria were observed on electron microscopy in biopsy specimens 
of 47% of patients with pouches compared with fourteen percent of patients with conventional 
ileostomies or normal ileum. 
 
 
Sandborn et al.(Sandborn et al., 1995) cultured stool from ten UC RPC non-pouchitis, ten UC 
RPC pouchitis, five FAP RPC non-pouchitis and five ileostomy patients. RPC patients 
demonstrated a higher ratio of anaerobic gram negative rods compared to ileostomy but no 
differences between pouchitis and non-pouchitis samples were found. Ohge et al. (Ohge et al., 
2005) studied faecal samples of 45 UC pouch patients separated into active pouchitis, ongoing 
pouchitis with antibiotic treatment, previous pouchitis (with no active disease for over a year or 
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within the last year but inactive within six weeks), eight UC non-pouchitis and five FAP pouch 
patients. FAP pouch patients demonstrated significantly lower release of hydrogen sulphide gas 
compared with all UC patients except those on antibiotic therapy. Sulphate reducing bacteria 
were higher in samples from active pouchitis patients than from all other groups (Table 1.2). 
1.3iv Studies of the pouch microbiota using molecular techniques 
 
 
Several studies to date have used molecular biological methods to analyse differences between 
the microbiota in pouchitis and non-pouchitis patients (Komanduri et al., 2007, Johnson et al., 
2009, Lim et al., 2009, Zella et al., 2010, McLaughlin et al., 2010b). However, differences 
between the techniques used, the definition of pouchitis, antibiotic washout periods and levels 
of analysis, complicate comparisons between these studies. Studies of the pouch microbiota 
using molecular techniques have consequently reached conflicting conclusions regarding 
differences in the abundance of particular species and phylotypes present in pouchitis or 
whether there is an increased or reduced diversity of the pouch microbiota (Table 1.3). 
 
 
Komanduri et al. (Komanduri et al., 2007) used length heterogeneity-polymerase chain reaction 
analysis (LH-PCR) to investigate mucosal biopsies from twenty patients who had undergone 
restorative proctocolectomy within the previous five years. Five patients had active pouchitis 
and fifteen patients had healthy pouches. LH-PCR products from three patients in the pouchitis 
group and five patients in the non-pouchitis group as well as three non-IBD control patients 
were then pooled. Only phylotypes representing more than five percent of the total clone 
library were analyzed. There was an increase in bacterial diversity in pouchitis samples 
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compared with non-IBD controls and an increase in the proportion of Enterobacter and 
Fusobacter, a reduction in Streptococci and differences in the Ruminococcus species comparing 
pouchitis and non-pouchitis samples. However, pooling of samples (considering the known 
significant inter-individual variability of the gut microbiota (Eckburg, 2005)) and analysis of only 
up to 73% of clones may be drawbacks to this study. 
 
 
Johnson et al. (Johnson et al., 2009) assessed mucosal biopsies from seven UC pouchitis, fifteen 
UC non-pouchitis, one FAP pouchitis and nine FAP non pouchitis patients. Two of the seven UC 
pouchitis patients met criteria for chronic pouchitis and in the UC non-pouchitis group two 
patients had either recurrent pouchitis or antibiotic dependent pouchitis. Mucosal biopsies 
were first cultured and the bacterial DNA was then extracted and amplified and profiles 
generated using Terminal Restriction Fragment Length- Polymorphisms (TRFL-P). No difference 
between pouchitis and non-pouchitis groups was demonstrated. However, the use of 
enrichment culture may have favored identification of bacteria supported by the culture 
conditions. 
 
 
Lim et al. (Lim et al., 2009) studied faecal samples of fifteen healthy and five inflamed (PDAI >7) 
UC pouches using a TRFL-P approach. Patients with chronic pouchitis were excluded. Bacterial 
diversity in healthy pouches was similar to that in inflamed pouches. Bacterial counts of seven 
dominant organisms were similar in patients with pouchitis and those with a healthy pouch. 
Seventeen non-dominant organisms were seen exclusively in patients with pouchitis. 
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Table 1.2. Studies of the pouch microbiota using culture methods 
 
Author Patients Studied 
Faecal/Mucosal 
Microbiota 
Pouch Findings 
Santavirta et al. 
(Santavirta et al., 
1991) 
30 UC RPC (9 
pouchitis), 10 UC 
ileostomy 
Faecal 
↑ total bacterial count, ↑ anaerobes, 
↑ anaerobe: aerobe ratio 
Nasmyth et al. 
(Nasmyth et al., 
1989) 
15 UC RPC, 14 UC 
ileostomy 
Faecal 
↑ anaerobe:aerobe ratio, ↑ 
Bacteroides and Bifidobacteria 
Duffy et al. (Duffy et 
al., 2002) 
10 UC RPC, FAP RPC, 
8 UC ileostomy 
Faecal ↑ total bacterial count (UC), ↑ 
sulphate reducing bacteria (UC) 
Smith et al. (Smith et 
al., 2005) 
9 UC RPC, 5 FAP RPC, 
7 UC ileostomy 
Faecal ↑ sulphate reducing bacteria (UC), ↑ 
strict anaerobes (UC) 
O’Connell et al. 
(O'Connell et al., 1986) 
20 UC RPC (8 good 
function, 6 poor 
function-no pouchitis, 
6 pouchitis) 
Faecal  
No differences seen 
Onderdonk et al. 
(Onderdonk et al., 
1992) 
78 biopsies from 
healthy and inflamed 
RPC and ileostomy 
Mucosal ↑ facultative anaerobes in inflamed 
pouch 
Ruseler van Embden 
et al. (Ruseler-van 
Embden et al., 1994) 
9 non-pouchitis, 5 
pouchitis, (12 UC 
RPC, 2 FAP RPC) 
Faecal ↑ aerobes (pouchitis), ↓ 
anaerobe:aerobe ratio (pouchitis), ↓ 
bifidobacteria, lactobacilli (pouchitis) 
McLeod et al. 
(McLeod et al., 1994) 
23 non-pouchitis, 12 
pouchitis, 14 
inflamed non 
pouchitis, 20 
ileostomy, 9 normal 
ileum 
Mucosal  
 
↑ facultative aerobes (pouchitis) 
Sandborn et 
al.(Sandborn et al., 
1995) 
10 UC non-pouchitis, 
10 UC pouchitis, 5 
FAP non-pouchitis, 5 
ileostomy 
Faecal  
No differences seen between 
pouchitis and non-pouchitis 
Ohge et al.(Ohge et 
al., 2005) 
45 UC RPC, 5 FAP RPC Faecal ↑ sulphate reducing bacteria (UC 
pouchitis) 
 
 
 
 
Zella et al. (Zella et al., 2010) compared the faecal and mucosal microbiota of nine UC pouchitis, 
three UC non-pouchitis and seven FAP pouchitis patients using a TRFL-P approach. This study 
again pooled faecal DNA from UC pouchitis and FAP pouches for further species analysis. In this 
study pouchitis patients had recurrent or persistent pouchitis. TRFL-P data revealed significant 
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differences in the mucosal and faecal microbiota between the groups. UC pouchitis samples 
showed more peaks matching Clostridium and Eubacterium compared with non-pouchitis and 
FAP pouches and fewer peaks matching Lactobacillus and Streptococcus compared to FAP. 
Further sequencing analysis revealed UC pouchitis samples to have more Firmicutes and 
Verrucomicrobia and fewer Bacteroidetes and Proteobacteria compared with FAP. 
 
 
McLaughlin et al. performed a study of the mucosal microbiota in eight UC pouchitis, eight UC 
non-pouchitis, five FAP non-pouchitis and three FAP pouchitis patients (McLaughlin et al., 
2010b). Pouchitis patients included were classified as having chronic pouchitis. PCR 
amplification of bacterial 16S rRNA genes was performed and the samples were individually 
cloned and sequenced. There was a significant increase in Proteobacteria and a significant 
reduction in Bacteroidetes and Faecalibacterium prausnitzii in the UC group compared with the 
FAP group, but only small differences between the UC pouchitis and non-pouchitis samples and 
between the FAP pouchitis and non-pouchitis samples. No individual species or phylotype was 
specifically associated with either UC or FAP pouchitis. However, analysis of bacterial diversity 
(using the Shannon Diversity Index) revealed significantly greater diversity in the FAP non- 
pouchitis group compared with the UC non-pouchitis group and lower diversity in the UC 
pouchitis group compared with the UC non-pouchitis group. 
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Table 1.3. Studies of pouch microbiota using molecular methods 
 
Author Patients Studied Method Faecal/Mucosal Findings 
Falk et al.(Falk et 
al., 2007) 
2 UC, over 1st year 
from RPC 
TRFL-P Mucosal More “colonic-like” microbiota, 
Unstable over 1
st 
year 
Kohyama et 
al.(Kohyama et 
al., 2009) 
26 UC <2 years 
RPC, 11 UC >2 
years RPC, 13 UC 
ileostomy, 31 
Healthy controls 
TRFL-P Faecal Time dependent shift to more 
“colonic-like” microbiota in UC 
RPC 
Komanduri et 
al.(Komanduri et 
al., 2007) 
5 UC RPC pouchitis, 
15 UC RPC non- 
pouchitis, 13 
Healthy control 
ileum 
LH-PCR Mucosal ↑ bacterial diversity pouchitis v 
healthy control, ↑ Enterobacter 
and Fusobacter in pouchitis v 
non-pouchitis, ↓ Streptococci 
and Ruminococci in pouchitis v 
non-pouchitis 
Johnson et 
al.(Johnson et al., 
2009) 
7 UC pouchitis, 15 
UC non-pouchitis, 1 
FAP pouchitis, 9 
FAP non-pouchitis 
TRFL-P Mucosal No differences between 
pouchitis and non-pouchitis 
seen 
Lim et al.(Lim et 
al., 2006) 
5 UC pouchitis, 15 
UC non-pouchitis 
TRFL-P Faecal Similar bacterial diversity 
between groups, Distinct non- 
dominant organisms in pouchitis 
Zella et al. (Zella 
et al., 2010) 
9 UC pouchitis, 3 
UC non-pouchitis, 7 
FAP 
TRFL-P Faecal and 
Mucosal 
↑ Clostridium and Eubacterium 
in pouchitis, ↓ Lactobacillus and 
Streptococcus 
McLaughlin et 
al.(McLaughlin et 
al., 2010b) 
8 UC pouchitis, 8 
UC non-pouchitis, 5 
FAP non pouchitis, 
3 FAP pouchitis 
Full-length 
sequencing 
Mucosal No individual species or 
phylotype associated with 
pouchitis, ↓ bacterial diversity 
in UC and ↓↓ bacterial 
diversity in UC pouchitis 
Tannock et 
al.(Tannock et al., 
2012) 
 
 
 
Mizoguchi et al. 
(Mizoguchi et al., 
2013) 
17 UC non 
pouchitis, 17 
chronic pouchitis 
on and off 
antibiotics, 14 FAP 
 
19 UC non 
pouchitis, 15 UC 
pouchitis, 19 CDL- 
phenotype, 18 FAP 
FISH, qPCR, 
high 
throughput 
sequencing 
 
16SrRNA 454 
pyrosequencing 
and qPCR 
Faecal 
 
 
 
 
Mucosal 
↓ diversity of microbiota in 
chronic pouchitis but ↑ diversity 
of Clostridiacaeae species in 
chronic pouchitis 
 
↑Proteobacteria ↓ 
Bacteroidetes in pouchitis, ↓ 
Bacteroides, Blautia, Dorea and 
Sutterella in pouchitis 
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Using a combination of culture and molecular techniques, Scarpa et al. (Scarpa et al., 2011a) 
identified a direct correlation between Bacteriodaceae spp. with granulocyte and monocyte 
infiltration and Clostridiaceae spp. with pouch ulceration. Conversely, Enterococcaceae spp., 
Enterobacteriaceae spp. and Streptococcaceae spp., correlated inversely with immune cell 
infiltration. Recently, Tannock et al. demonstrated a reduced diversity of the microbiota in 
patients with chronic pouchitis and the microbiota of chronic pouchitis patients was composed 
of less than 200 uncommon faecal species (Tannock et al., 2012). Another study recently 
characterised the pouch microbiota associated with outcome of pouch function. In this study, 
inflammatory outcomes were again associated with an increase in Proteobacteria and a 
reduction of Bacteroidetes and genera Bacteroides, Blautia, Dorea and Sutterella were found 
less frequently in patients with inflammatory pouch outcomes (Mizoguchi et al., 2013) (Table 
1.3). 
1.3v Studies of the pouch microbiota following therapeutic intervention 
 
 
Several studies have assessed changes in the microbiota following interventions of either 
antibiotic or probiotic therapy (Gosselink et al., 2004a, Kuisma et al., 2003). Analysis of faecal 
samples before and after treatment showed a significant decrease in total anaerobes and 
aerobes, Enterococci, Lactobacilli, Bifidobacteria and Bacteroides, while a non-significant 
reduction in the number of coliforms and Clostridium perfringens was also seen. Gosselink et al. 
(Gosselink et al., 2004b) treated patients with acute pouchitis with either metronidazole or 
ciprofloxacin and demonstrated different changes in the faecal bacteria depending on the 
antibiotic used. During pouchitis episodes, a significant decrease of anaerobes, an increase of 
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aerobic bacteria, more pathogens, such as Clostridium perfringens and haemolytic strains of 
Escherichia coli were seen. Treatment with metronidazole resulted in a complete eradication of 
the anaerobic flora, including C. perfringens. However, no changes in the numbers of E. coli 
were found. In contrast, when the patient was treated with ciprofloxacin, not only C. 
perfringens, but also all coliforms including hemolytic strains of E. coli were not cultured. The 
larger part of the anaerobic flora was left undisturbed during the administration of 
ciprofloxacin. 
 
 
Two studies assessed the effects of the probiotic Lactobacillus rhamnosus GG as prophylaxis for 
pouchitis following RPC (Gosselink et al., 2004a, Kuisma et al., 2003). Lactobacillus GG 
supplementation changed the pouch intestinal flora by increasing the ratio of total faecal 
Lactobacilli to total faecal anaerobes and enhancing the frequency of Lactobacilli-positive 
cultures in the pouch and afferent limb mucosal biopsy samples. However, only 40% of patients 
were colonized with Lactobacillus GG (Kuisma et al., 2003). 
 
 
The probiotic VSL#3 (containing 5 × 1011 per gram of viable lyophilised bacteria of four strains of 
 
Lactobacilli, three strains of Bifidobacteria, and one strain of Streptococcus salivarius subsp. 
Thermophilus) is effective in maintenance of remission of pouchitis. In the study by Gionchetti 
et al.(Gionchetti et al., 2000a), following induction of remission with open label Ciprofloxacin 
and Rifaximin, 40 patients received probiotic bacteria (VSL#3 6g/day; 1800 billion lyophilised 
bacteria) and 20 placebo. Faecal samples were taken before and after antibiotic treatment and 
monthly during maintenance therapy with VSL#3. Faecal concentration of Lactobacilli, 
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Bifidobacteria and Streptococcus salivarius increased significantly in the VSL#3 treated patients. 
However, no significant changes were noted for Bacteroides, Coliforms, Clostridia, Enterococci 
or in the total aerobe and anaerobe counts compared with baseline levels (Gionchetti et al., 
2000a). 
 
 
In a study of VSL#3 for the prevention of pouchitis onset following RPC similar microbiological 
findings were noted in the VSL#3 treated patients (Gionchetti et al., 2003). However, in a later 
study of VSL#3 for maintenance of remission of chronic pouchitis, analysis of mucosal biopsies 
using denaturing gel gradient electrophoresis (DGGE) analysis demonstrated an increased 
bacterial diversity and bacterial richness and a reduction in fungal diversity in the VSL#3 treated 
patients compared with placebo following antibiotic induced remission. The increase of 
diversity was independent of the bacterial strains included in the VSL#3 treatment (Kuhbacher, 
2006). 
 
 
A recently published study of elemental diet for chronic pouchitis analysed faecal samples of 
patients before and after treatment using Fluorescent in situ hybridisation (FISH). This did not 
demonstrate significant clinical or microbiological change, although there was a trend towards 
an increase in the concentration of Clostridium coccoides-Eubacterium rectale following 
exclusive elemental diet (McLaughlin et al., 2012) (Table 1.4). 
 
 
The results from early culture based studies of the pouch microbiota are limited by the more 
recently acknowledged inadequacies of culture techniques for this analysis as well as 
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heterogeneity between the classifications of pouchitis and the control groups used. More 
recent molecular studies also suffer from technical difficulties and heterogeneity of the types 
and definitions of pouchitis included. Acute and chronic pouchitis may well be distinct 
conditions or distinct ends of a spectrum of inflammatory disorders. Despite the discrepancies 
from the numerous studies of the pouch microbiota, a significant body of clinical and 
microbiological evidence has accumulated to suggest a dysbiosis of the pouch microbiota is 
likely to be important in the aetiology of this inflammatory disease process. It remains unclear 
whether the mucosal or faecal microbiota is predominantly responsible for the development of 
inflammation within the pouch or whether the dysbiosis is primary or secondary. Furthermore, 
it is unclear whether particular species of pathogenic or commensal bacteria are relevant to 
pathogenesis or whether the stability and diversity of the microbiota are essential. A dysbiosis 
of the gut microbiota has also been demonstrated in both Crohn’s disease and UC (Sartor, 
2008). Dysbiosis of the gut microbiota may be a pathogenic pre-requisite for the idiopathic 
development of gut inflammation, explaining the comparative frequency of pouchitis in UC RPC 
patients compared with FAP RPC patients. It is uncertain whether this is an epiphenomenon or 
predisposes to inflammation, but it is unlikely to singularly be the cause of pouch inflammation. 
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Table 1.4. Studies of pouch microbiota following therapeutic intervention 
 
Author Patients Studied Intervention Method Faecal/Mucosal Findings 
Gionchetti et 
al.(Gionchetti 
et al., 1999) 
Chronic Pouchitis Rifaximin and 
Ciprofloxacin 
Culture Faecal ↓ anaerobes and 
aerobes, ↓ Enterococci, 
Lactobacilli, 
Bifidobacteria and 
Bacteroides 
Gosselink et 
al.(Gosselink 
et al., 2004b) 
Acute Pouchitis Metronidazole or 
Ciprofloxacin 
Culture Faecal Metronidazole:↓ 
anaerobic bacteria, ↔ 
E. coli 
 
Ciprofloxacin: ↓ 
Clostridium perfringens 
and all E.coli 
Kuisma et 
al.(Kuisma et 
al., 2003) 
Previous pouchitis in 
remission 
Lactobacillus 
rhamnosus GG 
Culture Faecal ↑ Lactobacilli: total 
anaerobe ratio, ↔ total 
anaerobe 
/aerobe/Lactobacilli. 
40% Lactobacilli culture 
+ve 
Gionchetti et 
al.(Gionchetti 
et al., 2000b) 
Maintenance of 
antibiotic induced 
remission of 
pouchitis 
VSL#3 Culture Faecal ↑ Lactobacilli, 
Bifidobacteria, 
Streptococcus salivarius. 
↔ Bacteroides, 
Coliforms, Clostridia, 
Enterococci or total 
aerobe and anaerobes 
Gionchetti et 
al.(Gionchetti 
et al., 2003) 
Post ileostomy 
closure prophylaxis 
of pouchitis 
VSL#3 Culture Faecal ↑ Lactobacilli, 
Bifidobacteria, 
Streptococcus salivarius. 
↔ Bacteroides, 
Coliforms, Clostridia, 
Enterococci 
Kuhbacher et 
al.(Kuhbache 
r, 2006) 
Maintenance of 
antibiotic induced 
remission of 
pouchitis 
VSL#3 DGGE Mucosal ↑ bacterial and ↓ 
fungal diversity in 
remission with VSL#3 
Mclaughlin et 
al 
(McLaughlin 
et al., 2012) 
Chronic pouchitis Pre and post 
exclusive 
elemental diet 
FISH Faecal Trend to increased 
Clostridium coccoides- 
Eubacterium rectale 
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1.4 The pouch microbiota and host immunity 
 
 
There is a wealth of literature on the topic of the immune responses in UC and Crohn’s disease. 
Data regarding the immune responses to the alterations in the pouch microbiota are 
comparatively sparse. 
 
 
1.4i Genetics and pouchitis 
 
 
Genome wide association studies have successfully identified genes contributing to 
susceptibility to Crohn’s disease and UC. The elucidation of these susceptibility loci has also 
furthered our understanding of the underlying pathogenesis, in particular highlighting the role 
of the immune responses to microbial signalling and processing (Xavier and Podolsky, 2007) as 
well as epithelial barrier integrity (Anderson et al., 2011, Barrett et al., 2009). A few studies 
have analysed genetic susceptibility in pouchitis. All of these studies are limited by the small 
numbers of patients, but they point towards a genetic susceptibility in the immune responses 
to the gut microbiota. 
 
 
The interleukin-1 receptor antagonist gene allele 2 (Brett et al., 1996, Carter et al., 2001), 
tumour necrosis factor (TNF) allele 2 and NOD2/CARD15 polymorphisms (Meier et al., 2005, 
Sehgal et al., 2010, Tyler et al., 2011) have all been associated with pouchitis. Carriership of the 
TLR 9-1237C and CD14-260T alleles were significantly more frequent with chronic relapsing 
pouchitis (Lammers et al., 2005a). A TLR 1 polymorphism was associated with pouchitis, 
supporting the hypothesis that bacterial recognition is important in the pathogenesis of 
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pouchitis (Ferrante et al., 2008). Recently a larger study of North American Caucasian patients 
who had undergone RPC found a NOD2insC gene polymorphism to be associated with worse 
outcome with chronic pouchitis and a Crohn’s like phenotype (Tyler et al., 2012). 
1.4ii Serological markers for inflammation of the pouch 
 
 
The presence of serological markers in IBD has also signaled towards the underlying importance 
of the host immune responses to the microbiota in the pathogenesis of these diseases. 
Serological markers such as antibodies against OmpC, an outer membrane porin from E.coli, 
Anti-Saccharomyces cervisiae antibodies (ASCA) and antibodies against CBir1, an antigen closely 
related to flagellin have been studied in UC, indeterminate colitis and Crohn’s disease 
suggesting pathogenic immune responses to bacterial antigens (Mow et al., 2004, Lodes et al., 
2004, Targan et al., 2005, Dendrinos et al., 2006). 
 
 
In a small study, the presence of ASCA antibodies was associated with post-operative fistula 
development after RPC (Dendrinos et al., 2006). In another small study the presence of ASCA, 
OmpC and I2 (antigen to Pseudomonas fluorescens), were predictive of post-operative 
continuous inflammation of the pouch (Hui et al., 2005). Both ANCA and CBir1 have been 
associated with the development of pouchitis in some studies (Aisenberg et al., 2004). Anti- 
chitobioside carbohydrate (ACCA) antibodies were associated with pouchitis (Ferrante et al., 
2008). The presence of these serological markers may be predicting Crohn’s disease of the 
pouch rather than pouchitis in UC patients, but could also represent a subset of the spectrum of 
pouch inflammatory disorders suggesting pathogenic immune responses to bacterial antigens. 
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1.4iii Pouch immune responses to bacteria 
 
 
The hypothesis of immune responses to bacteria or their products as the underlying cause of 
pouchitis is supported by an ex vivo study by Bell et al. (Bell, 2004). Bacterial sonicates cultured 
from mucosal biopsies of UC pouch patients with healthy pouches and pouchitis were cultured 
with autologous and heterologous peripheral blood (PBMC) and lamina propria monocytes. 
Sonicates from pouchitis produced intense proliferation of the mononuclear cells (from PBMC 
and lamina propria) compared with minimal proliferation in sonicates from healthy pouches 
(Bell, 2004). Lammers et al. (Lammers et al., 2005b) demonstrated that patients treated with 
VSL#3 had significantly lower mucosal mRNA expression levels of interleukin-1 beta (Il1-β), 
interleukin-8, and interferon-gamma compared with placebo-treated patients. In addition, a 
lower number of lamina propria monocytes were found in the tissue of patients within the 
probiotic group compared with the placebo group and patients with pouchitis. Pronio et al. 
(Pronio et al., 2008) demonstrated a significant increase in the percentage of mucosal 
“regulatory” CD4+ cells in UC pouch patients treated with VSL#3. mRNA expression of Il1-β was 
reduced in the VSL#3 group and Foxp3 expression increased. 
 
 
These studies provide strong evidence for the role of bacteria in the stimulation of mucosal 
innate and adaptive immune responses in the ileal pouch. It is not clear how the pouch 
microbiota might interact with the mucosal immune system. 
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1.4iv Cytokine expression in pouchitis 
 
 
A number of studies have assessed the tissue cytokine profiles in pouchitis. These often show 
significant overlap with those seen in UC and it is postulated that the mucosal inflammation in 
pouchitis may be a result of an imbalance of inflammatory and immunoregulatory cytokines 
that regulate mucosal immune homeostasis. As outlined above a number of studies have 
suggested genetic polymorphisms relating to interleukin-1 (Brett et al., 1996, Carter et al.,  
2001) and TNFα (Facklis et al., 1999) are more frequently associated with pouchitis. Elevated 
levels of IL-1, Il-6, IL-8 and TNFα have been found in tissue from pouchitis patients and also 
from UC RPC compared with FAP RPC patients (Gionchetti et al., 1994, Patel et al., 1995a, 
Bulois       et al., 2000, Goldberg et al., 1996, Leal et al., 2008). 
 
 
The prominent neutrophilic inflammatory cell infiltrate seen in pouchitis also suggests an 
important role for chemo-attractants and adhesion molecules. Few studies have evaluated 
chemokines or adhesion molecules in pouchitis. A study of pouchitis and non-pouchitis patients 
demonstrated increased expression of IL-8 as well as chemo-attractants for monocytes and 
activated T-cells (Helwig et al., 2004). Two studies have assessed expression of adhesion 
molecules in pouchitis. ICAM-1 and soluble E-selectin were found to be elevated in plasma from 
pouchitis patients compared to non-pouchitis patients (Patel et al., 1995b). An open label 
uncontrolled study of twelve patients with chronic unremitting pouchitis treated with an 
antisense inhibitor of intercellular adhesion molecule-1 for six weeks showed a 58% remission 
rate (Miner et al., 2006). 
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As well as an important role in leukocyte migration, ICAM-1 is also an important co-stimulatory 
signal for T-cells. The dysregulation of serum and mucosal cytokine profiles may be relevant in 
the persistence of inflammation in the ileal pouch and may define the outcome of immune 
responses to a dysbiotic microbiota. However, they do not fully inform us of the underlying 
aberrant cellular mechanisms in the host innate and adaptive immune systems that are 
responsible for the sensing, processing and directing of appropriate effector responses to the 
microbiota that may predispose to the development of pouch inflammation. 
1.4v Innate immune responses in pouchitis 
 
 
Appropriate immune responses to the intestinal microbiota are mediated and carefully 
regulated by epithelial cells, macrophages, dendritic cells (DC), T-lymphocytes and B cells. 
Defects in these regulatory systems may lead to abnormal inflammatory responses. 
 
 
Recognition of bacterial antigens is dependent on pattern recognition receptors, such as Toll- 
like receptors (TLRs) and NOD-like receptors. In humans, TLRs comprise ten transmembrane 
glycoproteins containing multiple leucine-rich repeat motifs in the divergent ectodomain and a 
highly conserved region in the intracellular tail. TLRs recognise alarm signals from 
microbiota/viral-associated and damage-associated molecular patterns (Cario, 2010). Different 
microorganisms may include different molecular signatures interacting with different members 
of the TLR family e.g. lipopeptides: TLR2; lipopolysacharride: TLR4; flagellin: TLR5 and CpG DNA 
motifs: TLR9. Binding of molecular ligands elicits receptor activation. All TLRs may signal  
through the adaptor protein MyD88, whilst TLR4 uses both MyD88 dependent and independent 
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pathways. Engagement of MyD88 activates a series of signalling modules i.e. IRAK, TRAF6 and 
TAK1, ultimately leading to activation of transcription factors (Cario, 2010). 
 
 
In the normal intestine, TLR2 and 4 are present in low levels on intraepithelial and lamina 
propria mononuclear cells, minimising recognition of the commensal gut environment and 
maintaining a basal state of activation. Once host threats are encountered TLR signalling elicits 
immune responses to eliminate the danger. However, sustained TLR hyper-activation may 
provoke chronic inflammation as seen in IBD. Furthermore, stimulation of TLR 2 alters epithelial 
barrier integrity via an apical redistribution of ZO-1 in intraepithelial cells (Cario et al., 2004, 
Cario, 2008). 
 
 
Combined carriership of the TLR 9-1237C and CD14-260T alleles were significantly more 
frequent in chronic relapsing pouchitis (Lammers et al., 2005a). Expression of TLR2 and TLR4 on 
dendritic cells from colonic samples of UC patients is elevated compared with healthy controls 
(Hart et al., 2005a). Differences in the expression of TLRs have also been found in pouchitis and 
between UC RPC and FAP RPC patients (Heuschen et al., 2007, Toiyama et al., 2006, Leal RF, 
2010). mRNA expression of TLR 2,3,4 and 5 in UC RPC patients correlated with pouchitis score 
and compared with normal ileal mucosa, TLR 3 was decreased, whereas TLR 5 was increased in 
pouch mucosa. TLR 5 expression was increased in pouchitis and no differences were seen in 
TLR2 or TLR 4 expression (Heuschen et al., 2007). However, another study found TLR 2 and 4 
were barely detectable in normal ileal mucosa, but were strongly upregulated in active 
pouchitis and TLR 4 was also upregulated in the non-inflamed pouch (Toiyama et al., 2006). 
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Another study showed UC pouch patients (in the absence of clinical, endoscopic and histological 
inflammation)  had  significantly  higher  expression   of  TLR  4  than  FAP  pouch patients,            
whilst TLR 2 expression was similar between the groups (Leal RF, 2010). Scarpa et al. 
demonstrated the interplay of the mucosal immune response and the microbiota with 
increased TLR 2 and 4 expression in chronic pouchitis patients correlating with increased 
Clostridiaceae spp. (Scarpa et al., 2011b). These findings may explain an inherent tendency in 
UC pouch patients towards an increased immune sensitivity to bacterial signals. 
 
 
De Silva et al. demonstrated intense epithelial expression of HLA-DR in inflamed pouch mucosa 
compared with pouches without inflammation and normal ileum (de Silva et al., 1990). HLA-DR 
is a MHC class II cell surface receptor that presents peptide antigens to elicit immune system 
responses. These are typically found on antigen presenting cells such as macrophages and 
dendritic cells. In the inflamed pouch mucosa, an increase in the number of RFD9+ and CD16+ 
macrophages were noted (de Silva et al., 1991). CD40, a maturation and co-stimulatory marker 
on antigen presenting cells necessary for stimulation of naive T cells was significantly elevated 
on immunohistochemical analysis of biopsy samples from pouchitis compared with non- 
pouchitis patients (Polese et al., 2005). However, there are no previous studies of dendritic cells 
in pouchitis. 
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1.5 Dendritic cells 
 
 
Mucosal dendritic cells (DC) are at the intersection between the innate and adaptive immune 
systems and are central to the maintenance of immune homeostasis in the gut. DC continually 
survey the gut luminal contents, enabling tolerance of commensals and recognising pathogens 
(Stagg et al., 2003). DC contribute to the expansion and differentiation of most classes of 
lymphocytes (Ueno 2007). They play a role in the differentiation of B cells, NK cells and NK T 
cells although relatively little is known about the mechanisms involved. Important interactions 
have recently  been shown between DC and innate lymphoid cells, shaping the innate 
responses to the microbiota (Powell et al., 2012). DC are critical in determining whether T-cell 
responses generated are immunogenic or tolerogenic and maintain the delicate balance in the 
gut between immunogenicity against invading pathogens and tolerance of the commensal 
microbiota (Hart et al., 2005a). 
 
 
DC are bone marrow derived antigen presenting cells that are present in most tissues, but 
comprise only a small proportion of the total circulating leucocyte population. The two major 
functions of DC are to acquire antigen and to stimulate lymphocytes. DC undergo maturation 
and migrate to draining lymph nodes in response to signals such as microbial antigen or 
cytokines. During maturation DC upregulate expression of MHC class II and costimulatory 
molecules and acquire the ability to stimulate naive T cells. DC can determine whether non- 
responsiveness or active immune response occurs to a particular antigen and also the type of 
inflammatory response (Th1, Th2, Th17) that occurs (Stagg et al., 2003). 
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Functionally distinct subsets of DC have been defined in both mice and humans based on cell 
surface phenotpye and functional properties. In humans these subsets include myeloid DC 
(mDC) (CD11c+, CD123low, BDCA2 and 4-) and plasmacytoid DC (pDC) (CD11c-, CD123high, 
BDCA2 and 4+). The CD11c+ subset follows a myeloid differentiation pathway and is therefore 
termed myeloid DC (mDC). Recently, mDC have been further subdivided into two groups. Type 
1 mDC are identified by BDCA1+ (also known as CD1a+) and represent the majority of mDC in 
the human body (>90%). These DC are involved in presenting MHC class II antigens, leading to 
activation of a CD4+ T-cell response. Type 2 mDC (<10% total mDC) are BDCA3+ and carry out 
MHC class I antigen presentation to CD8+ T-cells with antigen-cross presenting capabilities. pDC 
come from an independent, possibly lymphoid-related, differentiation pathway. pDC combine 
features of both classical DC and lymphocytes and display unique molecular sensing of nucleic 
acids and type 1 interferon production. However, pDC are also capable of generating Th2 
responses (Ng et al., 2009c, Ng et al., 2010a, Shortman and Liu, 2002). 
 
 
The state of maturation and the type of DC can influence the subsequent T cell response. 
Immature DC, trafficking from peripheral to lymphoid tissue presenting self-antigen, inhibit 
potentially autoreactive T cells. Non-responsiveness can also be induced to foreign antigen. 
Mature DC can activate and drive clonal T cell expansion and shape the functional 
differentiation of dividing T cells through cytokine production (Stagg et al., 2003, Ng et al., 
2010a).  Naive T-cells require two signals from DC to become fully activated. The antigen  
(bound to MHC-II) provides the first signal and interacts with the T-cell receptor (TCR). The 
second signal is antigen non-specific and is provided by co-stimulatory molecules on the surface 
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of the DC binding with their corresponding receptors on the naïve T-cell. Examples of such co- 
stimulatory molecules are CD40, CD80 and CD86. This double signal is necessary for T-cell 
proliferation, differentiation, survival and cytokine secretion. Activation of T-cells without co- 
stimulation results in suppression of the immune response, and, in some cases, induces 
antigen-specific tolerance. Matured or activated DC provide a third signal to the T-cells via 
secretion of cytokines. The cytokines produced by DC determine the type of effector T-cell 
response that occurs. The decision between induction of tolerance or active immunity depends 
on the subpopulation of DC, the surface receptors involved and the tissue environment during 
DC activation and T-cell priming. 
 
 
1.5i Dendritic cell interaction with the microbiota 
 
 
The effects of the microbiota on intestinal DC are pivotal in early bacterial recognition and the 
shaping of the subsequent innate and adaptive immune responses. DC express pattern 
recognition receptors including Toll-like receptors (TLRs) and nucleotide binding and leucine  
rich repeat containing receptors (NLRs NOD1 +2) that recognise common structural elements of 
microorganisms. DC also express C-type lectin receptors such as DC-SIGN. These receptors 
interact with ICAM 2 on vascular endothelium promoting extravasation of immature DC and 
with ICAM 3 on T cells to stabilise the immunological synapse. Within the peripheral tissues and 
secondary lymphoid organs, immature DC constantly sample foreign and self-antigens (Stagg et 
al., 2003). 
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In the gastrointestinal tract a number of routes by which DC can acquire and process specific 
antigens have been described. The main route for antigen to access the mucosal immune 
system has traditionally been via M cells. These specialised epithelial cells overlie the dome of 
Peyer’s patches and shuttle luminal antigen to DC in the subepithelial dome regions. M cells 
may also be found within the villous epithelium to help deliver antigens to lamina propria DC. 
DC can also acquire antigen via internalisation of apoptotic epithelial cells or uptake of antigen 
exosomes shed from epithelial cells (Stagg et al., 2003). More recently DC have also been 
shown to express tight junction proteins and penetrate the epithelium to sample bacteria 
(Rescigno et al., 2001). Where the epithelial barrier is compromised DC may sample antigen 
directly (Figure 1.4). DC function can also be shaped indirectly via ligation of pattern recognition 
receptors and other indirect mechanisms on intestinal epithelial cells (Silva et al., 2008, Iliev et 
al., 2009). 
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Figure 1.4 Modes of antigen sampling and uptake by intestinal DC (based on image from 
Stagg et al. 2003)(Stagg et al., 2003). 
 
 
 
Four described pathways of DC sampling of antigen in the intestinal lumen. 1. following transport of antigens by 
M cells. 2. reaching between epithelial cells to directly sample the lumen. 3. via the epithelial cells, either by 
pinocytosis of material transported by epithelial cells or following uptake of apoptotic epithelial cells and 4. By 
direct paracellular transport of antigens as a result of breaks in the integrity of the epithelium. 
 
 
 
1.5ii Dendritic cells imprint gut-homing properties on lymphocytes 
 
 
On encountering foreign antigen, DC undergo maturation with upregulation of MHC and co- 
stimulatory molecules. In addition, expression of CCR7 is upregulated as DC move to the 
draining lymph node where they present antigens to naïve T cells. DC bearing antigen are 
consequently critical in “informing” T cells of the tissue and environment from which the DC 
encountered the antigen and can induce gut homing receptors on T cells enabling them to 
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home back to the intestine and access the anatomical site most likely to contain their cognate 
antigen (Ng et al., 2010a, Hart et al., 2010, Mann et al., 2012). 
 
 
Lymphocytes continuously migrate around the body optimising their probability of 
encountering an antigen. Lymphocyte subsets express unique patterns of homing molecules 
enabling guidance to their target tissue via site-specific pathways. Naive T cells express homing 
receptors allowing migration to lymphoid organs. Once they have become activated by antigen 
they alter their pattern of homing receptors and can migrate to peripheral sites. The tissue 
homing phenotype of T cells is established by tissue specific DC during T cell priming and B cell 
activation (Dudda et al., 2005, Mora et al., 2006). Tissue specific DC can also modulate homing 
patterns of effector B and T cells during an ongoing inflammatory response (Dudda et al., 2005, 
Mora et al., 2006). In the intestine, lymphocytes activated in mesenteric lymph nodes have a 
propensity to home back to the intestine. The molecules enabling homing to the intestine 
include the integrin α4β7, which is attracted to its ligand mucosal addressin cell adhesion 
molecule-1 (MadCAM-1). CCR9 and its ligand CCL-25/TECK are involved in homing to the gut, 
particularly the small intestine (Hart et al., 2010) (Figure 1.5). 
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Figure 1.5 Induction of intestinal T cell homing by DC (Figure courtesy of Mann ER, APRG) 
 
 
 
Intestinal dendritic cells imprint gut homing markers on naive T cells in the mesenteric lymph nodes and peyer’s 
patches in a Retinoic acid dependent manner, leading to gut specific homing of T cells. 
 
 
Mouse studies suggest that CCR9 expression confers small intestine specific homing properties 
for DC (Hart et al., 2010). However, a recent study found that the CCR9 ligand, CCL25/TECK, was 
expressed in the colonic mucosa (Linton et al., 2012). Similar to the gradient in the composition 
of the microbiota between the small and large bowel, a gradient exists in the small and large 
intestine with regard to expression of homing molecules and their ligands. In the small intestine 
both CCR9/CCL25/TECK and α4β7/MadCAM-1 are involved in lymphocyte migration. In 
contrast, CCR9/CCL25/TECK expression in the colon is limited. There is a gradient of expression 
of CCL25/TECK from the highest expression in the proximal small bowel to the lower expression 
in the distal ileum and limited expression is found in the colon.  Blockade of CCL25/TECK 
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prevents T cell migration to the small intestine, but has no effect on lymphocyte homing to the 
colon (Hart et al., 2010). The relative expression of CCR9 and β7 may therefore determine 
preferential homing to the small or large bowel. 
 
 
In mice, CD103+ DC have been shown to possess the ability to generate gut homing T cells in 
studies involving mesenteric lymph node and small-intestinal DC (Johansson-Lindbom et al., 
2005). There is no information regarding the imprinting capacity of colonic CD103+ DC in mice 
or humans. In mice, it is the CD103+ intestinal DC subset, but not other DC populations, that 
express the enzyme retinaldehyde dehydrogenase (RALDH) that mediates irreversible 
conversion of dietary retinal to Retinoic acid (RA) (Mann et al., 2013a). Retinoic acid is essential 
for the process of DC imprinting gut homing properties on lymphocytes (Dudda et al., 2005, 
Mora et al., 2006). Retinoic acid may synergise with other factors such as cytokines to 
determine tissue specific immune responses (Mora et al., 2006, Mann et al., 2013a). 
 
 
In a recent study, human colonic DC generated gut homing T-cells. The large fraction of CD103− 
DC identified in the human colon in this study, suggests the existence of CD103− DC subsets 
with the ability to generate gut homing T-cells (Mann et al., 2012). CD103- DC also conferring a 
gut homing phenotype to naive T-cells were also recently identified in murine intestinal lymph 
(Cerovic et al., 2013). CD103− DC may internalise RA from exogenous sources to be released 
during T-cell activation to generate gut-homing T-cells. 
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Soluble factors from the tissue microenvironment crucially influence homing receptor 
polarisation and can over-ride the DC tissue specificity (Dudda et al., 2005). Conditioning 
human blood DC with supernatants from healthy human colonic biopsies enhances β7 
expression on DC and their ability to prime gut-homing T cells (Mann et al., 2012) and is 
dependent on the presence of RA in the supernatant. MyD88-dependent TLR signalling confers 
DC ability to imprint gut-specific homing properties on T cells (Wang et al., 2011), directly 
linking bacterial activation of DC with imprinting capacity. The gut microbiota is likely to be 
crucial in influencing the gut homing properties of DC and their determination of tissue specific 
lymphocytes. 
1.5iii The role of dendritic cells in inflammatory bowel diseases 
 
 
The role of DC in IBD is increasingly recognised for their function in regulating intestinal 
immune responses (Hart et al., 2005a, Stagg et al., 2004). DC are increased and more mature 
within inflamed IBD tissue. In IBD, DC are activated with upregulated expression of TLRs and co- 
stimulatory molecules as well as production of pathologically important cytokines (Hart et al., 
2005a). Most studies of DC in IBD have focused on myeloid DC. 
 
 
Recently studies have begun to characterise plasmacytoid DC in IBD. In IBD patients a striking 
inverse correlation is seen between peripheral pDC and mDC and disease activity (Baumgart et 
al., 2005). pDC are present in greater numbers in the inflamed colonic mucosa and mesenteric 
lymph nodes of IBD patients (Baumgart et al., 2011). IBD patients have pDC displaying greater 
CD40 expression than healthy controls as well as increased secretion of TNF and interleukins 6 
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and 8 with impaired IFN secretion, suggesting an aberrant distribution and function of pDC in 
IBD (Baumgart et al., 2011). Lamina propria pDC are increased in inflamed and non-inflamed 
tissue in UC compared with controls without a concomitant increase of mDC, and these pDC are 
weakly stimulatory to T cells in mixed leucocyte reactions (Ng et al., 2009c). pDC may be of 
particular importance in the inappropriate innate immune responses to the microbiota in UC 
patients. 
 
 
In IBD, tissue specific homing of lymphocyte populations contribute to the dysregulated 
immune response. In Crohn’s disease, gut-specific adhesion molecules are increased. These are 
less well defined in UC and in pouchitis no increase in MadCAM-1, ICAM-1 or VCAM-1 was 
found between UC pouchitis tissue and FAP uninflamed pouch tissue (Thomas et al., 2002). 
However, activated CD27 and CD30+ T cells were increased in pouchitis mucosa (Thomas et al., 
2001). In colonic mucosa, β7+ lymphocytes are increased in active Crohn’s disease and UC. 
Relapse of disease in UC patients is associated with an increase in Th1 and Th2 cytokines from 
β7+ memory T cells (Hart et al., 2004a). No data currently reports DC or T cell homing 
properties in pouchitis. 
 
 
1.5iv Manipulation of DC function with probiotics 
 
 
Several mechanisms have been identified by which probiotics may exert their therapeutic 
effects. Mechanisms contributing to altered immune function include modulation of the host 
microbiota, improved barrier function and direct effects on immune cell types (Ng et al., 
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2009a). Attempts to alter the intestinal microbiota may have critical effects on DC function. A 
number of studies have demonstrated the modulation of DC by probiotic bacteria. In vitro, 
VSL#3 is a potent inducer of IL-10 by lamina propria DC and reduces co-stimulatory molecule, 
CD80 expression. Individual strains within VSL#3 display distinct immunomodulatory effects on 
DC; the most marked anti-inflammatory effects are produced by Bifidobacteria (Hart et al., 
2004b). In a study of VSL#3 treatment for patients with active UC, a reduction in TLR 2 
expression as well as an increase in IL-10 and a reduction in IL-12 production was seen in lamina 
propria mDC (Ng et al., 2010b). In patients with pouchitis treated with VSL#3 there were 
enhanced levels of IL-10 in their mucosa and decreased levels of TNF-, IL-1, inducible nitric  
oxide synthase, and matrix metalloproteinase (Ulisse et al., 2001). L. reuteri and L. casei bind 
the C-type lectin DC-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN). 
Blocking antibodies to DC-SIGN inhibited the induction of “T regs”, implying that ligation of DC- 
SIGN may actively prime DC to induce regulatory T cells (Smits et al., 2005). In an in vivo murine 
model, administration of VSL#3 skews the proportion of plasmacytoid and myeloid DC in the  
gut lamina propria, suggesting probiotics may also alter the distribution of intestinal DC subsets 
(Wang et al., 2009). Heat killed Lactobacilli caseii shirota increase DC stimulatory capacity and 
imprint skin homing markers on T cells (Mann et al., 2013b) and priming of intestinal DC with a 
secreted peptide of Lactobacillus plantarum imprint a skin homing profile on stimulated T cells 
(Bernardo et al., 2012a). 
 
 
The immune effects of probiotics are, however, complex. Differential effects are seen between 
different species and within different strains of the same species.  L. reuteri and L. casei, but not 
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L. plantarum, primed monocyte-derived DC to drive the development of T cells with regulatory 
properties (Smits et al., 2005). When tested in vivo, L. plantarum and L rhamnosus GG 
exacerbated the development of DSS-induced colitis and caused the death of treated mice, 
while, conversely L. paracasei was protective (Mileti et al., 2009). In addition, secreted peptides 
from probiotic bacteria (postbiotics) can exert “immunoregulatory” effects on DC (Bernardo et 
al., 2012a), whilst contact with the bacterium directly may exert stimulatory effects on DC and 
subsequent T cell responses (Mann ER personal communication). Furthermore, the immune 
effects of probiotic bacteria may depend on the local microenvironment in which they are 
acting and the integrity of the epithelial monolayer (Tsilingiri et al., 2012). In an ex-vivo model, 
probiotic inoculation with IBD tissue exerted destructive effects. This suggests that in the 
context of a loss of epithelial barrier integrity and increased translocation, otherwise non- 
pathogenic, non-invasive bacteria may worsen inflammation (Tsilingiri et al., 2012). Currently 
there are few data regarding the effect of intestinal barrier dysfunction on mucosal DC in 
human IBD. One limitation is the difficulty in predicting and detecting the onset of the first 
disease episode or relapse prior to their occurrence. In animal models of colitis, redistribution 
and maturation of DC are associated with impaired intestinal permeability and are regulated via 
TLR-2 (Silva et al., 2008, Silva, 2009). 
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1.6  Epithelial Barrier Function 
 
 
The mucosal epithelium limits the interactions between microbial antigens and the mucosal 
immune system at the mucosal surface. The intestinal epithelium is the largest barrier between 
the body’s internal and external environment. Gut epithelial cells prevent bacteria and 
associated toxins from penetrating the gut lumen. However, the intestinal epithelium is not 
only a static barrier but has evolved complex mechanisms to control and regulate bacterial 
interactions with the mucosal surface (Duerkop et al., 2009, Berkes, 2003). 
 
 
Epithelial goblet cells produce large amounts of mucus glycoprotein regulated by the  
expression of the MUC2 gene. MUC2 knockout murine models demonstrate the importance of 
this layer with knockout mice being more susceptible to intestinal inflammation. The outer  
layer of mucus is populated with bacteria that may be found in the lumen, whilst the inner 
mucus layer remains relatively sterile. The relative sterility of the inner mucus layer is achieved 
through a number of mechanisms including the secretion of antibacterial proteins (defensins, 
cathelicidins and cryptidens) by epithelial cells. IgA sequesters and compartmentalises bacteria 
away from the epithelial layer and epithelial M cells and intra-epithelial lymphocytes maintain a 
tight control on local immune responses limiting the passage of pathogens (Salim and 
Söderholm, 2011). 
 
 
A number of routes exist for passage across the epithelial barrier between the internal and 
external environment. Water, small ions and low molecular weight molecules (<600kDa), 
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typically utilise paracellular routes, whilst macromolecules pass transcellularly via pinocytosis 
and endocytosis. The intercellular spaces between adjacent cells, linked together by junctional 
complexes, are critical in regulating the mucosal barrier. The tight junctions form the apical 
most unit, defining the boundary between the apical and basolateral membranes and are 
predominantly the rate-limiting factor in paracellular passage (Salim and Söderholm, 2011). 
Tight junctions (TJ), adherens junctions (AJ) and desmosomes are collectively termed the 
adherens junctional complex (AJC) (Groschwitz and Hogan, 2009). The tight junction is built up 
by both transmembrane proteins such as occludin, tricellulin, different claudins and junctional 
adhesion molecules (JAMs), as well as peripheral membrane proteins such as zona occludens 
(ZO)-1,-2,-3 and cingulin. The peripheral membrane proteins are linked to the cell cytoskeleton 
by F-actin and myosin II (Edelblum and Turner, 2009, Groschwitz and Hogan, 2009). These ZO 
proteins have three PDZ domains that mediate binding to other transmembrane tight junction 
proteins such as claudins in a dynamic energy dependent manner (Shen et al., 2008b). They are 
also the direct targets and effectors of different signalling pathways (such as the myosin light 
chain kinase) thereby altering the assembly, maintenance, and barrier function of the tight 
junction complex (Schulzke et al., 2009). 
 
 
The expression of different TJs in the gut varies according to localisation (e.g. villus vs. crypt, 
small bowel vs. colon) (Rahner et al., 2001, Escaffit et al., 2005), cell membrane localisation (e.g. 
apical, lateral or basolateral) and the gut’s functional properties at the site (Groschwitz and 
Hogan, 2009, Amasheh et al., 2011, Rahner et al., 2001, Escaffit et al., 2005). For example, 
claudin 2 is expressed at the apical pole throughout the crypt-villus axis in the jejunum whilst in 
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the colon expression is restricted to the crypts, whereas claudin 4 expression is throughout the 
crypt-villus axis in the small and large intestine. The segmental distribution of claudin 
expression may relate to cell differentiation, carbohydrate metabolism and transcription factors 
such as HNF1α, Cdx2 and GATA-4 (Escaffit et al., 2005). 
 
 
In health, the apical TJs construct a dynamic intestinal barrier that regulates the paracellular 
uptake of water, nutrients and electrolytes (Edelblum and Turner, 2009, Shen et al., 2008b). 
The majority of TJs are cation selective and prevent contact between the proteins of the two 
cell poles: the basolateral and apical cell membranes (Hartsock and Nelson, 2008). AJs and 
desmosomes are mostly involved in communication between neighbouring epithelial cells. 
(Bruewer et al., 2006, Groschwitz and Hogan, 2009, Hartsock and Nelson, 2008). TJ dysfunction 
can lead to the disruption of the intestinal barrier integrity. This dysfunction can be initiated by 
multiple factors, including immunomodulatory cytokine responses, the ingestion of NSAIDs and 
alcohol, the presence of pathogens with or without the involvement of enterotoxins and other 
comorbidities such as food allergies, coeliac disease and type 1 diabetes (Groschwitz and 
Hogan, 2009). Changes in pH, osmotic load or cytoskeleton function all affect the barrier 
function of TJs (Schneeberger and Lynch, 1992). 
 
 
There are 24 different claudin isoforms that modulate the paracellular movement of ions based 
on charge and size (Turksen, 2004). Claudin 1 and claudin 2 are the major components of TJ 
strands (Morita et al., 1999). Claudin 2 controls the uptake of monovalent cations such as Na+ 
to the interstitium and directs the synthesis of aquaporins, thus making the epithelium more 
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leaky (Amasheh et al., 2002, Rosenthal et al., 2010) in contrast to other claudins (like -1,-3,-4,- 
5,-8) that tighten the epithelium (Furuse et al., 2002, Milatz et al., 2010, Van Itallie et al., 2001, 
Amasheh et al., 2005, Angelow et al., 2006, Angelow and Yu, 2007, Angelow et al., 2008). 
Claudin 2 also directly decreases the barrier function of claudin 1 and claudin 4 strands 
(Turksen, 2004). Therefore the ratio of different claudins in the TJ determines its functional 
property as either leaky or tight. 
 
 
1.6i Tight Junction Proteins in Inflammatory bowel diseases 
 
 
Patients with clinically active Crohn’s disease have increased intestinal permeability (Hollander 
et al., 1986, Munkholm et al., 1994). Furthermore, increased intestinal permeability in patients 
with inactive Crohn’s disease is predictive of clinical relapse (D'Inca et al., 1999) and has been 
shown in 10-25% of healthy first degree relatives of patients with Crohn’s disease (Peeters et 
al., 1997, Soderholm et al., 1999) which is associated with CARD15 mutations (Buhner et al., 
2006). Increased gut permeability is also characteristic of UC (Munkholm et al., 1994, Schmitz et 
al., 1999, Gitter et al., 2001) and and recent genetic studies have identified new UC 
susceptibility loci pertaining to defects of the epithelial barrier (Anderson et al., 2011, Barrett et 
al., 2009). Barrier properties of pouch mucosa in pouchitis and in UC pouches where backwash 
ileitis was present prior to restorative proctocolectomy are reduced (Merrett et al., 1996, 
Kroesen et al., 2006, Amasheh et al., 2009b) and increased bacterial translocation is reported in 
pouches more than one year following ileostomy closure (Kroesen et al., 2008). 
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Several studies have focused on expression of claudins in UC patients (Schmitz et al., 1999, 
Prasad et al., 2005, Oshima et al., 2008). Prasad et al. (Prasad et al., 2005) investigated the 
expression of claudins in the normal colon and the colon from IBD patients, demonstrating a 
higher expression of claudin 2 in samples from patients with IBD. Additionally, the increase in 
claudin 2 significantly correlated with disease severity. The changes were more pronounced in 
UC than in CD samples (Prasad et al., 2005). 
 
 
Oshima et al. (Oshima et al., 2008) found elevated claudin 2 levels in active UC samples, 
whereas claudin-4 and-7 levels were decreased at both protein and transcriptional level. 
Claudin 1 and 3 levels remained unchanged. In contrast, Poritz et al. (Poritz et al., 2011) found 
an increase in claudin 1:occludin ratios in colonic samples from UC patients compared with 
healthy controls and CD samples by Western blot analysis. This change in ratio was the result of 
both an increase in claudin 1 and a decrease in occludin. Disease severity, measured by the 
degree of inflammation, was directly proportional to the alterations seen in TJ structure in UC. 
In another study, claudin 18 was upregulated in the colon of UC patients compared to healthy 
controls, but did not correlate to disease severity and may represent a primary defect in 
epithelial barrier integrity (Zwiers et al., 2008). 
 
 
Barrier properties of ileo-anal pouch mucosa in pouchitis and in non-inflamed pouches are 
reduced (Kroesen et al., 2008) with increased bacterial translocation (Kroesen et al., 2006). 
Merrett et al (Merrett et al., 1996) assessed permeability through administration and urinary 
recovery of 51Cr-EDTA in patients prior to ileostomy closure, with samples obtained from a 
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“healthy” pouch, pouchitis and UC. An increase in pouch permeability in patients with pouchitis 
compared with those with a normally functioning pouch was found. Similarly, Amasheh et al. 
(Amasheh et al., 2009b) propose that the role of the epithelial barrier is critically important in 
the pathogenesis of pouchitis. Pouch biopsies were analysed before ileal pouch-anal 
anastomosis, during acute pouchitis and at a time point over a year after ileostomy closure. 
Claudin 1, 3, 4, 5 and 7 and occludin showed differential expression in this study, with a 
decreased level of claudin 1 and an elevation in claudin 2 levels. These observations suggest a 
mechanism of increased paracellular permeability due to faulty tight junctions as the basis of 
pouchitis. These changes are similar to the tight junction changes seen in UC. 
 
 
Figure 1.6 Electron microscopy of pouch epithelium demonstrating tight junctions and gap 
junctions. 
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1.6ii Chicken or egg? 
 
 
It is not clear whether the changes observed in tight junctions lead to abnormal epithelial 
barrier integrity and the aberrant immune responses, or whether the inflammation itself causes 
the alterations in tight junction expression and distribution. It is postulated that the primary 
cause for differences in CD and UC may be their differences in underlying immunological 
pathways. Inflammatory cytokines associated with gut inflammation alter permeability and 
tight junction expression (Heller et al., 2005, Zolotarevsky et al., 2002, Arrieta et al., 2008). 
 
 
Heller et al. (Heller et al., 2005) demonstrated a significant upregulation of IL-13 in patients  
with UC compared to CD patients and non-inflammatory controls. Following the upregulation of 
IL-13, there was a decrease in trans-epithelial resistance and an increase in epithelial cell 
apoptosis and conductance. Furthermore, IL-13 caused upregulation of the claudin 2 gene, thus 
elevating claudin 2 protein production threefold. IL-13 did not have a significant effect on the 
expression of occludin, claudin 1 and claudin 4. IL-6 is elevated in IBD patients and in CACO-2 
cells induces expression of claudin 2 via induction of increased Cdx 2 expression activating the 
claudin 2 promoter regions (Suzuki et al., 2011). 
 
 
In CD, interferon gamma (IFN-γ) contributes to impairment of epithelial barrier function 
through disrupting tight junction complexes by causing decreased expression and increased 
internalization of occludin and ZO-1 (Scharl et al., 2009). The effects of IFN-γ on barrier function 
may be mediated through 5' adenosine monophosphate-activated protein kinase (AMPK). 
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AMPK is key in sensing the cell’s energy levels, which decrease during inflammation and 
subsequently increase the demand for AMPK. Scharl et al. (Scharl et al., 2009) showed that 
inhibiting AMPK not only reverses its disastrous effect on TJs but also its negative effect on 
trans-epithelial resistance. In T84 cells (model intestinal epithelial cell line) IFN-γ increases 
intestinal permeability to large molecules such as E. Coli-derived lipopolysaccharide; effects 
were exerted by decreasing expression of occludin and increasing the expression of claudin 1 
(Watson et al., 2005). 
 
 
TNF-α can also affect tight junctions and decrease epithelial barrier function by increasing 
Myosin Light Chain Kinase (MLCK) phosphorylation. Inhibition of MLCK in TNF-α treated 
epithelial monolayers can acutely restore barrier function (Zolotarevsky et al., 2002). 
Furthermore, MLCK-activation promotes IL-13 expression and claudin 2 synthesis (Weber et al., 
2010). TNF-α induced MLCK expression may therefore be a critical mechanism for barrier 
dysfunction in UC and CD. Ileal MLCK expression is increased in ileal biopsies from Crohn’s 
patients compared with controls and increased MLCK correlates with disease activity (Blair et 
al., 2006). 
 
 
A recent study of transgenic mice expressing activated MLCK showed increased paracellular 
permeability without histological inflammation. Further analysis however, found an increase in 
the absolute numbers of lamina propria CD4+ lymphocytes and a significant redistribution of 
CD11c+ dendritic cells to the superficial lamina propria as well as polarisation to a Th1 cytokine 
profile (Su et al., 2009).  Other studies also suggest that tight junction abnormalities and 
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epithelial permeability may precede the increase of inflammatory cytokines. Interleukin-10 (IL- 
 
10) blocks IFN-γ induced epithelial permeability and IL-10 knockout mice have increased 
permeability and spontaneously develop chronic intestinal inflammation (Arrieta et al., 2008). 
Inhibition of the zonulin receptor (a key receptor in tight junction binding regulation) in IL-10 
knockout mice reduced intestinal permeability and attenuated the spontaneous development 
of colitis (Arrieta et al., 2008). However, increased intestinal permeability in IL-10 knockout 
mice not only preceded the onset of inflammation but also occurred significantly earlier than 
any differences in IFN-γ or TNFα. In the cadherin knockout mouse, disruption of the adhesion 
molecule E-cadherin by tissue specific expression of a dominant negative cadherin in small 
intestinal epithelial cells throughout the crypt-villus axis resulted in disruption of adherens 
junctions. When chimeric mice were created, it was evident that a defect in cell migration and 
proliferation only occurred in epithelial units expressing the dominant negative cadherin. By 
three months of age, the mice developed typical histological features of inflammatory bowel 
disease (Hermiston and Gordon, 1995). 
 
 
1.6 iii Therapeutic manipulation of tight junction proteins in inflammatory bowel diseases 
 
 
Strategies to manipulate tight junctions and intestinal permeability are likely to have an 
important role in the future treatment of IBD. Anti-TNF therapy is effective in the treatment of 
Crohn’s disease, UC and chronic pouchitis (Hanauer et al., 2002, Rutgeerts et al., 2005, Barreiro- 
de Acosta M, 2011). Barrier function is significantly restored following anti-TNF therapy for 
Crohn’s disease (Suenaert et al., 2002, Zeissig et al., 2004). In the study by Zeissig et al, this was 
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associated with a reduction in epithelial apoptosis but no significant changes in occludin, 
claudin 1 or claudin 4. However, other claudins including claudin 2 were not assessed (Zeissig et 
al., 2004). In a study of experimental colitis in mice, both etanercept and infliximab attenuated 
inflammation induced reductions in ZO-1 and occludin as well as reducing the upregulation of 
claudin 2 (Fries et al., 2008). 
 
 
Short chain fatty acids, in particular butyrate are thought to be the principal source of energy 
for colonocytes and in UC patients colonocytes have demonstrated diminished oxidation of 
butyrate (Roediger, 1980, Thibault et al., 2010). In vitro culture demonstrated butyrate 
enhanced claudin 1 transcription and enhanced barrier function (Wang et al., 2012). In colonic 
epithelial cells treated with butyrate, claudin 2 was downregulated (Daly and Shirazi-Beechey, 
2006). However, the clinical efficacy of butyrate for pouchitis has not been demonstrated 
(Wischmeyer et al., 1993). 
 
 
Novel therapies that alter epithelial barrier function may be available from nutritional sources. 
Several plant extracts have been observed to regulate tight junction expression. Quercetin, a 
common flavanoid, was shown to increase epithelial resistance in CACO-2 cell monolayers by 
upregulating claudin 4 expression (Amasheh et al., 2008). Berberine, an isoquinolone alkaloid, 
prevented TNFα induced claudin 1 disassembly and upregulation of claudin 2 in a cell culture 
model (Amasheh et al., 2010). Polyunsaturated fatty acids can also have beneficial effects on 
the assembly and morphology of tight junction proteins (Ulluwishewa et al., 2011). Omega-3 
and omega 6 polyunsaturated fatty acids up-regulate expression of occludin, reduce 
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permeability and strengthen the epithelial barrier (Li et al., 2008b) Polyunsaturated fatty acids 
also reverse the disruptions in tight junction proteins caused by proinflammatory cytokines in 
CACO-2 epithelial cells (Li et al., 2008a, Amasheh et al., 2009a) and might play a role in 
preventing the alteration in the epithelial barrier caused by inflammation or proinflammatory 
cytokines that could be exploited as a therapeutic target in the treatment of gut inflammation. 
 
 
Zonulin is a key regulator of intestinal permeability through modulation of epithelial tight 
junctions (Fasano, 2012). A synthetic peptide inhibitor of zonulin known as AT 1001 or 
Larazotide has undergone clinical studies in the treatment of coeliac disease (Paterson et al., 
2007). In the IL-10 knockout mouse, AT 1001 reduced intestinal permeability and attenuated 
the development of spontaneous colitis (Arrieta et al., 2008). Future studies are necessary to 
determine the role these proteins may have in modulating tight junctions and epithelial barrier 
function in inflammatory bowel diseases. 
 
 
Much attention has focused on the effects probiotic bacteria and their products may have on 
tight junction expression and epithelial barrier function. In vitro and animal models have shown 
Lactobacilli to attenuate epithelial permeability in experimental colitis and to upregulate tight 
junction expression of ZO-1, occludin and claudin 3 (Anderson et al., 2010, Liu et al., 2010, Patel 
et al., 2012). VSL#3 (a mixture of eight probiotic strains) prevented the reduction and 
redistribution of ZO-1 and claudins 1,3,4 and 5 in a murine model of colitis. Furthermore, 
bacterial products may be a source of novel therapies affecting epithelial barrier function. In a 
recent study, uncharacterized extracellular proteins secreted by B. longum subsp. infantis, 
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increased the production of ZO-1 and occludin in epithelial cells (Ewaschuk et al., 2008). 
Extracellular proteins derived from Lactobacillus rhamnosus GG attenuated reduction in 
epithelial resistance in an in vitro model, preventing the redistribution of tight junction proteins 
including ZO-1 and occludin in a dose dependent manner (Seth et al., 2008). In a recent study 
probiotics restored the mucosal barrier to E. coli and Horse radish peroxidase in patients with 
pouchitis and bacterial diversity correlated with barrier function (Persborn et al., 2013). 
 
 
Dysregulation of tight junction proteins is involved in the pathogenesis of IBD. However, a 
number of questions remain unanswered regarding the role of tight junctions in the aetiology 
of IBD. Whether tight junction abnormalities are primary or secondary to the aberrant immune 
responses present in these diseases remains to be proven. There does not appear to be 
consensus regarding the up or downregulation of the various claudin isoforms in UC, Crohn’s 
disease or pouchitis. Furthermore, significant differences may exist between animal models and 
human studies regarding tight junction expression profiles and further human studies are 
necessary (Alanne et al., 2009). 
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1.7 Faecal microbiota transplantation 
 
 
With the application of molecular techniques to the study of gut microbiology, mounting 
evidence is emerging regarding the relationship between intestinal dysbiosis and aberrant 
intestinal and also extra-intestinal immune responses (Sartor, 2008, Peterson et al., 2008b, 
Vrieze et al., 2010, Sekirov et al., 2010). Consequently modification of the microbiota itself is a 
target for immunotherapeutic manipulation. Studies of immune responses following 
modification of the microbiota in IBD are likely to further enhance our understanding of these 
diseases and the relationship between the microbiota and the intestinal immune system. 
 
 
The possibility of modifying the gut microbiota to replace harmful bacteria with more 
favourable microbes has been widely explored since Metchnikoff’s observations in 1907 of the 
potential health benefits of the “Bulgarian bacillus” (Metchnikoff, 1908). In vitro studies have 
demonstrated a positive effect of probiotic bacteria on gut inflammation by modulating gut 
immune cells (Hart et al., 2004b, Ng et al., 2010b). Probiotics have been extensively 
investigated in many gastrointestinal disease states where an abnormal microbiota is 
considered pathogenic (Hart et al., 2003, Preidis and Versalovic, 2009, Shanahan, 2010). The 
outcomes of these studies have however been variable and modest (Shanahan, 2010). 
Antibiotics and probiotics are the mainstay of treatment for acute and chronic pouchitis 
(Holubar et al., 2010, Gionchetti et al., 1999, Gionchetti et al., 2003, Gionchetti et al., 2000b, 
Mimura et al., 2004, Gionchetti et al., 2007). However, subsequent clinical studies have 
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reported disappointing results with less than 20% of patients able to maintain remission with 
VSL#3 following antibiotic induced remission (Shen et al., 2005a, McLaughlin, 2008). 
 
 
As previously stated, the immune effects of probiotic bacteria may depend on the local 
microenvironment in which they are acting and the integrity of the epithelial monolayer 
(Tsilingiri et al., 2012). Another confounding factor of the probiotic approach is the 
comparatively low number and diversity of bacterial species available in a typical commercial 
probiotic in comparison with the gut microbiota. Furthermore, probiotic bacterial strains may 
not be able to compete against the complex interactions of an established and adapted 
indigenous gut microbial community. An alternative approach is transplantation of the entire 
“organ” of the gut microbiota. 
 
 
1.7i Animal studies of faecal microbiota transplantation 
 
 
There is a considerable body of work involving transplantation into sterile-gut animals. Less 
work has evaluated the transplantation of microbiota into animals with intestines 
already populated with bacteria. Studies of knockout mouse models of colitis have shown 
transfer of colitogenic microbiota to wild type mice by co-housing and cross fostering (Garrett 
et al., 2007, Garrett et al., 2010, Elinav et al., 2011). Two groups have reported transferring 
colitis phenotypes from two different knockout mouse models to wild-type mice. Garrett et al. 
found that ulcerative colitis (TRUC) mice, deficient in both innate and adaptive immune 
responses, transferred their colitis phenotype to wild-type mice by cohousing and cross- 
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fostering (Garrett et al., 2007). The group showed by pyrosequencing that Proteus mirabilis and 
Klebsiella pneumonia were overrepresented and may be responsible for the colitis phenotype 
(Garrett et al., 2010). In similar experiments, Elinav et al. found that ASC–/– mice, transfer their 
colitic phenotype to wild-type mice by cohousing and cross fostering (Elinav et al., 2011). A 
recent study of NOD2 deficient mice demonstrated transfer of colitogenic microbiota to 
cohoused and cross-fostered mice and that the colitis susceptibility from NOD2 deficiency was 
mitigated by faecal microbiota transplantation (FMT) from wild type mice (Couturier-Maillard 
et al., 2013). 
 
 
Mouse models of enteric infections have shown prevention of infection following transfer of 
the microbiota from resistant to susceptible mice (Willing et al., 2011, Ghosh et al., 2011). 
Manichanh et al. studied the effects of FMT and antibiotic therapy in rats demonstrating three 
important outcomes: i) there was a marked and a durable increase in the microbial diversity 
following FMT up to three months following a single gavage of rat caecal content, ii) the 
increased microbial diversity resulted from both capture of new phylotypes as well as an 
increase in those already present and iii) antibiotics prior to transplantation are not necessary 
to engraft the exogenous microbiota and may be deleterious to the intended increase in 
microbial diversity with faecal transplantation (Manichanh et al., 2010) . When transplantation 
was performed after antibiotic intake, the resulting state combined the reshaping effects of 
each treatment. Consequently lowering the bacterial load by antibiotic intake prior to 
transplantation did not increase establishment of donor phylotypes and in fact reduced the 
overall diversity of the microbiota following FMT (Manichanh et al., 2010). 
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A recent study of FMT in a mouse model of Clostridium difficile (Gilmore et al., 2012) 
demonstrated that suppression of Clostridium difficle following FMT was associated with a shift 
in the recipients’ microbiota to a composition similar to that of the healthy input bacterial 
community and this was closely linked to a rapid increase in species diversity. Furthermore the 
critical bacterial mix necessary for the effectiveness of the transplant was phylogenetically 
diverse, included both obligate and facultative anaerobic species, and represented three of the 
four predominant intestinal microbiota phyla. Importantly, these species appear to be common 
inhabitants of the mouse intestine in health and they are phylogenetically distinct from the 
dominant members of the diseased mice microbiota (Gilmore et al., 2012). 
 
 
1.7ii Human studies of faecal microbiota transplantation 
 
 
Faecal microbiota transplantation has been described in ruminants for hundreds of years (Rager 
et al., 2004). Its use as therapy in humans was first reported by Eisemen et al. in 1958 in the 
treatment of fulminant pseudomembranous enterocolitis (Eiseman et al., 1958). Over the 
subsequent decades, there have been a small number of case reports and case series of FMT for 
Clostridium difficile (Bowden et al., 1981, Schwan et al., 1983, Tvede and Rask-Madsen,       
1989, Borody et al., 1989, Paterson et al., 1994, Gustafsson et al., 1998, Persky and Brandt, 
2000, Aas et al., 2003, You et al., 2008, MacConnachie et al., 2009, Rubin et al., 2009, Russell et 
al., 2010, Silverman et al., 2010, Rohlke et al., 2010, Yoon and Brandt, 2010, Khoruts et al., 
2010, Garborg et al., 2010) with the recent publication of the first randomised controlled trial of 
FMT for this indication (van Nood et al., 2013). Faecal microbiota transplantation has also been 
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performed for constipation (Borody et al., 1989, Grehan et al., 2010, Andrews and Borody, 
1993) irritable bowel syndrome and inflammatory bowel diseases (Borody et al., 2003, Grehan 
et al., 2010, Borody et al., 1989, Bennet and Brinkman, 1989) as well as diseases beyond the gut 
such as metabolic syndrome (Vrieze et al., 2012).  In recent years there has been a resurgence 
of interest in this procedure and its potential to modify the gut microbiota. 
 
 
Patient Details 
 
The majority of patients undergoing FMT were treated for Clostridium difficile after standard 
treatments had failed. Borody et al. in 1989 (Borody et al., 1989) reported 55 patients treated 
for constipation, diarrhoea, abdominal pain, ulcerative colitis or Crohn’s disease. Andrews et al. 
(Andrews and Borody, 1993) described faecal enema treatment for two patients with 
constipation and in the recent paper from Grehan et al. (Grehan et al., 2010), nine patients had 
a diagnosis of constipation or diarrhoea predominant IBS and one patient had Crohn’s disease. 
One patient in the series from Aas et al. (Aas et al., 2003) had Clostridium difficile diarrhoea on 
a background of Crohn’s colitis. Seven other patients with UC are reported to have undergone 
FMT (Bennet and Brinkman, 1989, Borody et al., 2003). A recent study of ten patients with mild 
to moderate UC has been reported in the paediatric population (Kunde et al., 2013) as well as 
studies in adults with UC reported this year including five and six patients respectively 
(Angelberger et al., 2013, Kump et al., 2013). 
 
 
Faecal microbiota transplantation has been described in patients as young as two years (Russell 
et al., 2010) to patients over 90 years of age (Rubin et al., 2009). Several reports include 
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patients with serious co-morbidities. Three of the four patients reported by Eiseman et al. 
(Eiseman et al., 1958) were in a critical condition requiring the use of vasopressors. In the 
patients reported by Bowden et al. (Bowden et al., 1981), eight had a previously treated 
carcinoma, two chronic renal failure and two an aortic aneurysm. In the study by Aas et al. (Aas 
et al., 2003) five patients undergoing FMT were hospitalised and of those treated as 
outpatients, three were nursing home residents. MacConnachie et al. (MacConnachie et al., 
2009) described FMT in eighteen patients, eleven of whom were hospitalised with significant 
co-morbidity and a high proportion having hypoalbuminaemia, leucocytosis and renal 
dysfunction before FMT. The patient in the report of You et al.(You et al., 2008) was treated in 
an intensive care unit with vasopressors and continuous veno-venous haemofiltration. 
 
 
Donor Screening 
 
The potential risk of transmission of viral, bacterial or parasitic infection during the course of 
FMT is a concern. No guidelines currently exist regarding faecal transplantation. A number of 
studies have proposed screening procedures (Aas et al., 2003, Russell et al., 2010). In a recent 
review of FMT for recurrent Clostridium difficile (Bakken, 2009) Bakken suggests a screening 
process based on previous studies. However, without established guidelines or data from 
randomised controlled trials, ethical approval for the procedure has to date depended on 
physician discretion with patient and donor consent, local hospitals’ or authorities’ approval or 
occurred within the framework of ethically approved research studies. Screening methods of 
stool donors are not always detailed. In the majority of reports a spouse or partner, close 
relative, or household member of the patient is preferred as the stool donor. However, in a 
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number of reports, donors who are unrelated healthy individuals have been used (Bowden et 
al., 1981, Gustafsson et al., 1998, Borody et al., 2003, van Nood et al., 2013). Earlier cases did 
not employ rigorous screening protocols, whereas more recently increased screening of donors’ 
medical histories, blood and stool tests have been implemented. 
 
 
Donors have been screened for a history of gastrointestinal illness, cancer or polyps, 
hospitalisation within the three previous months (Silverman et al., 2010) and between 6 weeks 
(Borody et al., 2003) to 6 months (Aas et al., 2003) without the use of antibiotics. Screening 
blood tests have included full blood count and liver function tests (Grehan et al., 2010) as well 
as screening of viral pathogens including  HIV 1+2 ,(Paterson et al., 1994, Gustafsson et al., 
1998, Persky and Brandt, 2000, Aas et al., 2003, MacConnachie et al., 2009, Rubin et al., 2009, 
Russell et al., 2010, Silverman et al., 2010, Rohlke et al., 2010, Yoon and Brandt, 2010), HTLV I/II 
(Silverman et al., 2010) hepatitis A, B and C (Gustafsson et al., 1998, Persky and Brandt, 2000, 
Aas et al., 2003, MacConnachie et al., 2009, Rubin et al., 2009, Russell et al., 2010, Silverman et 
al., 2010, Garborg et al., 2010, Borody et al., 2003), CMV, EBV (Gustafsson et al., 1998, Borody 
et al., 2003)and also for Treponema pallidum (Aas et al., 2003, MacConnachie et al., 2009, 
Rubin et al., 2009, Russell et al., 2010, Grehan et al., 2010)and Helicobacter pylori antibody 
(Silverman et al., 2010). 
 
 
Donor faecal specimens have been screened for Salmonella, Shigella, Campylobacter spp, 
Staphylococcus aureus, Aeromonas hydrophila, Yersinia, Vibrio parahaemolyticus, Vibrio 
cholerae, Candida albicans, Escherichia-coli O157 and Clostridium difficile toxins A and B 
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(Paterson et al., 1994, Gustafsson et al., 1998, Aas et al., 2003, MacConnachie et al., 2009, 
Rubin et al., 2009, Garborg et al., 2010, Russell et al., 2010, Silverman et al., 2010, Rohlke et al., 
2010, Yoon and Brandt, 2010, Khoruts et al., 2010). Stool microscopy has been screened for 
protozoa (trophozoites and cysts), helminths and ova including Entamoeba histolytica, Giardia 
lamblia, Microspora (Aas et al., 2003, MacConnachie et al., 2009, Rubin et al., 2009, Russell et 
al., 2010, Silverman et al., 2010, Yoon and Brandt, 2010, Borody et al., 2003) , Cryptosporidium 
(Silverman et al., 2010), Dientamoeba fragilis, Blastocystis hominis, Ascaris lumbricoides, 
trematodes and tape worms (Aas et al., 2003, MacConnachie et al., 2009, Rubin et al., 2009, 
Russell et al., 2010, Silverman et al., 2010, Yoon and Brandt, 2010, Borody et al., 2003) (Table 
1.5). 
Table 1.5. Suggested screening investigations for faecal transplant donors 
 
Sample Investigation 
Blood Full Blood Count, Liver Function Tests 
Hepatitis A,B,C 
HIV 1+2, HTLV I/II 
CMV, EBV 
Treponema pallidum 
 
Stool 
 
Selective stool culture 
Clostridium difficile toxin A and B 
Microscopy for ova, cysts and parasites 
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Route of Administration 
 
The initial report of Eisemen et al. described administration of faecal enemas (Eiseman et al., 
1958), which has been replicated in other studies (Bowden et al., 1981, Schwan et al., 1983, 
Tvede and Rask-Madsen, 1989, Paterson et al., 1994, Gustafsson et al., 1998, You et al., 2008, 
Silverman et al., 2010, Grehan et al., 2010, Andrews and Borody, 1993, Borody et al., 2003, 
Kunde et al., 2013). Others subsequently have used instillation via a colonoscope to the right 
colon (Persky and Brandt, 2000, Rohlke et al., 2010, Yoon and Brandt, 2010, Khoruts et al., 
2010, Garborg et al., 2010, Grehan et al., 2010) or instillation of donor faeces via nasogastric 
tube (Aas et al., 2003, MacConnachie et al., 2009, Rubin et al., 2009, Russell et al., 2010) or 
duodenal (Garborg et al., 2010, van Nood et al., 2013) or nasojejunal intubation (Bowden et al., 
1981, Grehan et al., 2010). The study of Grehan et al. employed a combination of colonoscopic 
instillation followed by enemas or nasojejunal tube (Grehan et al., 2010). The majority of 
studies entailed a single administration of donor faeces. Some studies used repeated infusions 
over 2 to 15 days (Eiseman et al., 1958, Bowden et al., 1981, Schwan et al., 1983, Tvede and 
Rask-Madsen, 1989, Paterson et al., 1994, Borody et al., 2003). In the study by Garborg et al. 
(Garborg et al., 2010), six patients underwent a second infusion of donor faeces having not 
responded to the initial transplantation. 
Patient preparation 
 
Preparation of the patient prior to FMT has varied depending on the method of administration 
of the donor stool. Studies in which donor stool is instilled at colonoscopy or via rectal enemas 
include patient preparation with bowel lavage treatments. Bennet and Brinkmann describe a 
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bowel sterilisation procedure (Bennet and Brinkman, 1989) prior to transplantation of donor 
stool. Persky and Brandt described the use of prior bowel lavage with polyethylene glycol 
(Persky and Brandt, 2000) The series of Borody et al. in six patients with refractory ulcerative 
colitis, gave seven to ten days of treatment with vancomycin, metronidazole and rifampicin 
prior to bowel lavage (Borody et al., 2003). This protocol was repeated in the study by Grehan 
et al. (Grehan et al., 2010). Two recent studies stopped treatment with metronidazole or 
vancomycin 24-48 hours prior to faecal transplantation (Yoon and Brandt, 2010, Garborg et al., 
2010). The study by Silverman et al., included prior treatment with Saccharomyces boulardii 
which was continued up to 60 days after the procedure (Silverman et al., 2010). Patients 
treated at one centre in the study by Rholke et al. (Rohlke et al., 2010) were treated with 
loperamide immediately following the procedure and again 6 hours later in order maximise 
contact time of the donor faeces with the colonic mucosa. 
 
 
Studies of FMT administered into the upper gastrointestinal tract, do not report the use of prior 
bowel lavage. The method described by Aas et al. in 2003 and followed by those of 
MacConnachie, Rubin and Russell et al., includes pre-treatment with more than four days of 
vancomycin and 20mg of omeprazole the evening before and the morning of the procedure 
(Aas et al., 2003, MacConnachie et al., 2009, Rubin et al., 2009, Russell et al., 2010). However, a 
recently published randomised controlled trial of faecal transplantation for recurrent 
Clostridium difficile infection implemented pre-treatment with four days of vancomycin as well 
as bowel lavage prior to duodenal infusion (van Nood et al., 2013). 
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Preparation of donor stool 
 
The interval between obtaining donor stool and its administration to the patient has varied 
between studies, from 24 hours before, 6 hours before (Aas et al., 2003, MacConnachie et al., 
2009, Rubin et al., 2009, Russell et al., 2010) or immediately. One study homogenised donor 
stool in pasteurised cow’s milk and filtered the solution which was then stored at -20°C and 
thawed in water at 37°C 30-60 minutes prior to administration as an enema (Gustafsson et al., 
1998). Some studies have described the homogenisation of the stool and filtering to remove 
debris. The use of between 10 to 200g of stool, diluted in sterile saline 20-500ml has been 
reported depending on the method of administration. Studies using an upper gastrointestinal 
protocol for FMT instilled between 30 and 50g of stool homogenised with 50-500ml sterile 
saline. 
 
 
Outcomes 
 
In many reports of FMT response is not clearly defined. Resolution of symptoms is most 
commonly stated. Some papers include absence of Clostridium difficile toxin. For Clostridium 
difficile, FMT effective in 87% of patients. Time to response is often not stated, although 
“immediate”, “prompt” or “rapid” response is often reported. Where time to response is 
stated, this has been recorded to occur within 24 hours to twelve days (Bowden et al., 1981, 
Gustafsson et al., 1998, Russell et al., 2010, Garborg et al., 2010, Borody et al., 2003). Response 
appears durable with follow up of patients up to 8 years (Yoon and Brandt, 2010). In the 
recently published RCT remission rates in the FMT group were 94% at ten weeks (van Nood et 
al., 2013). In the initial report of Eiseman et al. three of the four patients were described as 
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terminally or critically ill. All of these had cessation of diarrhoea and were completely 
asymptomatic between 24 hours and ten days following faecal transplantation. The report of 
Bowden et al. describe response as a reduction in frequency of bowel motions, absence of 
fever, normalisation of leucocyte counts and increased general well-being. Tvede and Rask- 
Madsen describe normalisation of bowel function as well as reduction in inflammatory markers 
and increased albumin levels as response to faecal transplantation. In the report of You et al. 
the patient rapidly displayed normalisation of leucocytosis, stabilisation of blood pressure 
enabling cessation of vasopressors and improvement in renal function allowing cessation of 
continuous veno-venous haemofiltration as well as normalisation of bowel function. In the 
reports of Schwann et al., Gustaffson et al. Persky and Brandt, Aas et al., MacConnachie et al., 
Khoruts et al, Rholke et al and Russell et al. cessation of diarrhoea is defined as response. Five 
of these studies also document a change from a positive to a negative Clostridium difficile stool 
test. The only published RCT of FMT defined cure as an absence of diarrhoea or persistent 
diarrhea that could be explained by other causes with three consecutive negative stool tests for 
C. difficile toxin (van Nood et al., 2013). 
 
 
 
Until recently the majority of UC patients reported responded to FMT and remained in 
remission from 1 months to 13 years (Borody et al., 2003, Bennet and Brinkman, 1989, Kunde 
et al., 2013). Patients with UC in the series of Borody et al. responded within one to six weeks 
and were considered in remission by four months following FMT (Borody et al., 2003). Five out 
of the six patients reported in this series had moderate to severe disease with moderate to 
severe endoscopic findings. All of the patients were asymptomatic with no endoscopic evidence 
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of active inflammation following FMT. However, no response was noted in three patients 
reported by Kunde et al. and only 1 patient showed response to FMT in the two recently 
published studies (Kunde et al., 2013, Kump et al., 2013, Angelberger et al., 2013)(Table 1.6). 
 
 
Adverse events 
 
No studies of FMT report any serious adverse events related to the procedure. Some studies 
report patient deaths due to the underlying disease where the patient has not responded to 
FMT. In one study in which donor faeces were instilled via a nasogastric tube, the patient died 
of peritonitis. Although considered unlikely, the nasogastric tube insertion could not be 
discounted to have been contributory (Paterson et al., 1994). One patient in the study by 
Silverman et al. developed irritable bowel symptoms following FMT (Silverman et al., 2010). In 
the recent study in paediatric UC patients cramping, bloating and fever were noted (Kunde et 
al., 2013). Van Nood et al. reported belching, nausea, vomiting and abdominal cramps in the 
RCT of FMT for recurrent C. difficile (van Nood et al., 2013). 
 
 
Analysis of effects of FMT on stool composition and faecal microbiota 
 
Studies have attempted to analyse stool before and after FMT. Using culture, Tvede and Rask- 
Madsen observed an absence of Bacteroides before bacteriotherapy and during vancomycin 
therapy whilst patients were symptomatic. During follow up after bacteriotherapy (including 
faecal enemas in two patients), Bacteroides were regularly cultured (Tvede and Rask-Madsen, 
1989). Gustafsson et al. studied stool short chain fatty acid concentrations before and after 
faecal transplantation in nine patients. All short chain fatty acids were found to be reduced in 
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the patient group compared with healthy adults and following faecal enema therapy the 
relative distribution and absolute amounts of short chain fatty acids returned to patterns 
similar to those in healthy adults (Gustafsson et al., 1998). 
 
 
More recently using modern molecular 16S rRNA gene sequencing techniques, two studies  
have shown a significant change in the microbiota following FMT. Khoruts et al. demonstrated a 
reduction in Bacteroidetes and Firmicutes in a patient with Clostridium difficile diarrhoea. 
Following faecal transplantation there was a rapid change in the patient’s microbiota to a 
composition that was highly similar to that of the healthy donor for at least four weeks (the 
duration of follow-up stool analysis) in this study (Khoruts et al., 2010). Grehan et al. undertook 
analysis on the stool of 10 patients who underwent FMT. A dramatic change was shown in the 
recipients’ microbiota to a composition similar to their donors’ microbiota. This study analysed 
stool from patients up to 24 weeks following FMT demonstrating a durable change in the 
recipients’ microbiota up to 24 weeks (Grehan et al., 2010). Following FMT in the randomised 
trial by van Nood et al., patients showed increased faecal bacterial diversity, similar to that in 
healthy donors, with an increase in Bacteroidetes species and Clostridium clusters IV and XIVa 
and a decrease in Proteobacteria species (van Nood et al., 2013). 
 
 
Two recent studies have assessed the microbiota following FMT in IBD. Faecal microbiota 
transplantation reduced the relative abundance of Proteobacteria and increased Bacteroidetes 
and at family level the most prominent relative changes were a decrease in Enterobacteriaceae 
and Enterococcaceae and a relative increase in Bacteroidaceae. However, abundant bacteria 
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from donors established in some of the recipients, but the efficiency and stability of donor 
microbiota colonization varied greatly (Angelberger et al., 2013, Kump et al., 2013). To date, no 
studies have attempted to assess the immune responses to modification of the microbiota with 
faecal transplantation. 
 
 
Evidence regarding the use of FMT as a means of modifying the gut microbiota and effecting 
cure of gastrointestinal illness is accumulating. To date the majority of studies of FMT have 
been in fulminant or refractory Clostridium difficile. However, studies to date are 
heterogeneous regarding the patients treated, donors used, optimal screening protocols, 
methods and frequency of administration, and definition of response. Furthermore, reports to 
date may suffer from reporting bias of positive outcomes and under-reporting of adverse 
effects. 
 
 
Faecal microbiota transplantation, a therapy used for more than half a century, could hold 
great promise as a future treatment where a dysbiosis of the gut microbiota is responsible for 
disease. This therapy is inexpensive as well as being effective in some cases. A second 
randomised controlled study of FMT in Clostridium difficile is on-going in North America and 
results are eagerly awaited.  Standardised controlled studies are necessary to ascertain the 
most effective regimen as well as the most acceptable method of treatment. Studies of FMT for 
other gastrointestinal diseases, such as inflammatory bowel diseases, where a dysbiosis of the 
gut microbiota is evident are necessary. Rigorous screening of potential donors is essential as is 
the use of partners or close relatives as donors to minimise the potential for transmitting 
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disease. Close monitoring and long term follow up are necessary. Combining clinical studies 
with molecular analysis of the microbiota and the effects on the immune response may 
significantly enhance our understanding of the gut microbiota and its relationship with health 
and disease. 
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Table 1.6. Summary of studies of faecal transplantation 
 
Author Year Indication Number of 
Patients 
Route of faecal 
instillation 
Response Stated Time 
to Response 
Duration of 
Follow-up 
Eiseman 1958 PMC 4 Rectal 4/4 2 days  
Bowden 1981 PMC 16 Rectal/Jejunal 14/16 1-12 days 5 days- 3years 
Schwan 1984 Relapsing CDAD 1 Enema 1/1  9 months 
Tvede 1989 Relapsing CDAD 2 Enema 1/2  6 months 
Bennet 1989 UC 1 Enema 1/1  6 months 
Borody 1989 IBS, IBD, CDAD 55 Enema 26 cure 
 
20 response 
 
9 no response 
 1-12 months 
Andrews 1992 Constipation 1 Enema 1/1  18 months 
Paterson 1994 Chronic CDAD 7 Enema 7/7  2 years 
Gustaffson 1998 AAD/CDAD 9 Enema 9/9 6-10 days 18 months 
Persky 2000 Recurrent CDAD 1 Colonic 1/1  5 years 
Aas 2003 Recurrent CDAD 18 Nasogastric 15/18  90 days 
Borody 2003 UC 6 Enema 6/6 1-6 weeks 1-13 years 
You 2008 Fulminant 
CDAD 
1 Enema 1/1 36 hours  
MacConnachie 2009 Recurrent CDAD 15 Nasogastric 11/15  4-24 weeks 
Rubin 2009 CDAD 12 Nasogastric 10/12  90 days 
Khoruts 2010 Chronic CDAD 1 Colonic 1/1 2 days 6 months 
Rholke 2010 Relapsing CDAD 19 Colonic 19/19  6 months- 5 
years 
Russell 2010 Relapsing CDAD 1 Nasogastric 1/1 36 hours 6 months 
Yoon 2010 Refractory/ 
 
Recurrent CDAD 
12 Colonic 12/12  3 weeks- 8 
years 
Garborg 2010 Recurrent CDAD 40 Duodenal/Colonic 33/40 24 hours  
Silverman 2010 Chronic CDAD 7 Enema 7/7   
Van Nood 2013 Recurrent CDAD  Duodenal 15/16  10 weeks 
Kunde 2013 UC 10 Enema 7/10 1 week 4 weeks 
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PMC- Pseudomembranous colitis; CDAD- Clostridium difficile associated diarrhoea; AAD- antibiotic associated 
diarrhoea; IBS- Irritable bowel syndrome; IBD- Inflammatory bowel disease; UC- ulcerative colitis. 
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1.8 Hypothesis 
 
 
Aberrant host immune characteristics and impaired epithelial barrier properties in the presence 
of a dysbiosis of the pouch microbiota are responsible for inflammation of the ileal pouch in 
ulcerative colitis patients. 
 
 
Manipulation of the pouch microbiota with faecal microbiota transplantation will alter the 
aberrant immune characteristics and impaired epithelial barrier properties. 
 
 
1.9 Aims 
 
 
1. To identify and characterise lamina propria dendritic cells in the ileum, non-inflamed and 
inflamed ileal pouch of patients with ulcerative colitis 
2. To characterise epithelial tight junction expression in the ileal pouch of patients with 
ulcerative colitis 
3. To assess longitudinally the alterations of tight junction protein expression and immune 
function in ulcerative colitis patients following restorative proctocolectomy 
4. To determine the clinical, microbiological and immunological effects of faecal transplantation 
therapy for patients with chronic refractory pouchitis 
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Chapter 2.  Materials and Methods 
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2.1 Materials 
 
 
2.1.1 Human Intestinal Tissue 
 
Human intestinal biopsies were obtained at flexible pouchoscopy or surgery from ulcerative 
colitis patients and FAP patients following restorative proctocolectomy. All patients undergoing 
flexible pouchoscopy received preparation with a phosphate enema prior to pouchoscopy. Ten 
mucosal biopsies were taken per patient. Tissues were stored in complete medium on ice and 
transported immediately for processing. Ethical approval and written informed consents were 
obtained from all patients [EC nos. 11/LO/0170, 12/LO/0913, 08/H0717/24]. 
2.1.2 CACO 2 cells 
Seeding and culture performed by Drs E Shaw and R Rigby Lancaster University 
 
This is a human caucasian colon adenocarcinoma epithelial cell line isolated from a primary 
colonic tumour in a 72-year-old Caucasian male using the explant culture technique. These cells 
form moderately well differentiated adenocarcinomas in nude mice. Cells were seeded in 
twelve well plates at a density of 2-4x104cells/cm2 and cultured in EMEM (EBSS) + 2mM 
Glutamine + 1% Non-Essential Amino Acids (NEAA) + 10% Foetal Bovine Serum (FBS) at 37◦C. 
 
Experiments were performed at day 3 and day 7 post confluence. 
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2.1.3 Buffers and Media 
 
Complete medium RPMI 1640 Dutch modification (Sigma Aldrich Co. Ltd, Irvine, UK) 
supplemented with 2mM L-glutamine, 100ug.ml-1 streptomycin, 100units.ml-1 penicillin and 
gentamicin (50ug.ml-1). To complete the medium RPMI was supplemented with 10% foetal calf 
serum (FCS). Dutch modified RPMI 1640 medium incorporates both HEPES buffer for partial pH 
control and bicarbonate for gas exchange. 
 
 
 
FACS buffer 
 
Cells prepared for flow cytometry were washed and re-suspended in FACS buffer. This buffer 
was prepared from Phosphate buffered saline (PBS) with added FCS (2%), sodium azide 
(0.02%)(Sigma, UK) and EDTA (1mM)(Sigma, UK). Phosphate buffered saline (PBS) calcium and 
magnesium free balanced salt solution- maintains the integrity of mammalian cells in vitro 
(Sigma, Poole). 
 
 
T0.1E Buffer (Invitrogen 1162066) 
 
Lyophilised primers were diluted in low EDTA concentration buffer. PCR pellets were 
resuspended prior to storage in T0.1E Buffer. 
 
 
Sterile Saline Solution 
 
NaCl (0.9%) Baxter was used for preparation of donor faecal transplant material. 
99 
 
 
 
 
1M Saline Solution (Sigma Aldrich) 
 
1M Saline Solution was used for ethanol precipitation of PCR products. 0.3 volume of 1MNACl 
and 2 volumes of cold 100% ethanol were mixed by inversion and left overnight at -20C. They 
were then centrifuged at 750g for 20min and 600 microliters of cold 70% ethanol was added 
prior to recentrifugation at 750g for 15 min before being left to air dry for 30-60 minutes. 
Pellets were then resuspended in 20-30 microliters of T0.1E buffer and left overnight at 4C. 
 
 
 
Trisborate EDTA buffer 
 
Borate- BDH 1005845, EDTA- Sigma E5134 and Tris- Fisus T/3712/56 were used to make 
Trisborate EDTA buffer used for gel electrophoresis. 
 
 
RNA later (Ambion) 
 
Used for storage of bio-samples prior to DNA extraction. 
 
 
 
2.1.4 Reagents 
 
Foetal calf serum (FCS) 
 
FCS (TCS cellworks, Buckingham, UK) was added to cell culture media to provide growth factors 
for cells. FCS also blocks non-specific binding during monoclonal antibody labelling. 
 
 
Normal mouse serum (NMS) 
 
NMS was used to block non-specific binding during monoclonal antibody labelling. 
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Sodium azide 
 
Sodium azide (Sigma, MO, USA) is an inorganic compound that prevents capping and shedding 
of monoclonal antibodies used for flow cytometric analysis of cells. Sodium azide (0.02%) was 
one of the constituents of FACS buffer. 
 
 
Hanks’ balanced salt solution (HBSS) 
 
Calcium- and magnesium-free HBSS (Gibco BRL, Paisley, Scotland) was used to make up EDTA 
solution and DTT. 
 
 
Dithiothreitol (DTT) 
 
DTT (Sigma-Aldrich) is a strong reducing agent and was added to calcium- and magnesium- free 
HBSS to make a solution of 1mmol.L-1 concentration in order to remove mucus, faeces and 
debris from human intestinal biopsies. 
 
 
Ethylenediaminetetraacetic acid (EDTA) 
 
EDTA (Sigma, Dorset) is a chelating agent; it chelates metal ions to prevent cell clustering. It was 
added to calcium- and magnesium-free HBSS to remove epithelial cells from human intestinal 
biopsies to make a solution of 1mmol.L-1 concentration. 
 
Collagenase Digestion Medium 
 
Collagenase D (1mg.ml-1) (Roche Diagnostics Ltd, Lewes, UK), in RPMI 1640 Dutch modification 
was used to digest whole biopsy samples to free cell suspensions. 
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Leucoperm A and B 
 
Leucoperm A (Serotec, UK) was used as a fixative and contains paraformaldehyde. Leucoperm B 
(Serotec, UK) was used to permeabilise cells and is detergent based. 
 
 
Paraformaldehyde 
 
Paraformaldehyde (BDH chemicals, UK) was dissolved in Saline (0.85%) through slow heating at 
60C at pH 7.0-7.4 to make a 1% stock solution which was added directly to antibody labelled 
cells as a fixative. 
 
 
Ficoll-Paque 
 
Ficoll- paque (Amersham Pharmacia, Sweden) was used to isolate PBMCs from freshly isolated 
whole blood. 
 
 
Monensin 
 
Inhibits intracellular protein transport and causes newly synthesised cytokines to be trapped 
within the Golgi apparatus of cells. (Sigma, MO, USA). 
 
 
Mounting medium with 4',6-diamidino-2-phenylindole (DAPI) 
 
DAPI (Vector Laboratories, USA) is a counterstain for DNA and RNA that produces a blue 
fluorescence. Fluorescence is maintained by storage at 4◦C. 
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2.1.5 Antibodies 
 
Antibodies with the following specificities and fluorochrome labels were used and isotype 
matched controls were obtained from the same manufacturers. 
Antibody 
TLR4 
Clone 
HTA125 
Channel 
FITC 
Isotype 
mIgG2a 
Company 
AbdSerotec 
TLR2 
TLR 5 
CD40 
Β7 
CCR9 
CD3 
CD16 
CD14 
CD19 
TLR2.3 
85B152.5 
LOB7/6 
FIB504 
112509 
UCHT1 
3G8 
61D3 
H1B19 
FITC 
FITC 
FITC 
PE 
PE 
PE-CY5 
PE-CY5 
PE-CY5 
PE-CY5 
mIgG2a 
mIgG2a 
mIgG2a 
rIgG2a 
mIgG2a 
mIgG1 
mIgG1 
mIgG1 
mIgG1 
AbdSerotec 
Abcam 
AbdSerotec 
BD Pharmingen 
R&D systems 
BD Pharmingen 
BD Pharmingen 
AbdSerotec 
AbdSerotec 
CD34 
HLA-DR 
CD11c 
581 
L243 (G46-6) 
KB90 
PE-CY5 
APC 
FITC 
mIgG1 
 
mIgG1 
BD Pharmingen 
BD Pharmingen 
DAKO 
CD123 
ZO-1 
PCK (c-11) 
Claudin-1 
Claudin-2 
9F5 
ZO1-1A12 
 
421403 
12H12 
PE 
FITC 
PE 
Unconjugated 
Unconjugated 
mIgG1 
mIgG1 
mIgG1 
rIgG2a 
mIgG2b 
BD 
Invitrogen 
abcam 
R&D systems 
Invitrogen 
Goat anti-rat IgG Fab2 
Goat anti-mouse IgG Fab2 
PE-CY7 
APC-CY7 
 Santa Cruz 
Santa Cruz 
IL4 
IL10 
IL12 
IL17 
8D4.8 
JES3-9D7 
C11.5 
BL168 
PE-CY7 
PE 
FITC 
APC-CY7 
 BD Pharmingen 
AbdSerotec 
BD Pharmingen 
Biolegend 
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Antibodies used for immunofluorescence 
Primary Antibodies 
ZO-1 Goat anti-ZO-1 (dilution 1:200) SantaCruzBiotechnology 
Claudin 1 Rabbit anti-Claudin 1 (dilution 1:200) Invitrogen 
Claudin 2 Rabbit anti-Claudin 2 (dilution 1:200) Invitrogen 
 
Secondary Antibodies 
 
ZO-1 Anti-goat FITC (dilution 1:70) SantaCruz Biotechnology 
Claudin 1 Anti-rabbit TRITC (dilution 1:500) SigmaAldrich 
Claudin 2 Anti-rabbit TRITC (dilution 1:500) Sigma-Aldrich 
 
Blocking Agent 
 
ZO-1 Normal goat serum (1:200) Vector laboratories 
Claudin 1 and 2 Normal rabbit serum (1:200) Vector laboratories 
 
 
 
Anitmouse BD Compensation beads 
 
The BD™ CompBeads Set Anti-Mouse Ig, κ are polystyrene microparticles which are used to 
optimize fluorescence compensation settings for multicolor flow cytometric analyses. The set 
provides two populations of microparticles, the BD™ CompBeads Anti-Mouse Ig, κ particles, 
which bind any mouse κ light chain-bearing immunoglobulin, and the BD™ CompBeads 
Negative Control (FBS), which has no binding capacity. When mixed together with a 
fluorochrome-conjugated mouse antibody, the BD™ CompBeads provide distinct positive and 
negative (background fluorescence) stained populations which can be used to set 
compensation levels. 
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2.1.6 Materials for DNA extraction and PCR 
 
Agarose 
Type 1 Sigma 083K001 agarose was used for gels for DNA extraction and PCR checks. 
 
 
SYBR green (Biotium 1161122) 
Gelgreen nucleic acid stain 10,000x in water was used to stain nucleic acid for confirmation of 
DNA or PCR products under UV light examination. 
 
Loading buffer (Promega) 
Used for loading of genetic material onto gels for electrophoresis 
 
 
1Kb Plus DNA ladder (Invitrogen) 
Used for sizing DNA fragments 
 
 
dNTPs 
GeneAmp® deoxynucleotide triphosphates (dNTPs) dissolved in glass-distilled water and 
titrated to pH 7.0 with NaOH were used for the PCR mastermix (dATP, dCTP, dGTP, dTTP). 
dNTPs were made up to a concentration of 200μM prior to use. 
 
FastDNA® SPIN kit for soil and FastPrep® (MP Biomedical) 
Used for DNA extraction as per manufacturer’s instructions 
 
 
Q5TM polymerase (New England Biolabs 0041207) 
High fidelity DNA polymerase used for PCR of bacterial DNA. 
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2.2 Methods 
 
 
2.2.1 Ethics Committee Approval 
 
The study protocols and associated laboratory investigations were approved by the Brent 
Research and Ethics Committee EC No 08\H0717\24 and the North London REC 2 EC no. 
11/LO/0170. Approval for investigations relating to patients with FAP was given by the South 
East London NRES committee EC no. 12/LO/0913. Written informed consent was obtained from 
all participants, patients and healthy volunteers. 
Local NHS Research and Development approval and sponsorship to conduct the studies were 
secured from Imperial College London and North West London Hospital NHS Trust. 
 
 
2.2.2 Patients and Controls 
 
Patients were recruited from an adult tertiary pouch clinic at St Mark’s Hospital. Diagnosis for 
ulcerative colitis patients with an ileal pouch was made by previous clinical, endoscopic and 
histological criteria. FAP patients had been previously diagnosed based on family history, 
endoscopic phenotype and genetic analysis. Diagnosis of pouchitis was based on clinical, 
endoscopic and histological criteria meeting a PDAI of ≥7 (Table 1). Patients with pouchitis were 
characterised as acute or chronic as per the definition described above (Section 1.3i). Five 
patients with UC were followed longitudinally over the first year following ileostomy closure 
(Table 5.1). In total 15 UC patients with pouchitis, 18 UC patients without pouchitis and 8 
patients with FAP were recruited for a cross-sectional study (Table 2.2). Healthy controls (n=9) 
consisted of patients with macroscopically and histologically normal intestine that had been 
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referred with symptoms of rectal bleeding, change in bowel habit or a family history of 
colorectal cancer. 
Table 2.2 Patient characteristics of UC pouchitis, UC non-pouchitis and FAP patients in 
cross-sectional study 
Diagnosis Age (range) Sex Median interval since 
RPC (years) 
PDAI Median pouch 
frequency in 
24 hours 
(range) 
UC Pouchitis (n=15) 51 (24-66) 8 male 7 (1-35 years) 12 (7-14) 12 (6-22) 
UC Non pouchitis (n=18) 50 (32-72) 9 male 8.5 (1-33 years) 0 (0-3) 6 (3-20) 
FAP (n=8) 42 (25-54) 3 male 10.5 (1-16 years) 0 (0-2) 6 (3-15) 
 
 
 
2.2.3 Grading of histological inflammation 
 
The severity of histological inflammation in each pouch biopsy specimen was reported by an 
expert pathologist. The degree of inflammation was graded according to acute histological 
criteria as per PDAI (Table 1). 
2.2.4 Isolation of peripheral blood mononuclear cells 
 
PBMC were obtained by centrifugation of human peripheral blood over Ficoll-Paque Plus at 
800g, for 30 minutes at room temperature (RT) and harvesting the buffy coat layer from the 
interface. The PBMC were washed twice in complete medium by centrifugation at 650g for five 
minutes. 
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2.2.5 Isolation of epithelial cells and lamina propria mononuclear cells 
 
The method used was as described in previous work from the Antigen Presentation Research 
Group (Bell et al., 2001). Biopsy specimens were collected on cold ice in Complete medium (see 
above). Tissues were incubated for ten minutes with DTT solution (see above) and then washed 
with EDTA solution (see above) before being incubated with gentle agitation in 25ml EDTA 
solution at 37◦C for 60 minutes. After 60 minutes the supernatant containing released epithelial 
cells was removed and passed through a cell strainer. This was then washed with complete 
medium and then washed again with FACS buffer. 
 
 
After the 60 minute wash with EDTA solution the remaining biopsy tissues were then digested 
in 25ml of collagenase digestion medium for 90-120 minutes at 37◦C. LPMC released from the 
tissue samples were passed through a cell strainer and washed in complete medium and then 
washed again with FACS buffer. 
 
 
2.2.6 Cell surface and intracellular labelling 
 
Cells were labelled in FACS buffer. Antibodies were added at predetermined optimal 
concentrations. For surface staining involving only directly conjugated reagents, all antibodies 
were added simultaneously prior to washing twice with FACS buffer. Where unconjugated 
antibodies were used, cells were initially labelled with the unconjugated antibody, washed and 
then labelled with secondary antibody before the cells were washed again. To prevent non- 
specific binding, unoccupied binding sites were blocked with foetal calf serum prior to the 
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addition of primary or directly conjugated antibodies. Labelling was performed for 20 minutes 
in the dark on ice. 
 
 
For intracellular staining, cells were fixed with 50μl of Leucoperm A for 15 minutes, washed and 
then 100μl of Leucoperm B, normal mouse serum and the directly conjugated or primary 
antibodies were added for 20 minutes in the dark on ice. The cells were then washed prior to 
addition of secondary antibody. Cells were washed twice and finally resuspended in 1% 
paraformaldehyde and stored at 4◦C until acquisition within 24 hours. 
 
2.2.7 Cytokine labelling for ongoing intracellular production of dendritic cell cytokine 
 
Production of cytokines was determined by intracellular staining and flow cytometry. The 
experimental approach and analysis of data has been described in detail by Panoskaltsis et al. 
(Panoskaltsis et al., 2003). Paired cultures of LPMC, one incubated with monensin to maintain 
cytokine within the Golgi apparatus of cells and the other incubated without monensin were 
cultured for four hours at 37◦C in a humidified atmosphere of 5% CO2 in air. Cells were fixed 
with 50μl of Leucoperm A and permeabilised with 100μl of Leucoperm B. To prevent non- 
specific binding, unoccupied binding sites were blocked with foetal calf serum prior to the 
addition of 5μl of anti-cytokine antibody. The cells were labelled in the dark for 20 minutes 
before the cells were washed twice in FACS buffer and then fixed in 1% paraformaldehyde. 
Samples were then stored at 4◦C until acquisition within 24 hours. 
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2.2.8 Flow Cytometry 
 
Multi-colour flow cytometry characterises and measures the physical properties of individual 
cells in suspension as they pass through one or more focused laser beams. As the cells pass 
through the laser beam(s), they disrupt and scatter light in two different planes. This degree of 
scatter correlates with the cell morphology with forward scatter (FSC) giving a representation of 
the cell size, and side scatter (SSC) correlating with granularity, allowing cell populations to be 
identified (Figure 2.1). 
 
 
Monoclonal antibodies conjugated to fluorescent dyes, which are conjugated to cells, can be 
detected by colour-specific detectors (channels) of the flow cytometer. Each fluorochrome 
emits light at a different wavelength (Table 2.1). The FACSCanto flow cytometer (BD 
Biosciences) was used. The cytometer is capable of detecting the fluorochrome dyes 
Fluorescein (FITC), Phycoerythrin (PE), PE-Cy5, Allophycocyanin (APC)Pe-Cy7 and APC-Cy7, 
corresponding to wavelengths FL1, FL2, FL3 and FL4, FL5 and FL6 respectively (Table 2.1). 
Table 2.1 Fluorochrome dyes and corresponding wavelengths 
 
Channel Name Emission 
wavelength (nm) 
FL1 FITC 519 
FL2 PE 578 
FL3 Pe-CY5 670 
FL4 Pe-CY7 767 
FL5 APC 660 
FL6 APC-CY7 780 
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During acquisition, 20μl of flow-count fluorospheres at a known concentration was added to 
each tube. Samples were acquired for approximately 3 minutes. All data were then saved as 
list-mode files and transferred to a computer for analysis. 
2.2.9 FACS Analysis 
 
DCs only constitute a small proportion of total leucocytes and cells from different samples emit 
different levels of innate/background autofluorescence. Therefore, compensation was carried 
out separately for each individual experiment. To perform partial online compensation, 6 
compensation tubes are made, each containing 60μl BD™ CompBeads Anti-Mouse Ig, κ 
particles, which bind any mouse κ light chain-bearing immunoglobulin, 60μl of the BD™ 
CompBeads Negative Control (FBS), and 10μl of a mouse κ light chain-bearing antibody for each 
fluorochrome channel (FL1-6). The tubes were vortexed and incubated in the dark for 30 
minutes prior to acquisition. DIVA software (BD Biosciences) was used for partial online 
compensation prior to cell acquisition, and generation of list mode data files. Completion of 
compensation and analysis of list mode data was carried out using WinList software (Verity 
Software House, Maine). Compensation was completed offline using the compensation toolbox 
on the WinListTM software program, using positive and negative populations of the 
fluorochrome stained compensation beads. Each individual experiment has its own unique 
compensation settings, saved as compensation files.  
111 
 
 
 
 
Dead cells and debris were excluded on the basis of light scatter (Figure 2.1) 
 
 
 
Figure 2.1 Histogram of cell distribution according to forward scatter and side scatter.Live cells were gated within 
region 1 (R1). 
 
 
Live cells were analysed on a plot of HLA-DR versus lineage cocktail staining. Lineage cocktail 
comprised specific monoclonal antibody labels for T cells (CD3), monocytes (CD14, CD16), B 
cells (CD19) and stem cells (CD34). There is no single specific marker in humans that identifies 
all DC, but they can be recognised by excluding other cell types. In humans, these cells are 
characterised by their high expression of HLA-DR and they lack the expression of lineage 
markers (Bell et al., 2001). Using multicolour flow analysis, DCs were identified as an HLA DR+ 
lineage – (CD3-, CD14-, CD16-, CD19-, CD34-) population and are defined as such throughout 
this thesis. (Figure 2.2). 
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Figure 2.2 Histogram of cell distribution staining positive for DR (x axis) and Lineage (y axis). Dendritic cell 
population is defined as DR+ (>10
1 
) and Lineage negative (<10
1
): gated region R3. 
 
 
Epithelial cells were identified as staining positive for pancytokeratin (C-11) and a positive 
region was drawn in reference to the isotype antibody e.g. Figure 4.7 Chapter 4. 
 
 
Enhanced Normalised Subtraction (Winlist software) was used to measure the percentage of 
positive staining cells and the level of staining for cell surface and intracellular markers as well 
as the percentage of cytokine-positive cells. The level of staining expressed as an intensity ratio 
(IR) represents the ratio of the median value of positive events in the test histogram to the 
median value of staining with the isotype-matched control antibody. The percentage of positive 
staining cells was determined by superenhanced Dmax (SED) normalised subtraction. Single 
parameter histograms were created for both test antibody and isotype control and the isotype 
control was subtracted from the test antibody using the super-enhanced Dmax (SED) normalised 
subtraction facility in WinList. This results in accurate values for percentage expression of that 
antibody and the intensity ratio (IR) of positive cell staining, i.e. the level of staining of a 
particular marker. This subtraction technique allows positive cells to be identified in situations 
where the distribution histograms overlap. The Dmax is given as a percentage following 
subtraction of the test and control histograms. If the two histograms are identical and overlap 
perfectly, a Dmax of 0% is the result (Figure 2.3). 
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Figure 2.3. Super-enhanced normalised subtraction example histograms A is the isotype control which represents 
non-specific staining. B is the positive staining (shaded area) of the relevant marker (here β7). This represents 
specific labelling for β7 combined with an element of non-specific staining. Using Enhanced Normalised 
Subtraction WinList software generates both the percentage of positive staining cells and the IR after subtracting 
the non-specific binding component from the phenotype labelling histogram. The median channel of fluorescence 
and distribution of each histogram is compared and the proportion of positive events calculated (B- shaded area). 
 
 
Normalised cumulative histograms of isotype controls were subtracted from histograms of 
positive staining. Where cells were cultured with or without monensin, the control samples 
were used as a reference allowing for gain or loss of cytokine to be measured (Holden et al., 
2008). In some cases secreted protein binds back to the surface of cell in the no monensin 
sample together with the loss of pre-existing cytokine from cells in the monensin sample, which 
contribute to the overall loss of cytokine. In such a situation the subtraction process can be 
reversed to generate negative results. In this system, the control sample does not represent 
zero but a reference point on which to quantify the build-up or loss of cytokine in the test 
sample. 
B A 
114 
 
 
 
 
2.2.10 Multiplex 
 
From each patient, one biopsy sample was blotted and weighed prior to being cultured 
overnight in complete medium at 37◦C in a humidified atmosphere of 5% CO2 in air. Following 
removal of the biopsy tissue, the supernatant was then centrifuged to remove residual cell 
debris and the supernatant was snap frozen in liquid nitrogen and stored at -80◦C. 
BD Cytometric Bead Array (CBA). Human Th1/Th2/Th17 Cytokine Kit. Catalogue no 560484 
Includes: IL-2, IL-4, IL-6, IL-10, TNF, IFN-gamma, IL-17A. The BD CBA Human Th1/Th2/Th17 
Cytokine Kit uses bead array technology to simultaneously detect multiple cytokine proteins in 
research samples. Seven bead populations with distinct fluorescence intensities have been 
coated with capture antibodies specific for their specific cytokine (IL-2, IL-4, IL-6, IL-10, TNF, 
IFN-gamma and IL-17A). The seven bead populations are then mixed together to form a bead 
array, which is analysed in the FL2 (PE) channel of the flow cytometer. 
 
 
During the assay procedure, the cytokine capture beads were mixed with the recombinant 
standards and research samples and incubated with FL2 (PE)-conjugated detection antibodies 
to form sandwich complexes. The intensity of PE fluorescence of each sandwich complex 
revealed the concentration of that cytokine. Standard curves were plotted to calculate the 
detection limit for the concentration of each cytokine. Values falling below the level of the 
detection limit are reported as being equal to that level. 
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2.2.11 Electron Microscopy 
Performed by Nicholas English of the Antigen Presentation Group 
 
Tissue biopsy (2 mm3) samples were fixed in 3% glutaraldehyde in 0.1M sodium phosphate 
buffer ph 7.4 for 2 hours at room temperature. After glutaraldehyde fixation, the samples were 
kept at 4oC until convenient for further processing. The samples were given three washes with 
0.1M sodium phosphate buffer pH 7.4 and post fixed in 1% osmium tetroxide in 0.1M ph7.4 
sodium phosphate buffer for 1 hour. They were given three washes with water to remove the 
phosphate and kept in water at 4oC overnight.  The samples were given two further washes 
with water and en bloc stained with 2% aqueous uranyl acetate for 2-4 hours in the dark. 
After three washes with water, the tissue samples were gradually dehydrated with changes of 
increasing concentration of acetone.  Acetone concentrations of 25%, 50%, 75% and 95%  
were used, the samples being kept for 20 minutes in each acetone concentration. The samples 
were then given four changes of 100 % dry acetone over 1 hour. The small bottles containing 
the samples were placed on a rotating mixer. The tissue samples were gradually infiltrated with 
araldite resin in a 1:1 solution of araldite resin in acetone overnight, later with the caps of the 
bottles loosened or removed to allow the gradual evaporation of acetone. After at least two 
changes of 100 % araldite over 4- 8 hours, the tissue samples were embedded in the araldite 
resin and cured for 18 hours at 65 ◦C. The araldite blocks of tissue were sectioned using a 
Reichert –Jung Ultracut E microtome. The ultrathin sections (100 nm thick) were collected on 
200 mesh copper grids. They were stained with Reynolds lead citrate and carbon coated. 
The grids of sections were viewed using a Jeol JEM- 1200 EX electron microscope. Electron 
micrographs were taken, the negatives developed and the images printed. 
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2.2.12 Immunofluorescent microscopy 
Assisted by Dr HO Al-Hassi 
 
The fresh human intestinal biopsy samples were snap-frozen and kept in -80◦C until embedded 
in a drop of water. ImmEDge pen was used to draw a hydrophobic barrier around the cells. 
Sections were (fixed in cold methanol: acetone (1:1) for 1 minute and afterwards washed with 
0,1% Tween 20 in PBS detergent. After washing and blocking with with normal goat serum and 
normal rabbit serum, double labelling with primary antibodies was performed and the sections 
were left to incubate overnight. After washing, sections were then incubated with secondary 
fluorescent antibodies (FITC- and TRITC-conjugated) for at least 4 hours (Sigma). Sections were 
then washed and mounted under cover slip with mounting medium (DAPI) and left overnight to 
harden. Control experiments were performed by omitting the primary antibodies. 
 
 
2.2.13 DNA extraction 
 
Biopsy samples were washed in PBS prior to being snap frozen in liquid nitrogen and stored at 
 
-80◦C. Faecal samples were homogenised by hand before mixing with sterile PBS and vigorous 
vortexing for five minutes and centrifugation at 250g for 1 min to settle large particulate 
matter. Aliquots were stored in RNA later (1:10) snap frozen and stored at -80◦C. 
Samples were thawed slowly on ice and the FastDNA® SPIN kit for soil and FastPrep® (MP 
Biomedical) instrument were used for DNA extraction as per manufacturer’s instructions. DNA 
was left overnight at 4◦C before being frozen at -20◦C. 
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2.2.14 Gel electrophoresis 
 
For confirmation of the DNA test samples of DNA extraction were mixed with loading buffer 
and run on 2.5% agarose gels mixed with SYBR green at 90V for 1 hour. For confirmation of the 
PCR products test samples were mixed with loading buffer and run on 1% agarose gels at 130V 
for 1.5 hours. Moulds were visualised under UV light. Bands were checked against a 1kb DNA 
ladder. 
2.2.15 PCR of bacterial DNA 
 
DNA samples were thawed on ice. 16SrRNA-gene PCR amplicons were generated for Lib-L 454 
Titanium sequencing with the use of barcoded primers targeting the V3–V5 regions of the 16S 
rRNA gene. 16SrRNA genes were amplified using lyophilised Golay barcoded primers (Eurofins 
MWG Operon). Bacterial primers 454-338F (5’- CCTATCCCCTGTGTGCCTTGGCAGTCT 
CAGACTCCTACGGGAGGCAGCAG-3’) and 926R (5’-CCATCTCATCCCTGCGTGTCTCCGACTCAG 
GAGTCT GAGTCTCCGTCAATTCMTTTRAGT-3’) were used to amplify 16Sr RNA genes. 
The Golay barcodes that were used are as follows: 
 
Sample Barcode 
Donor1_Faeces GAGTGGTAGAGA 
Patient1_Faeces_Pre GCATAGTAGCCG 
Patient1_Faeces_Post GCATATAGTCTC 
Patient1_Biopsy_Pre GATCTCATAGGC 
Patient1_Biopsy_Post GATCTTCAGTAC 
Donor2_Faeces GATACGTCCTGA 
Patient2_Faeces_Pre GCATCGTCAACA 
Patient2_Faeces_Post GCATGTGCATGT 
Patient2_Biopsy_Pre GATGATCGCCGA 
Patient2_Biopsy_Post GATGCATGACGC 
Donor3_Faeces GATAGCTGTCTT 
Patient3_Faeces_Pre GCATTGCGTGAG 
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Patient3_Faeces_Post GCCACTGATAGT 
Patient3_Biopsy_Pre GATGTCGTGTCA 
Patient3_Biopsy_Post GATGTGAGCGCT 
Donor4_Faeces GATAGTGCCACT 
Patient4_Faeces_Pre GCCAGAGTCGTA 
Patient4_Faeces_Post GCCTATACTACA 
Patient4_Biopsy_Pre GATTAGCACTCT 
Patient4_Biopsy_Post GCAATAGCTGCT 
Donor5_Faeces GATATGCGGCTG 
Patient5_Faeces_Pre GCGACTTGTGTA 
Patient5_Faeces_Post GCGAGATCCAGT 
Patient5_Biopsy_Pre GCACATCGAGCA 
Patient5_Biopsy_Post GCACGACAACAC 
Donor6_Faeces GATCAGAAGATG 
Patient6_Faeces_Pre GCGATATATCGC 
Patient6_Faeces_Post GCGGATGTGACT 
Patient6_Biopsy_Pre GCACTCGTTAGA 
Patient6_Biopsy_Post GCACTGAGACGT 
Donor7_Faeces GATCCGACACTA 
Patient7_Faeces_Pre GCGTACAACTGT 
Patient7_Faeces_Post GCGTATCTTGAT 
Patient7_Biopsy_Pre GCAGCACGTTGA 
Patient7_Biopsy_Post GCAGCCGAGTAT 
Donor8_Faeces GATCGCAGGTGT 
Patient8_Faeces_Pre GCGTTACACACA 
Patient8_Faeces_Post GCTAAGAGAGTA 
Patient8_Biopsy_Pre GCAGGATAGATA 
Patient8_Biopsy_Post GCAGGCAGTACT 
Control1_Neg GATCTATCCGAG 
Control1_Pos GATCGTCCAGAT 
Control2_Neg GCAGTTCATATC 
Control3_Neg GCTAGTCTGAAC 
Control4_Neg GGTGCGTGTATG 
Control5_Neg GTAGAGCTGTTC 
 
 
Q5TM taq polymerase (New England Biolabs) was used for PCR reactions according to product 
protocol. Reaction components were assembled quickly on ice and mixed prior to 
thermocycling. Mastermix was made up as follows for a 25μl reaction: 5μl Q5 reaction buffer, 
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2.5μl dNTPs, 1μl forward primer, 1μl reverse primer, 0.25μl Q5 high fidelity DNA polymerase, 
0.5μl template DNA, 14.75μl nuclease free water. The following PCR cycling conditions were 
used: 98 ◦C for 2mins, followed by 25 cycles of 98 ◦C for 30 seconds, 52 ◦C for 30 seconds and 72 
◦C for 2 minutes, followed by a final extension of 72 ◦C for 5 minutes. 
 
2.2.16 16SrRNA gene sequencing and analysis 
Performed by Dr Alan Walker of the Wellcome Trust Sanger Institute 
 
To characterize the microbiota, bacterial 16S rRNA gene sequences were analysed using 454- 
based analysis tools such as QIIME and mothur. 16SrRNA gene amplicons from each sample 
were then pooled in equimolar amounts into a mastermix for sequencing using the Lib-L kit on 
the 454 GS FLX Titanium platform. The resulting sequence data was processed using the mothur 
software package (Schloss et al., 2009) as described previously (Cooper et al., 2013), except that 
sequences with less than a minimum length of 320 base pairs rather than 350 base pairs were 
discarded. 
Any contaminant OTUs that were detected in the sequenced negative control samples were 
removed from the final dataset. Diversity comparisons (Chao, Shannon and inverse Simpson) 
were carried out using mothur after first sub-sampling the data down to 391 reads per sample 
to ensure equal sampling depth across all samples. Good’s coverage (an estimate of 
completeness of species sampling) at 391 reads per sample was on average greater than 92% 
for all sample groups (overall median 95.9%, range 87.9 to 99.7%). Similarity indices were 
assessed using Bray-Curtis and Theta Yue & Clayton calculators using mothur. OTUs/phylotypes 
were classified, set at a 97% minimum pair-wise similarity definition against public databases to 
monitor changes in bacterial composition (The 454 pyrosequence data has been deposited at 
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the European Nucleotide Archive under Study Accession Number ERP005254/ Sample 
Accession Number ERS421606). In order to monitor changes in overall bacterial community 
structure after administration of FMT cluster dendrograms/principal co-ordinates analysis plots 
were calculated using QIIME/mothur. OTUs that were differentially abundant between cohorts 
were assessed by Metastats (White et al., 2009), as applied in mothur. 
2.2.17 Statistical Analysis (advised by Paul Basset) 
 
 
Pooled data are expressed as mean and mean standard error for experimental data and median 
and range for clinical data. Pooled data from separate experiments were compared with the 
Mann Whitney U test. Where multiple groups (≥3) were analysed Kruskal-Wallis test with 
Dunn’s post test for multiple comparisons was performed. Where appropriate data were paired 
using Wilcoxon matched-pairs signed rank test. Friedman’s test was used to assess repeated 
measures (over time). A p-value of ≤0.05 was considered significant. GraphPad Prism® Version 5 
(GraphPad Software Inc., La Jolla, California, USA) was used for statistical analysis. 
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Chapter 3. Characterisation of lamina propria dendritic cells in 
ulcerative colitis patients following restorative proctocolectomy 
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3.1 Abstract 
 
 
Introduction: Immune responses to the ileal pouch microbiota instigate pouch inflammation. 
Lamina propria dendritic cells (DC) are pivotal in the interactions between the host immune 
system and the gut microbiota. We hypothesised that DC may be involved in the development 
and perpetuation of pouch inflammation and aimed to characterise DC in the ileum and ileal 
pouch. 
Methods: HLA DR+ lineage negative cells were identified in freshly isolated lamina propria 
mononuclear cells (LPMC) by multicolour flow cytometry. Bacterial pattern recognition 
receptors TLR 4 and 2; homing markers β7 and CCR 9 and the co-stimulatory marker CD40 were 
determined on DC extracted from ileal tissue of ulcerative colitis (UC) patients (9) and controls 
(9); from pouch tissue of UC patients with (15) and without pouchitis (14) and FAP patients (8). 
Results: DC expressing integrin β7 and CD40 were reduced in ileal tissue from UC patients 
compared with ileal tissue from controls. In UC patients without pouchitis, DC expressing 
integrin β7 were increased compared with ileal tissue of UC patients and DC expressing gut 
homing marker CCR9 were increased compared with FAP patients, but no other differences 
were noted. In UC patients with pouchitis, DC expressing CD40 and TLR 4 and β7 were 
increased and DC expressing CCR9 were decreased. 
 
Conclusions: DC phenotype in the ileum and in the non-inflamed pouch of UC patients suggests 
an aberrant expression of homing markers, which could promote colitogenic susceptibility in 
the pouch of patients with UC. DC phenotype in pouchitis suggests an activated innate immune 
response to microbial signals in inflammation of the pouch of UC patients. 
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3.2 Background 
 
Data regarding the immune responses to the alterations in the pouch microbiota are sparse. 
Previous studies provide evidence for the role of bacteria in the stimulation of mucosal innate 
and adaptive immune responses in the ileal pouch (Bell, 2004, Lammers et al., 2005b, Pronio et 
al., 2008). It is not clear how the pouch microbiota might interact with the mucosal immune 
system. The intestinal immune system maintains a delicate balance between immunogenicity 
against invading pathogens and tolerance of the commensal microbiota and food antigens. 
Intestinal dendritic cells (DC) are pivotal in the maintenance of this balance (Chapter 1.5) lying 
at the intersection between the innate and adaptive immune systems maintaining homeostasis 
in the gut. 
 
 
In inflammatory bowel diseases (IBD), DC are increased and more mature within inflamed IBD 
tissue. In IBD, DC are activated with upregulated expression of TLRs and co-stimulatory 
molecules as well as production of pathologically important cytokines (Hart et al., 2005a). Most 
studies of DC in IBD demonstrating these findings have focused on myeloid DC (mDC). Recently 
studies have begun to characterise plasmacytoid DC (pDC) in inflammatory bowel diseases 
finding pDC to be present in greater numbers in the inflamed colonic mucosa and MLN of IBD 
patients (Baumgart et al., 2011). In ulcerative colitis (UC), lamina propria pDC are increased 
significantly in inflamed and non-inflamed tissue compared with controls without a  
concomitant increase of mDC (Ng et al., 2009c). pDC may be of particular importance in the 
inappropriate innate immune responses to the microbiota in UC patients. There are no previous 
reports of the role of DC in pouchitis. 
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3.3 Aims 
 
 To identify and characterise lamina propria dendritic cells in the ileum, non-inflamed 
and inflamed ileal pouch of patients with UC 
3.4 Identification of human intestinal lamina propria dendritic cells 
 
 
Patients were recruited and characterised as described (Chapter 2.2.2). Lamina propria 
mononuclear cells (LPMC) were obtained from ileal or pouch biopsies by immediate  
collagenase digestion (Chapter 2.2.5). DC were identified as HLA DR+ lineage- populations on six 
colour flow cytometry (Chapter 2.2.8, Figure 2.2). 
3.5 Aberrant immune characteristics in the ileum of ulcerative colitis patients 
 
 
The phenotype of HLA DR+ lineage negative cells was determined in ileal tissue from both UC 
patients and healthy controls. Specifically, antibody staining for the bacterial pattern 
recognition receptors TLR 4 and 2, homing markers β7 and CCR9 and the co-stimulatory marker 
CD40 was performed (Chapter 2.2.5) and dendritic cells were acquired and analysed by flow 
cytometry as described (Chapter 2.2.7-2.2.8). 
There were no significant differences between UC patients and healthy controls with regard to 
the percentage expression of TLR 4 (39 +-5.8% vs. 31 +-6.6%; p=0.4) or TLR 2 (31 +-11.7% vs. 28 
+- 8.1%; p=0.8) on ileal dendritic cells (Figure 3.1). 
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Figure 3.1 TLR 4 and TLR 2 expression on HLA DR+ lineage negative cells in ileal tissue from healthy controls and 
ulcerative colitis patients. A and B. One parameter histograms representative of TLR 4 and TLR 2 staining in 
healthy controls (n=9) and ulcerative colitis patients (n=9). C and D. Percentage expression of TLR 4 and TLR 2 in 
healthy controls and ulcerative colitis patients. 
 
 
 
There was significantly lower percentage expression of β7 on DC from the ileum of patients 
with UC compared with healthy controls (6.4 +- 3.2% vs. 32 +-6.6%; p=0.001). There was no 
significant difference in CCR9 expression in UC patients (42 +-5.3% vs. 30 +-5.9%, p=0.1) (Figure 
3.2). 
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Figure 3.2 β7 and CCR9 expression on HLA DR+ lineage negative cells in ileal tissue from healthy controls and 
ulcerative colitis patients. A and B. One parameter histograms representative of β7 and CCR9 staining in healthy 
controls (n=9) and ulcerative colitis patients (n=9). C and D. Percentage expression of β7 and CCR9 in healthy 
controls and ulcerative colitis patients. **denote p values ≤0.01. 
 
 
 
There was a significantly lower percentage expression of the activation marker CD40 on 
dendritic cells from the ileum of ulcerative colitis patients compared with controls (49 +-5.7% 
vs. 76 +-3.6%; p=0.004) (Figure 3.3). 
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Figure 3.3 CD40 expression on HLA DR+ lineage negative cells in ileal tissue from healthy controls and ulcerative 
colitis patients. A. One parameter histograms representative of CD40 staining in healthy controls (n=9) and 
ulcerative colitis patients (n=9). B. Percentage expression of CD40 in healthy controls and ulcerative colitis 
patients. ** denotes p values ≤ 0.01. 
 
 
 
Overall, these data indicate a pre-existing altered dendritic cell phenotype in the ileum of 
patients with UC. To determine whether the abnormal expression of β7 and CD40 on dendritic 
cells in the ileum of UC patients was due to differences in DC subsets, further characterisation 
of myeloid and plasmacytoid dendritic cells was performed. 
 
 
In three independent experiments LPMC were obtained by collagenase digestion as described 
and expression of CD123 and CD11c was analysed by six colour flow cytometry within the 
region of HLA DR+ lineage negative cells. A region was drawn on CD123+ve cells and CD11c+ 
cells respectively in reference to their isotype antibodies and this positive staining region was 
back gated to show the regions of CD123+CD11c- and CD11c+CD123- dendritic cells 
respectively (Figure 3.4). 
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Figure 3.4 Backgating of CD123 and CD11c positive cells on HLA DR versus lineage plot. A and B. Histograms 
showing region of positive staining (R5) for CD123 and CD11c (R4) in reference to their isotype control (n=3). C. 
CD11c+ (red) and CD123+ (yellow) DC were backgated to the DC region on the HLA-DR versus lineage cocktail dot 
plot. All plots were compared to isotype-matched controls (n=3). 
 
 
The regions denoting CD123+CD11c- and CD11c+CD123- cells that were HLA DR+ lineage 
negative were drawn for each of the HLA DR versus lineage plots for each experiment to 
identify putative plasmacytoid and myeloid DC. In addition, plasmacytoid and myeloid DC were 
also differentiated on the level of staining for HLA DR as previously described (Bell et al., 2001). 
There was a significantly lower level of expression of HLA DR on putative pDC compared with 
putative mDC in healthy controls (p=0.03), but in UC patients this trend did not reach 
significance (p=0.06) (Figure 3.5). 
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The overall percentage of HLA DR+ lineage negative cells represented approximately 6% of 
LPMC in the ileum of UC patients compared with 2.5% in the ileum of healthy controls 
(p=0.008). The increase in DC in UC patients was accounted for only by a significant increase in 
putative plasmacytoid DC (pDC) (5%+-0.8 vs. 1.7%+-0.4; p=0.01) as there was no difference in 
putative myeloid DC (mDC) between UC ileum and healthy controls (0.9%+-0.1 vs. 1.1%+-0.3; 
p=0.7) (Figure 3.6). 
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Figure 3.5. Median intensity of HLA DR expression on putative pDC and putative mDC from ileal tissue of 
 
healthy controls and ulcerative colitis patients. * denotes p values ≤0.05. 
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Figure 3.6. Mean percentage of LPMC in the ileum of UC patients and healthy controls. Percentage of cells 
identified as pDC and mDC in ileum from healthy controls (n=9) and UC patients (n=9). ** denote p values ≤0.01. 
 
 
Further analysis was performed to assess whether the differences in β7 and CD40 expression 
were as a result of this discrepancy, or due to genuine differences in the proportion of cells 
expressing β7 and CD40. A significantly higher percentage of putative mDC expressed β7 
compared with putative pDC in both healthy controls (12+-4.8% vs. 67+-9.1%; p=0.004) and UC 
patients (1.2+-0.8 vs. 49 +-2.8; p=0.01). There was a significantly lower percentage expression of 
β7 on putative mDC in UC patients compared with healthy controls (p=0.01), but not putative 
pDC in UC patients compared with healthy controls (p=0.1) (Figure 3.7 A). The percentage 
expression of CD40 was significantly higher on putative mDC than on putative pDC in healthy 
controls (87.4 +-3.4% vs. 48.2+-7.8%; p=0.004) and trended towards a higher percentage 
expression on putative mDC compared with putative pDC in UC patients (91 +-9.8% vs. 55 +-2.0; 
p=0.06), but there were no significant differences between UC patients and healthy controls 
(p=0.5). This suggests that the lower proportion of DC expressing CD40 in all DC from UC ileal 
tissue is due to the increased ratio of pDC to mDC. (Figure 3.7 B). 
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Figure 3.7 Mean percentage expression of β7 and CD40 on DC subsets in the ileum of UC patients and healthy 
controls. A. Percentage expression of β7 on putative pDC and mDC from the ileum of healthy controls and 
ulcerative colitis patients. B Percentage expression of CD40 on putative pDC and mDC from the ileum of healthy 
controls and ulcerative colitis patients. ** denotes p values ≤ 0.01. 
 
 
 
3.6 Dendritic cell phenotype differs between the ileum and colon 
(For these studies ileal tissue experiments were performed by J Landy and colonic tissue 
experiments by D Bernardo. This is the only work where dual operators were used). 
 
Following ileostomy closure the pouch microbiota has a more colon-like phenotype (Kohyama 
et al., 2009, Falk et al., 2007). To assess the differences in dendritic cell phenotype that could be 
attributed to adaptive changes to the more colonic microenvironment rather than the 
underlying disease, TLR, homing marker and CD40 expression on DC were compared between 
that found in ileal and colonic tissues in healthy controls. The percentage expression of TLR 4 on 
colonic DC was significantly higher compared to the ileum of healthy controls (57 +-5.6% vs. 31 
+-6.6%; p=0.02) (Figure 3.8 A). There was no significant difference in DC expression of TLR 2 (39 
 
+-5.0% vs. 28 +-8.1%; p=0.3) (Figure 3.8 B). 
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Figure 3.8 TLR 4 and TLR 2 expression on HLA DR+ lineage negative cells in ileal and colonic tissue from healthy 
controls and ulcerative colitis patients. Percentage expression of A TLR 4 and B TLR 2 in the ileum (n=9) and colon 
(n=8) of healthy controls. * denotes p values ≤ 0.05. 
 
 
 
The percentage expression of β7 on colonic DC was significantly higher compared with the 
ileum of healthy controls (54 +-6.3% vs. 32 +- 6.6%; p=0.04) (Figure 3.9 A). The percentage 
expression of CCR9 on colonic DC was significantly lower compared with the ileum (11 +-3.6% 
vs. 30 +-5.9%, p=0.02) (Figure 3.9 B). The percentage expression of CD40 on colonic DC was 
significantly lower compared with the ileum of healthy controls (49 +-4.4% vs. 76 +-3.6%; 
p=0.002) (Figure 3.10). 
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Figure 3.9 β7 and CCR9 expression on HLA DR+ lineage negative cells in ileal and colonic tissue from healthy 
controls and ulcerative colitis patients. Percentage expression of A β7 and B CCR9 in the ileum (n=9) and colon 
(n=8) of healthy controls. * denotes p values ≤0.05. 
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Figure 3.10. CD40 expression on HLA DR+ lineage negative cells from the ileum and colon of healthy controls. 
Percentage expression of DC β7 expression in the ileum (n=9) and colon (n=8) of healthy controls. ** denotes p 
values ≤ 0.01. 
 
 
 
3.7 Aberrant immune characteristics in the non-inflamed pouch of ulcerative colitis 
patients 
 
To assess DC characteristics in the pouch of UC patients LPMC were obtained from UC patients 
without clinical, endoscopic or histological evidence of pouch inflammation. As a further control 
group for the non-inflamed UC pouch group, LPMC were obtained from FAP patients with non- 
inflamed ileal pouches. 
There were no significant differences in the percentage expression of TLR 4 on DC from the 
ileum of UC patients, the pouch of UC patients (39 +-5.8% vs. 29 +- 4.6 %) or the pouch of FAP 
patients (25 +-6.7%) (χ2=2.53, p=0.3). There were also no significant differences in the 
percentage expression of TLR 2 on DC from the ileum and pouch of UC patients (31 +-11.6% vs. 
27 +- 4.5%) or the pouch of FAP patients (22 +-7.1%) (χ2= 0.15, p=0.9) (Figure 3.11). 
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Figure 3.11 TLR 4 and TLR 2 expression on HLA DR+ lineage negative cells in ileal tissue and non-inflamed pouch 
tissue from ulcerative colitis patients and non-inflamed pouch tissue from FAP patients. A and B. One parameter 
histograms representative of TLR 4 and TLR 2 staining in the ileum of ulcerative colitis patients (n=9), the non- 
inflamed pouch of ulcerative colitis patients (n=14) and the non-inflamed pouch of FAP patients (n=8). C and D. 
Percentage expression of TLR 4 and TLR 2 in the ileum and pouch of UC patients and in the pouch of FAP patients. 
 
 
 
There were significant differences in the percentage expression of β7 on DC (χ2=14.9, 
p=0.0006). The percentage expression of β7 on DC in the non-inflamed pouch of UC patients 
was higher compared with the ileum of UC patients (27 +-2.5% vs. 6 +-3.2%, p≤0.001). The 
percentage expression of β7 on DC from the pouch of FAP patients was elevated compared 
with the ileum of UC patients (37 +-7.9% vs. 6 +-3.2%, p=0.002). The proportion of DC 
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expressing β7 from the pouch of FAP patients compared with the pouch of UC patients was not 
significantly different (p=0.2). 
 
 
There were significant differences in the percentage expression of CCR9 on DC (χ2=7.9, p=0.02). 
The percentage expression of CCR9 on DC was not significantly different between the pouch of 
UC or FAP patients compared with the ileum of UC patients (51 +-2.8% vs. 33 +- 3.9% vs. 42 +- 
5.3%), but was significantly lower in the pouch of FAP patients compared with the pouch of UC 
patients (p=0.006) (Figure 3.12). 
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Figure 3.12 β7 and CCR 9 expression on HLA DR+ lineage negative cells in ileal tissue and non-inflamed pouch 
tissue from ulcerative colitis patients and non-inflamed pouch tissue from FAP patients. A and B. One parameter 
histograms representative of β7 and CCR9 staining in the ileum of ulcerative colitis patients (n=9), the non- 
inflamed pouch of ulcerative colitis patients (n=14) and the non-inflamed pouch of FAP patients (n=8). C and D. 
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Percentage expression of β7 and CCR9 in the ileum and pouch of UC patients and in the pouch of FAP patients. ** 
denote p values ≤ 0.01. 
 
 
 
 
There were no significant differences in the percentage expression of the co-stimulatory marker 
CD40 on DC in the pouch of UC (62 +-3.1%) or FAP patients (66 +-5%) compared with the ileum 
of UC patients (49 +-5.7%) (χ2=4.5, p=0.09) (Figure 3.13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13 CD40 expression on HLA DR+ lineage negative cells in ileal tissue and non-inflamed pouch tissue 
from ulcerative colitis patients and non-inflamed pouch tissue from FAP patients. A. One parameter histograms 
representative of CD40 staining in the ileum of ulcerative colitis patients (n=9), the non-inflamed pouch of 
ulcerative colitis patients (n=14) and the non-inflamed pouch of FAP patients (n=8). B. Percentage expression of 
CD40 in the ileum and pouch of UC patients and in the pouch of FAP patients. 
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3.8 Aberrant immune response in ulcerative colitis patients with pouchitis 
 
 
There are considerable data to suggest that the pouch microbiota drives inflammation of the 
pouch. Experiments were undertaken to determine whether there were differences in pattern 
recognition receptor expression on DC in the inflamed pouch of UC patients. 
In patients with active pouchitis (diagnosed clinically, endoscopically and histologically) with a 
PDAI ≥7, there was a significantly higher proportion of DC expressing TLR 4 (44 +-4.8% vs. 29 +- 
5.3%, p=0.04) but not TLR 2 (42 +-4.2% vs. 27 +-5.9%, p=0.09) compared with UC patients with 
no pouch inflammation (Figure 3.14). 
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Figure 3.14 TLR 4 and TLR 2 expression on HLA DR+ lineage negative cells in pouch tissue from ulcerative colitis 
patients without inflammation and with pouchitis. A and B. One parameter histograms representative of TLR 4 
and TLR 2 staining in ulcerative colitis patients without pouchitis (n=14) and ulcerative colitis pouchitis patients 
(n=15). C and D. Percentage expression of TLR 4 and TLR 2 in ulcerative colitis patients without pouchitis and 
ulcerative colitis pouchitis patients. * denotes p values ≤0.05. 
 
 
 
Lamina propria DC in pouch tissue from patients with active pouchitis had significantly altered 
expression of gut homing markers, with an increase in the percentage expression of β7 (40 +- 
4.9% vs. 27 +- 2.5%, p=0.04) and a significant reduction in the percentage expression of CCR9 
(35 +-4% vs. 51 +- 2.8%, p=0.006) compared with UC patients without pouch inflammation 
(Figure 3.15). The percentage expression of the co-stimulatory marker CD40 was also 
significantly elevated on DC in pouch tissue from patients with active pouchitis compared with 
UC patients without pouch inflammation (80 +-2.6% vs. 62 +-3.1%, p=0.0008) (Figure 3.16). 
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Figure 3.15 β7 and CCR9 expression on HLA DR+ lineage negative cells in pouch tissue from ulcerative colitis 
patients without inflammation and with pouchitis. A and B. One parameter histograms representative of β7 and 
CCR9 staining in ulcerative colitis patients without pouchitis (n=14) and ulcerative colitis pouchitis patients (n=15). 
C and D. Percentage expression of β7 and CCR9 in ulcerative colitis patients without pouchitis and ulcerative colitis 
pouchitis patients. * and ** denote p values ≤0.05 and 0.01 respectively. 
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Figure 3.16 CD40 expression on HLA DR+ lineage negative cells in pouch tissue from ulcerative colitis patients 
without inflammation and with pouchitis. A. One parameter histograms representative of CD40 staining in 
ulcerative colitis patients without pouchitis (n=14) and ulcerative colitis pouchitis patients (n=14). B. Percentage 
expression of CD40 in ulcerative colitis patients without pouchitis and ulcerative colitis pouchitis patients. ** 
denotes p values ≤ 0.01. 
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3.9 Discussion 
 
 
This is the first study to identify and characterise DC in the pouch of UC and FAP patients. Here 
an aberrant DC phenotype was identified to be pre-existent in the non-inflamed ileal tissue of 
UC patients undergoing RPC. In the ileum of UC patients compared with healthy controls, there 
was abnormal expression of gut homing markers (reduced β7) and reduced expression of 
activation marker CD40. Further analysis revealed that the abnormal DC phenotype in UC 
patients was due to the expansion of the plasmacytoid DC subset in these patients. This has 
been demonstrated in other studies of colonic mucosa from UC patients (Baumgart et al., 2011, 
Ng et al., 2009c). Others have also demonstrated CD11c- HLA DR+ cells in UC to express lower 
levels of activation and co-stimulatory markers including CD40 and to be weak stimulators of 
allogeneic T cell proliferation (Ng et al., 2009c). 
 
 
A lower proportion of plasmacytoid DC expressed β7 compared with mDC in both UC patients 
and healthy controls; but in UC patients, β7 expression was also reduced in mDC compared 
with controls. Aberrant homing to the intestine in UC patients may therefore not only be as a 
consequence of the relative expansion of pDC, but a genuine loss of DC expressing β7. β7 pairs 
with the integrin α4 to designate gut homing. β7 also pairs with the integrin αE (CD103). Our 
group previously demonstrated reduced expression of CD103 on colonic DC from UC patients. 
This finding was again present in both the CD11c+ and CD11c- subsets (Ng Sc, 2008). 
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This may suggest that in UC patients there is an increase in DC homing to the ileum as well as 
imprinting small bowel homing of lymphocytes (see below). This should be interpreted with 
caution however. The ileal tissue in UC patients was taken from patients who had previously 
undergone subtotal colectomy and further work is necessary to evaluate whether our findings 
are consistently present in the terminal ileum of UC patients with intact anatomy. 
 
 
In a recent study, DC expressing α4β7 induced Treg and IL-10 producing T cells and lack of α4β7 
in the bone marrow innate immune compartment accelerated T cell mediated colitis which 
correlated with a reduction of intestinal CD103+DC (Villablanca et al., 2013). The expression of 
CCR9 on DC may also impact on the type of T cell responses. Murine studies demonstrate 
CCR9+ DC are less activated or mature than CCR9 low DC (Drakes et al., 2009). The expansion of 
the pDC subset in UC patients and reduced expression of CD40 may lead to weaker stimulation 
of T cells on presentation of microbial antigens (Steinman et al., 2003) encountered. Recent 
work from our group also found less mature, less stimulatory DC in the colon of quiescent UC 
with lower expression of CD40 and CD80 and CD86 and a reduced capacity of colonic and blood 
DC to stimulate allogeneic T cells (Al-Hassi et al., 2013, Mann et al., 2013b). Further study is 
necessary to assess the ability of DC in the ileum of UC patients to stimulate T cells, the type of 
T cell responses they stimulate and the homing markers they imprint. Gut derived DC also 
effect B lymphocyte intestinal homing and IgA secretion (Mora et al., 2006). This might impact 
not only on IgA-specific responses to antigen, but also the shaping of the microbiota and 
control of antigenic exposure at the epithelial surface layer. Further study is necessary to assess 
the impact of reduced DC β7 expression on B lymphocyte gut homing. 
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DC characteristics in the ileum and colon of healthy controls were assessed to ascertain the 
differences that may be accountable to the more colonic microenvironment and those that may 
be inherent to patients with UC. This is the only part of this work that involved dual operators 
and this should therefore be taken with caution. However, more recently published work from 
our group confirms differences between ileal and colonic DC (Mann et al., 2013a) and the 
differential imprinting of gut homing markers on T-cells by ileal and colonic DC (Mann et al., in 
submission). 
 
 
In the colon of healthy controls there was increased expression of TLR 4 compared with the 
ileum. This may reflect the increased requirement for microbial sensing due to the increased 
number of bacterial antigens present. CD40 expression was reduced in the normal colon 
compared with the ileum of healthy controls, possibly suggesting an increased tolerance of 
colonic DC to the increased microbial content. 
 
 
In the colon, β7 expression was increased and CCR9 expression reduced compared with the 
ileum. Recent work from our group found ileal, but not colonic DC were able to generate 
CCR9+ T-cells (Mann et al., in submission). The relative expression of CCR9 and β7 may 
therefore determine a gradient of preferential homing to the small or large bowel. Changes in 
DC homing markers in the pouch of UC patients might represent changes in the microbial 
microenvironment following RPC. In UC patients without pouchitis DC β7 expression was 
increased compared with the ileum of UC patients. However, there was not an expected 
reduction in the proportion of CCR9+ DC. β7 expression was not significantly increased in FAP 
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pouch DC compared with UC patients. However, CCR9 expression was significantly reduced in 
FAP patients compared with UC patients with non-inflamed pouches. The combination of the 
proportion of DC expressing β7 and CCR 9 in FAP and UC pouches suggest a trend towards less 
“colon-like” patterns of DC homing marker expression in UC patients that may be aberrant and 
not solely accounted for by the change in the microenvironment to a more colon like 
phenotype. The number of FAP patients was small and further samples from patients with FAP 
are necessary for more robust statistical analysis. 
 
 
FAP patients are the only pouch control group available and as a group where the development 
of pouchitis is rare, offer a comparison to the UC patients where pouchitis is common. 
However, the inclusion of the FAP pouch group as another control may also add complexity as 
little is known regarding DC characteristics in FAP. FAP may not represent a “normal” pouch 
response to the altered microbiota following ileostomy closure. Increasing data demonstrate 
inflammatory signatures in non-colitis associated colorectal cancer (Grivennikov et al., 2012). 
 
 
In the inflamed pouch of UC patients the proportion of DC expressing TLR 4 was significantly 
increased. This has been previously demonstrated in colonic DC in IBD (Hart et al., 2005b). 
Increased expression of TLRs by DCs and other cells interacting with the microbiota may lead to 
increased recognition of bacterial products and enhanced responses to them. The presence of 
elevated DC expression of TLRs only in inflammation suggests a number of factors found in 
inflammation may be responsible. Cytokines, including IL-6, TNF-α, and interferon, that are 
present in the inflamed mucosa of patients with IBD can cause increased expression of TLR2 
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and/or TLR4 (Martins et al., 2003). Bacterial products may act directly via TLRs to upregulate 
further TLR expression on DCs. In a study of TLR 4 and 2 expression in UC patients, positively 
stained cells accumulated subepithelially and were preferentially detectable close to the crypts 
(Hausmann et al., 2002). Increased intestinal permeability may therefore lead to greater 
exposure to microbial products and bacterially driven increases in TLR expression. 
 
 
In pouchitis, DC expression of β7 was significantly increased and CCR9 expression significantly 
reduced. This may represent an increased specificity of DC homing and potentially T-cell 
homing to the pouch in the presence of intestinal inflammation. Increased activation is also 
supported by the significant increase in DC expressing CD40 in pouchitis patients. 
 
 
Overall, the DC phenotype in pouchitis suggests a critical role in the maintenance of 
inflammation in the pouch of UC patients, in response to microbial signals. The findings 
regarding DC phenotype in the ileum and the non- inflamed pouch of UC patients also suggest 
that aberrant DC characteristics, in particular aberrant homing marker expression in UC 
patients may also play a critical role in the colitogenic susceptibility following RPC for UC. 
Further work assessing DC function and B and T cell responses is necessary to understand the 
impact these aberrant DC characteristics may hold for UC patients undergoing and following 
RPC. Understanding the molecular defects enabling interaction between the pouch microbiota 
and lamina propria DC is likely to further elucidate the aetiology of pouch inflammation. 
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Chapter 4. Epithelial tight junction protein expression in pouchitis 
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4.1 Abstract 
 
 
Introduction: Impaired barrier function is a feature of active IBD, but is also present in 
quiescent disease. Underlying molecular defects of cell to cell junctions that might selectively 
enhance the interactions between luminal antigens and lamina propria antigen presenting cells 
are likely to be critical primary factors in the pathogenesis of pouchitis. We hypothesised that 
epithelial cell tight junction protein expression would be altered in the non-inflamed as well as 
inflamed pouch tissue of UC patients and may differ between early and late phases of pouch 
inflammation. We aimed to characterise epithelial tight junction expression in the non-inflamed 
pouch of patients with UC and in acute and chronic pouchitis. 
Methods: Freshly isolated epithelial cells were identified from pouch mucosal samples of UC 
patients with pouchitis (13) (chronic pouchitis n=9, acute pouchitis n=4) and without pouchitis 
(n=18) and FAP patients (8). Epithelial cell expression of ZO-1, claudin 1 and claudin 2 were 
measured by multicolour flow cytometry. 
Results: The proportion of pouch epithelial cells expressing claudin 2 was increased in the non- 
inflamed pouch of UC patients compared with FAP patients. In acute pouchitis the proportion 
of epithelial cells expressing claudin 2 was increased whereas in chronic pouchitis there was a 
reduction in the level of expression of both ZO-1 and claudin 1 expression. 
Conclusions: The increased proportion of epithelial cells expressing claudin 2 in the non- 
inflamed pouch of UC patients and in acute but not in chronic pouchitis suggests that increased 
expression of claudin 2 is an early event in the development of pouch inflammation in UC 
patients. 
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4.2 Background 
 
 
The intestinal mucosal epithelium limits interactions between luminal microbial antigens and 
the immune cells in the intestinal lamina propria. Bacterial translocation is defined as the 
passage of viable bacteria from the gastrointestinal tract to extra-intestinal sites. Three primary 
mechanisms promoting bacterial translocation are: (a) disruption of the microbiota, (b) 
increased permeability of the intestinal mucosal barrier, and (c) deficiencies in host immune 
defenses. These mechanisms act synergistically to promote inflammatory responses in the gut 
(Berg, 1999, Bowden et al., 1981). 
 
 
Disruption of the epithelial barrier is a feature of gut inflammation and contributes to the 
pathogenesis of inflammatory bowel diseases (IBD) (Edelblum and Turner, 2009). Both Crohn’s 
disease and ulcerative colitis (UC) share common features of epithelial barrier disruption, such 
as epithelial breaks, a reduction in tight junction strands, and glandular atrophy (Bruewer et al., 
2006, Weber and Turner, 2007, Clayburgh et al., 2004). Barrier dysfunction is likely to be 
caused by epithelial damage including apoptosis, erosion and ulceration that are characteristic 
of gut inflammation. Inflammatory cytokines associated with gut inflammation alter epithelial 
permeability through their effects on the junctional complexes (Heller et al., 2005, Zolotarevsky 
et al., 2002, Arrieta et al., 2008). 
 
 
However impaired barrier function is also evident in quiescent IBD and even in first degree 
relatives of Crohn’s disease patients (D'Inca et al., 1999, Peeters et al., 1997). Dysregulation of 
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the epithelial barrier with changes in paracellular permeability due to altered cell to cell 
junctions is likely to be significantly more selective and may be a critical primary factor in the 
pathogenesis of IBD. 
 
 
Genome wide association studies (GWAS) in UC have identified susceptibility defects pertaining 
to barrier dysfunction (Barrett et al., 2009). The most significant association noted is for a single 
nucleotide polymorphism (SNP) of the HNF4α gene. This gene encodes the transcription factor 
hepatocyte nuclear factor 4 α that regulates control of multiple elements of cell to cell junction 
including desmosomes, adherens junctions and tight junctions including claudins (Battle, 2006). 
Numerous studies demonstrate increased expression of claudin 2 and reduced expression of 
claudins 1, 4, 5 and 8 in active UC and Crohn’s disease (Prasad et al., 2005, Zeissig et al., 2007, 
Oshima et al., 2008, Poritz et al., 2011, Das et al., 2012). 
 
 
Barrier properties of ileal pouch mucosa in pouchitis and in non-inflamed pouches are also 
reduced (Kroesen et al., 2008, Merrett et al., 1996, Kroesen et al., 2006, Amasheh et al., 2009b) 
and increased bacterial translocation has been reported in pouches functioning for more than 
twelve months (Kroesen et al., 2008). Amasheh et al. reported increased claudin 2 and reduced 
claudin 1 expression in acute pouchitis. No previous studies have assessed differences in tight 
junction expression in acute and chronic pouchitis or in non-inflamed pouches of ulcerative 
colitis patients compared with FAP patients. 
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4.3 Aims 
 To assess tight junction protein expression in the non-inflamed pouch of ulcerative 
colitis patients compared with FAP patients with ileal pouches 
 To assess tight junction protein expression in the non-inflamed and inflamed pouch of 
ulcerative colitis patients. 
 To assess differences in tight junction protein expression between UC patients with 
acute and chronic pouchitis. 
 
 
4.4 Electron micrographs of non-inflamed and inflamed pouch epithelium 
(performed by Mr N English APRG) 
 
To gain insight into the differences between the inflamed and non-inflamed pouch epithelium, 
electron microscopy was performed on mucosal biopsies from UC patients with and without 
pouchitis. In pouchitis the epithelial villi appeared atrophied with irregularity of the epithelial 
cell luminal surface. The membranes between cells were more loosely arranged with increased 
intercellular distance, and condensation of the peri-junctional cytoskeleton (Figure 4.1). In 
addition, dendritic cells penetrated the epithelial cell layer more frequently (Figure 4.2) 
whereas in the non-inflamed pouch the dendritic cells appeared to be confined to the lamina 
propria. 
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Figure 4.1. Electron micrograph of mucosal epithelium from A. non- inflamed pouch and B. pouchitis. Black bar = 
0.2 micron.  Solid line black arrow = Epithelial tight junction complex.  Dashed black arrow = Desmosomes. 
White arrow showing increased intercellular distance, grey arrow peri-junctional cytoskeleton condensation. 
 
 
 
 
 
Figure 4.2 Electron micrograph demonstrating dendritic cell penetrating between two epithelial cells in 
pouchitis. Black bar = 0.1 micron. Solid black arrow = Dendritic cell. Dashed black arrow = Tight junction complex 
between epithelial cell and dendritic cell. 
B A 
152 
 
 
 
 
4.5 Immunofluorescence microscopy of tight junction proteins 
 
 
To confirm the expression of tight junction proteins ZO-1, claudin 1 and claudin 2, staining of 
frozen sections of pouch tissue was undertaken (as described in chapter 2.2.12). This 
demonstrated the expression of these tight junction proteins in pouch tissue (Figure 4.3). It was 
intended to demonstrate comparisons of the distribution and co-localisation of tight junction 
proteins by immunofluorescence microscopy between pouch tissue from clinically different 
groups of patients. However, sections of tissue from pouchitis samples were of poor quality 
with significant destruction of the epithelial architecture leading to difficulties in adequate 
staining to assess comparisons between samples and differences between different patient 
groups. 
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B 
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Figure 4.3. Immunofluorescence microscopy of tight junction protein expression in pouch and pouchitis samples. 
Panel A. ZO-1 and claudin 1 staining on epithelium from an ulcerative colitis patient with a non-inflamed pouch. 
From left to right panel shows staining with DAPI only, claudin 1, ZO-1 and all three stains combined. 20x 
magnification. Panel B. ZO-1 and claudin 2 staining on epithelium from an ulcerative colitis patient with pouchitis. 
From left to right panel  shows staining with DAPI only, claudin 2, ZO-1 and all three combined. 20x magnification. 
 
 
 
4.6. Flow cytometry for the assessment of epithelial tight junction protein expression- 
optimisation of methodology 
 
The vast majority of studies assessing quantitative differences in tight junction expression 
employ either western blot analysis or RT-PCR. Neither of these methods enables analysis of 
expression on specific cell types, assuming the vast majority of tight junctions expressed will be 
derived from the epithelium. Furthermore, mRNA expression does not necessarily correlate 
with protein expression (Ogasawara et al., 2009a). In order to assess quantitative differences in 
the epithelial expression of ZO-1, claudin 1 and claudin 2 between non-pouchitis and pouchitis 
samples in this study, flow cytometry was undertaken. This has previously been described 
(Drudy et al., 2001, Russ et al., 1998). 
 
 
Removal of the epithelium from biopsy tissue requires incubation with EDTA. This methodology 
has been described previously (Mennigen et al., 2009). Western blotting and RT-PCR, to 
quantify tight junction expression also require the use of EDTA (Amasheh et al., 2012). 
However, calcium chelation by EDTA is used as a method of disrupting tight junctions and 
dissociating confluent monolayers of epithelial cells. EDTA in monolayers of epithelial cell lines 
affects the distribution of ZO-1 (Siliciano and Goodenough, 1988). To demonstrate expression 
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of tight junction proteins by flow cytometry and to assess the effect of EDTA incubation on tight 
junction protein expression, a group of cells previously well defined using flow cytometric 
analysis and from a readily accessible source was initially assessed. 
 
 
Dendritic cells express tight junction proteins in order to penetrate the epithelium whilst still 
preserving barrier function (Rescigno et al., 2001). Studies have also demonstrated expression 
of JAM-A and mRNA expression of other tight junction proteins in circulating dendritic cells and 
other peripheral blood cells, which may be necessary for trafficking of immune cells across the 
endothelium (Ogasawara et al., 2009a, Ostermann et al., 2002, Liu et al., 2000). The expression 
of other tight junction proteins has not previously been demonstrated in human peripheral 
blood cells. ZO-1, claudin 1 and claudin 2 expression were therefore assessed on HLA DR + 
lineage negative cells from PBMCs (Figure 4.4). ZO-1 (96 +-2.8%; IR 8.8 +-1) and to a lesser 
extent claudin 1 (33 +-7.3%; IR 5 +-2.7), but not claudin 2 were expressed on dendritic cells 
from peripheral blood of healthy controls. 
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Figure 4.4. ZO-1 and claudin 1 expression on HLA DR+ lineage negative PBMCs. A. Histogram of cell distribution 
staining positive for DR (x axis) and Lineage (y axis). Dendritic cell population is defined as DR+ (>10
1) 
and Lineage 
negative (<10
1
). B. Single parameter histograms representative of isotype control and ZO-1 expression, C. claudin 1 
expression and D. claudin 2 expression on peripheral blood DCs. E. Percentage expression and F. Median intensity 
ratio of ZO-1, claudin 1 and claudin 2 representing the levels of tight junction expression on healthy control 
peripheral blood dendritic cells (n=3). 
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To assess whether EDTA incubation may reduce the level of expression in addition to 
redistributing tight junctions, PBMCs were incubated without EDTA and with 1mM EDTA for 30 
and 60 minutes (Figure 4.5). Contrary to the expected reduction in expression of ZO-1 following 
EDTA incubation, there was a slight increase in the level of expression, although there appeared 
to be no effect of a longer incubation at 60 minutes compared with 30 minutes incubation with 
1mM EDTA (IR 17 +-1.4 vs. 23.5 +-2.1 vs. 21 +-2.8). 
 
 
Figure 4.5 ZO-1 expression on HLA DR+ lineage negative PBMCs with and without EDTA incubation. Median 
intensity ratio of ZO-1 expression after 0, 30 and 60 minutes incubation with 1mM EDTA (One experiment 
performed in duplicate). 
 
 
Experiments on CACO-2 cells were next performed to provide a positive control and to further 
assess the effect of EDTA incubation on the level of tight junction expression in an intestinal 
epithelial cell line. CACO-2 cells are of an epithelial cell line originally obtained from a human 
colonic adenocarcinoma. However, differentiation of these cells on culture leads to a 
heterogeneous population of cells ranging between colonocytes and foetal and mature ileal 
enterocytes (Sambuy et al., 2005). CACO-2 cells have been extensively used as a model of the 
intestinal epithelial barrier and barrier properties and tight junction expression on these cells is 
well established (Sambuy et al., 2005, Sun et al., 2008). 
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CACO-2 cells were cultured as described (Chapter 2.1.2). Cells were removed from wells using a 
sterile cell scraper and treated with 1mM EDTA for 30 or 60 minutes. Staining of CACO-2 cells 
with antibodies for ZO-1, claudin 1 and claudin 2 was then undertaken. ZO-1 (80 +-4%, IR 13.7 
+-2.8) and claudin 1 (30 +-17% IR 10.8 +-9.6), but not claudin 2 were detected on CACO-2 cells 
by flow cytometry after 1mM EDTA incubation for 30 minutes. There were no significant 
changes in ZO-1 (80 +-4%, IR 12 +- 3; p=1, 0.3) or claudin 1 (29 +-17%, IR 9.4 +-8; p=0.4, 0.5) 
expression following incubation with 1mM EDTA for 60 minutes (Figure 4.6). 
 
 
 
 
Figure 4.6. ZO-1 and claudin 1 expression on CACO-2 cells. A. Percentage expression of CACO-2 cells expressing 
ZO-1, claudin 1 or claudin 2 after 30 and 60 minute incubations with 1mM EDTA. B. Median intensity ratio of ZO-1, 
claudin1 or claudin 2 expression after 30 and 60 minute incubations with 1mM EDTA. Results representative of 
three independent experiments. 
 
 
Mucosal biopsies of pouch tissue were next taken from patients undergoing follow-up 
pouchoscopy. The epithelium was removed following incubation with EDTA. To assess the 
distribution of the mucosal epithelial cells on the basis of light scatter, the epithelium removed 
B A 
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following EDTA incubation was combined with the lamina propria cells following separate 
collagenase digestion and staining for pancytokeratin (PCK) was undertaken. A region was 
drawn to exclude the lymphocytes and include only the PCK positive staining region when back 
gated to show the distribution of PCK positive cells on the light scatter histogram. This gating 
strategy was then used to define the distribution of epithelial cells on the light scatter 
histogram when the epithelium was analysed without the addition of the lamina propria cells. 
Epithelial cells were identified as staining positive for pancytokeratin (C-11) and a positive 
region was drawn in reference to the isotype antibody and ZO-1, claudin 1 and claudin 2 were 
analysed gating on the PCK positive region (Figure 4.7). 
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Figure 4.7. Identification of epithelial cells and tight junction protein expression. Ai. Forward scatter versus side 
scatter plot of mixed epithelial and lamina propria cells within live cell gate. Aii. Single parameter histogram 
demonstrating region of CD3+ staining cells. Aiii. CD3+ staining back gated on light scatter histogram. Bi and Bii. 
Histograms demonstrating positive region of PCK positive staining in reference to isotype control antibody. A 
region was drawn that excludes irrelevant isotype-matched control antibody and nonspecific staining and all 
events exceeding isotype control staining intensity were regarded as positively labeled epithelial cells. Biii. PCK + 
staining back gated on light scatter histogram. Ci. Forward scatter versus light scatter plot of isolated epithelial 
cells with region drawn to exclude CD3+ contamination (percentage expression of CD3+ cells= 0.4%; n=3). Cii and 
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Ciii. Single parameter histograms representative of isotype control and epithelial positive staining of tight junction 
protein antibody (here ZO-1) using super-enhanced Dmax (SED) normalised subtraction. The shaded areas of 
histograms represent the proportion of DC expressing each marker after subtraction of staining with an isotype- 
matched control. 
 
 
 
4.7 Tight junction protein expression in the non-inflamed pouch of ulcerative colitis 
patients and FAP patients 
 
 
Employing the methods described above, flow cytometric analysis of tight junction expression 
was next undertaken in non-inflamed pouch tissue from patients with UC and with FAP. There 
was a significantly greater proportion of epithelial cells expressing claudin 2 in UC patients 
compared with FAP patients (28 +-7% vs. 6 +-3.9%; p=0.05). There were no significant 
differences between UC patients without pouchitis and FAP pouch patients, in the proportion 
of epithelial cells expressing  ZO-1 (81 +-2.5% vs. 78 +-2.9%; p=0.4) or claudin 1 (28 +-5.7% vs. 
19 +-6.8%; p=0.4). There were no significant differences between UC patients without pouchitis 
and FAP pouch patients in the median intensity ratio of epithelial cell expression of ZO-1 (5.6 +- 
0.6 vs. 5.9 +-0.4; p=0.9), claudin 1  (4.2 +-1 vs. 2.6 +-0.9; p=0.4) or claudin 2 (0.8 +-0.2 vs. 0.5 +- 
0.5; p=0.2) (Figure 4.8). 
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Figure 4.8. Epithelial cell tight junction protein expression in ulcerative colitis patients without pouchitis and FAP 
patients with ileal pouches. A. Representative histograms of ZO-1, claudin 1 and claudin 2 staining for FAP and non 
pouchitis. B. Percentage expression of ZO-1, claudin 1 and claudin 2 in epithelial cells of ulcerative colitis patients 
without pouchitis (n=18) and FAP pouch patients (n=8). C. Median intensity ratio of ZO-1, claudin 1 and claudin 2 in 
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epithelial cells of ulcerative colitis patients without pouchitis and FAP pouch patients. * denotes p values ≤0.05. 
 
 
 
 
 
 
4.8 Tight junction protein expression in the non-inflamed pouch of ulcerative colitis 
patients and acute and chronic pouchitis patients 
 
 
The median intensity ratio of ZO-1 (5.8+-0.6 vs. 3.6 +-0.7; p=0.009) and claudin 1 (4.2 +-1 vs. 1.3 
 
+-0.2; p=0.01) (i.e. the level of staining per cell) was significantly lower in pouchitis compared 
with non-pouchitis patients. However, there were no significant differences in the proportion of 
epithelial cells expressing ZO-1 (81 +-2.5% vs. 83 +-2.2%; p=0.7) or claudin 1 (28 +-5.7% vs. 42 +- 
8.9%; p=0.1) between UC patients without pouchitis and those with pouchitis. There were no 
significant differences in either the proportion of epithelial cells expressing claudin 2 (28 +-7% 
vs. 31 +-9.5%; p=0.8) or the median intensity ratio of claudin 2 expression between pouchitis 
and non-pouchitis patients (0.8 +-0.2 vs. 1.5 +-0.5; p=0.2) (Figure 4.9). 
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Figure 4.9. Epithelial cell tight junction protein expression in ulcerative colitis patients with and without 
pouchitis. A. Representative histograms of ZO-1, claudin 1 and claudin 2 staining for non pouchitis and pouchitis. 
B. Percentage expression of ZO-1, claudin 1 and claudin 2 in epithelial cells of ulcerative colitis patients without 
pouchitis (n=18) and pouchitis patients (n=13). C. Median intensity ratio of ZO-1, claudin 1 and claudin 2 in 
epithelial cells of ulcerative colitis patients without pouchitis and pouchitis patients. ** denotes p values ≤0.01 
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On further analysis, differences were noted in tight junction expression between UC patients 
with acute and with chronic pouchitis (as defined in section 1.3i). There were significant 
differences in the percentage expression of ZO-1 on epithelial cells between patients with acute 
and chronic pouchitis and those without pouch inflammation (χ2=8.7, p=0.01). The percentage 
expression of ZO-1 on epithelial cells was significantly higher in acute pouchitis compared with 
chronic pouchitis (92 +-0.9% vs. 79 +-2%, p=0.01) and compared with non-pouchitis patients (81 
+-2.5%, p=0.01). There were also significant differences in the percentage expression of claudin 
2 (χ2=8.95, p=0.01). In acute pouchitis the proportion of epithelial cells expressing claudin 2 (74 
+-3%) was significantly greater compared to both patients without pouchitis (28 +-7%, p=0.006) 
and those with chronic pouchitis (12 +-7%, p=0.02) (Figure 4.10 A). 
 
 
There were significant differences in the median intensity ratio of ZO-1 between patients with 
acute and chronic pouchitis and those without pouch inflammation (χ2=12.5, p=0.002). The 
median intensity ratio of ZO-1 was significantly lower in chronic pouchitis patients (2.5+-0.3) 
compared with non-pouchitis patients (5.6 +-2.6, p=0.007), greater in acute pouchitis patients 
compared with chronic pouchitis patients (6 +-1.6 vs. 2.5 +-0.3; p=0.03), but not significantly 
different between acute pouchitis and non-pouchitis patients (p=0.8). There were significant 
differences in the median intensity ratio of claudin 1 expression (χ=6.4, p=0.04), but there were 
no significant differences with Dunn’s post-test comparison. 
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Figure 4.10. Epithelial cell tight junction protein expression in ulcerative colitis patients without pouchitis and 
with acute and chronic pouchitis A. Percentage expression of ZO-1, claudin 1 and claudin 2 in epithelial cells of UC 
patients without pouchitis (n=18) and acute (n=4) and chronic pouchitis (n=9) patients. B. Median intensity ratio of 
ZO-1, claudin 1 and claudin 2 in epithelial cells of UC patients without pouchitis and acute and chronic pouchitis 
patients. ** denotes p values ≤ 0.01. 
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4.9 Cytokine expression in the inflamed and non-inflamed pouch of ulcerative colitis 
patients 
 
It is not clear whether the alterations in tight junction protein expression in IBD are primary or 
secondary to inflammation. A number of studies show pro-inflammatory cytokines regulate 
tight junction proteins (Heller et al., 2005, Suzuki et al., 2011, Weber et al., 2010). To assess the 
cytokine levels in supernatants of mucosal samples from ulcerative colitis patients without 
pouch inflammation and those with pouchitis, cytokine bead array (multiplex analysis) was 
undertaken (Chapter 2.2.10). 
IL-6 levels in the supernatants of mucosal biopsies from patients with pouchitis (2371+- 
538pg.ml-1) were significantly higher compared with UC patients without pouchitis (637 +- 
102pg.ml-1, p=0.02) and this difference was most significant in patients with acute pouchitis 
(2404 +- 599pg.ml-1) compared to patients without pouchitis (637 +-102pg.ml-1, p=0.009), but 
showed only a trend towards significance for patients with chronic pouchitis (2360 +-716 pg.ml- 
1, p=0.08; χ2=8.8, p=0.03). TNF levels in the supernatants of mucosal biopsies from pouchitis 
patients compared with UC patients without pouchitis were significantly higher (20 +-5.5pg.ml-1 
v 10 +-0.5pg.ml-1, p=0.005). The level of TNF was significantly greater in the supernatants of 
mucosal biopsies from patients with chronic pouchitis compared with ulcerative colitis patients 
without pouchitis (20 +-7.8 pg.ml-1, p=0.008), but did not reach significance in patients with 
acute pouchitis (18 +-7.9 pg.ml-1, p=0.06; χ2=7.9, p=0.02) (Figure 4.11). 
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Figure 4.11. IL6 and TNF levels from pouch biopsy supernatants in ulcerative colitis patients without pouchitis 
and with acute and chronic pouchitis. A. IL6 levels in supernatants of ulcerative colitis patients without pouchitis 
(n=16) and those with acute (n=4) and chronic pouchitis (n=9). B. TNF levels in supernatants of ulcerative colitis 
patients without pouchitis (n=16) and those with acute (n=4) and chronic pouchitis (n=9). ** denotes p values 
≤0.01. 
 
 
 
 
There were no differences in levels of IL-2 (11.9 +-0.8 vs. 12+-0.5 pg.ml-1   vs. 12+-0.6 pg.ml-1, χ2 
=1.53 p=0.46), IL-4 (13 +-0.5 pg.ml-1   vs. 13.5 +-0.7 vs. 13.7 +-0.9 pg.ml-1, χ2=1.6, p=0.46) or IL-10 
 
(10.6 +-0.7 pg.ml-1  vs. 12.3 +-2.7 pg.ml-1 vs. 10.7 +-0.7 pg.ml-1, χ2=0.9, p=0.6) in the 
supernatants of mucosal samples between UC patients without pouch inflammation and those 
with acute or chronic pouchitis (Figure 4.12). 
A B 
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Figure 4.12. Mucosal cytokine levels from pouch biopsy supernatants in ulcerative colitis patients with and 
without pouchitis. IL-2, IL-4 and IL-10 levels in supernatants of ulcerative colitis patients without pouchitis (n=16) 
and those with acute (n=4) and chronic pouchitis (n=9). 
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4.10 Discussion 
 
 
Significant differences in tight junction protein expression were found between UC patients and 
FAP patients, and between UC patients without pouch inflammation, those with pouch 
inflammation and those with acute or chronic pouchitis. There are no previous studies 
comparing tight junction protein expression between UC and FAP pouch patients. Similarly 
there are no previous studies assessing differences between acute and chronic pouch 
inflammation. 
 
 
These results suggest an increase in claudin 2, the “pore-forming” tight junction protein, in the 
non-inflamed pouch of UC patients compared with FAP patients. In acute pouchitis the 
proportion of epithelial cells expressing claudin 2 and ZO-1 was increased whereas in chronic 
pouchitis there was a reduction in the level of expression of both ZO-1 and claudin 1 
expression. Claudin 2 is a “pore-forming” tight junction that reduces trans epithelial resistance 
and can also directly decrease the “tightening” barrier function of claudin 1 (Turksen, 2004). In 
the pouch, the distribution of claudin 2 along the crypt-villus axis is not known. However, in the 
distal ileum and colon, expression is restricted to the crypts (Rahner et al., 2001). An increase in 
the proportion of epithelial cells expressing claudin 2 could present a mechanism by which UC 
patients are more susceptible to microbial signalling compared with FAP patients. 
 
 
The elevation of claudin 2 expression in acute but not in chronic pouchitis compared with the 
non inflamed pouch of ulcerative colitis patients may suggest that increased expression of the 
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“pore forming” tight junction claudin 2 is an early event in the development of inflammation. In 
chronic pouchitis, there was lower expression of ZO-1 and claudin 1 that represents a loss of 
integral tight junction function and a reduction in the “tightening” effect of claudin 1 
expression. Electron micrographs of the epithelium from pouchitis suggested a destruction of 
the villi and a loosening of cell to cell contacts in the inflamed pouch. This could represent an 
ongoing defect in epithelial barrier function leading to the persistence of microbial stimulation 
of the immune response as suggested in chapter 3 by increased TLR 4 and CD40 expression on 
DC in pouchitis. 
 
 
Tight junction expression may be secondary to increases in the levels of pro-inflammatory 
cytokines. The levels of both IL-6 and TNF were elevated in acute pouchitis compared with non 
pouchitis samples. IL-6 has been demonstrated to be elevated in UC, Crohn’s disease and in the 
inflamed and non-inflamed pouch of UC patients when compared with FAP patients (Hart et al., 
2005a, Bernardo et al., 2012b, Leal et al., 2008, Gionchetti et al., 1994). In CACO-2 cells IL-6 
increases expression of claudin 2 via trans-signalling by activating the MEK/ERK and PI3K 
pathways and increased expression of Cdx2 acting at the promoter region of claudin 2 (Suzuki 
et al., 2011). TNF alters epithelial barrier function by reorganisation of tight junction proteins 
including ZO-1 and claudin 1 (Bruewer et al., 2003). TNF-α increases Myosin Light Chain Kinase 
(MLCK) phosphorylation and inhibition of MLCK in TNF-α treated epithelial monolayers can 
acutely restore barrier function (Zolotarevsky et al., 2002). Furthermore, MLCK-activation 
promotes IL-13 expression and claudin 2 synthesis (Weber et al., 2010). 
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The distribution and co-localisation of tight junction proteins are likely to be critical with regard 
to their functional effects on barrier function in addition to the relative amounts of the 
different tight junction proteins expressed. Tight junction proteins are found both localised to 
the tight junction complex as well as within an intracellular pool, with dynamic shifts between 
these two pools enabling rapid structural and functional responses to stimuli (Shen et al., 
2008b). It had been intended to study the localisation of tight junction proteins in inflamed and 
non inflamed pouches of patients with ulcerative colitis by immunofluorescence microscopy. 
However, using frozen sections, the epithelial architecture, particularly from patients with 
severe inflammation was too distorted to allow for any relevant comparisons, although staining 
for ZO-1, claudin 1 and claudin 2 was demonstrated on inflamed and non-inflamed pouch 
samples. The disruption of the epithelial architecture in severe pouchitis itself demonstrates  
the disturbance of the epithelial barrier in pouchitis. 
 
 
Flow cytometry with labelling of epithelial cells enables a quantitative analysis of tight junction 
protein expression specifically on epithelial cells. The use of EDTA, a chelating agent that is used 
to dissociate epithelial cells in confluent monolayers may have altered the level of expression of 
tight junction proteins. However, the results from both the experiments of PBMC and CACO-2 
cells did not demonstrate any significant alteration in the level of tight junction protein 
expression following incubation with EDTA. 
 
 
Expression of ZO-1 and Claudin-1 has not been previously demonstrated in human peripheral 
dendritic cells. JAM-A has been identified on human peripheral blood neutrophils, monocytes, 
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lymphocytes and erythrocytes (Liu et al., 2000), but only ZO-1 mRNA expression has been 
previously identified in peripheral blood dendritic cells (Ogasawara et al., 2009b). The finding of 
ZO-1 and claudin 1 expression on peripheral blood DC may have implications regarding the 
trafficking of these cells across the endothelium. Further investigation regarding the expression 
of tight junction proteins on PBMCs and their functional importance in endothelial 
transmigration in health and disease is necessary. 
 
 
CACO-2 cells are an established model of the intestinal barrier and were studied as a positive 
control for the expression of tight junction proteins. ZO-1 and claudin 1, but not claudin 2 were 
identified on CACO-2 cells. CACO-2 cells in culture undergo a process of differentiation leading 
to the formation of a monolayer of cells, which express several morphological and functional 
characteristics of mature enterocytes. Depending on the degree of differentiation and other 
factors including the number of passages, plating and culture conditions, CACO-2 cells will be 
characterised by subpopulations with differing morphologies of both enterocytic and 
colonocytic characteristics (Engle et al., 1998).   Subsequently, endogenous expression of 
claudin 2 on these cells is controversial. Previous studies have suggested that CACO-2 cells do 
not endogenously express claudin 2 (Amasheh, 2008). Other studies suggest claudin 2 
expression in CACO-2 cells may depend on the degree of differentiation of these cells with loss 
of expression of claudin 2 following differentiation and an absence of claudin 2 expression 
within between one and five days post confluence (Escaffit et al., 2005). 
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Altered expression of the tight junction proteins ZO-1, claudin 1 and claudin 2 are likely to be 
critical to the mechanism of impaired epithelial barrier function in pouch inflammation. 
Increased claudin 2 expression could be an early event in the development of pouch 
inflammation and may be key in the aetiology of pouchitis. However, the findings of altered 
tight junction expression may be secondary to the elevation in inflammatory cytokines that 
were demonstrated in both acute and chronic pouchitis. In this study analysis of cytokines from 
FAP patients was not available. Previous studies demonstrate elevated IL-6 levels in non- 
inflamed pouches of ulcerative colitis patients when compared with FAP patients (Leal et al., 
2008). The interaction of altered epithelial barrier function through altered tight junction 
expression and aberrant immune activation may occur concomitantly creating an amplifying 
cycle leading to the development of histologically and clinically apparent mucosal inflammation 
(Clayburgh et al., 2004). To determine the aetiological role of these factors, longitudinal studies 
of patients prior to disease onset are needed. These are not feasible in Crohn’s disease or 
ulcerative colitis, but the pouch offers a unique opportunity for such investigation. 
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Chapter 5. Longitudinal assessment of epithelial and immune cell 
changes following ileostomy closure in patients with ulcerative colitis 
175 
 
 
 
 
5.1 Abstract 
 
Introduction: The temporal inter-relationships between defective barrier function, abnormal 
immune responses and the microbiota in the development of gut inflammation are unknown. 
The ileal pouch offers a unique opportunity to study these factors before the onset of disease 
and map temporal changes between these factors to inform differences between cause and 
effect. We aimed to assess changes in epithelial tight junction expression, dendritic cell 
phenotype and mucosal cytokine production over the first year following restorative 
proctocolectomy (RPC) for UC. 
Methods: Mucosal biopsy samples were taken from the same UC patients (5) undergoing RPC, 
from the ileostomy afferent loop, the pouch pre-ileostomy closure (P0) and the pouch 6 and 12 
months post-ileostomy closure. Epithelial cells and lamina propria DC were isolated from biopsy 
tissue and epithelial cell expression of ZO-1, claudin 1, claudin 2 and DC expression of TLR 2 and 
4, CCR9, β7 and CD40 were measured by multicolour flow cytometry. Cytokines were assessed 
by multiplex analysis of biopsy supernatants. 
Results: Epithelial expression of claudin 2 was increased at 6 months. No changes were seen in 
ZO-1 or claudin 1 expression. DC expressing integrin β7 and CCR9 were increased after 
ileostomy closure, but no differences in TLR or CD40 expression were seen. There was an 
increase in IL-6 levels at 12 months after ileostomy closure. 
Conclusions: In patients with UC, altered tight junction expression with increased epithelial 
expression of the “pore-forming” tight junction claudin 2 was an early event after ileostomy 
closure that was concurrent with alterations in DC homing marker expression and preceded 
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increased IL-6 levels, as well as increased TLR4 and CD40 activation marker expression in 
patients with mucosal inflammation of the pouch at twelve months following ileostomy closure. 
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5.2 Background 
 
 
The temporal inter- relationships between defective barrier function, abnormal immune 
responses and the microbiota in the development of gut inflammation are uncertain. Animal 
models are inconclusive, but suggest a primary defect in epithelial barrier function as an early 
event in the development of gut inflammation. 
 
 
In the SAMP murine model, impaired epithelial barrier function most likely secondary to altered 
tight junction protein expression preceded the development of pathogenic lymphocytic 
properties and inflammation. The commensal microbiota was not necessary for the 
development of the epithelial defect in this model (Olson et al., 2006). Increased intestinal 
permeability in IL-10 knockout mice not only precedes the onset of inflammation but also 
occurs prior to increased levels of pro-inflammatory cytokines (Arrieta et al., 2008). 
 
 
Other models demonstrate epithelial barrier dysfunction to occur in parallel with redistribution 
of DC, elevations in pro-inflammatory cytokines and recruitment of lymphocytes that 
predispose to the early development of inflammation and amplify immune-mediated 
inflammation (Silva et al., 2008, Su et al., 2009). Transgenic mice expressing activated MLCK 
show increased paracellular permeability without histological inflammation with an increase in 
the absolute numbers of lamina propria CD4+ lymphocytes and a significant redistribution of 
CD11c+ DC to the superficial lamina propria as well as polarisation to a Th1 cytokine profile (Su 
et al., 2009). A recent study of a MLCK and RAG2 knockout model demonstrated that barrier 
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loss in immune-mediated colitis occurs by two temporally and morphologically distinct 
mechanisms. MLCK dependent tight junction permeability increases occur early and promote 
disease initiation. Later, as disease progresses, apoptosis and gross ulceration of the epithelium 
causes tight junction-independent barrier loss (Su et al., 2013). 
 
 
The onset of the first episode of pouchitis is most common within twelve months of ileostomy 
closure (Abdelrazeq et al., 2008). Following closure of the ileostomy, the ileal mucosa in the 
pouch is exposed to faeces containing bacterial concentrations a million or more times greater 
than in the normal terminal ileum (Nicholls et al., 1981, Santavirta et al., 1991) and the overall 
composition of the pouch microbiota shows similarities with the colonic microbiota (Falk et al., 
2007, Kohyama et al., 2009). Mucosal morphological changes occur within six weeks of 
ileostomy closure and remain stable at six months post ileostomy closure (Apel et al., 1994). 
Groups of patients without pouchitis, or with acute or chronic pouchitis, may be differentiated 
on the basis of mucosal histological changes at six months following ileostomy closure 
(Stallmach et al., 1999, Setti Carraro et al., 1994). Early responses of epithelial barrier function 
and immune responses to the changes in the microbiota are therefore likely to be critical in 
determining the predisposition to and development of pouch inflammation. 
 
 
The two preceding chapters have demonstrated aberrant DC phenotype and tight junction 
expression in UC patients with and without pouchitis. It is not clear whether these are primary 
factors in the aetiology of pouch inflammation or secondary to inflammation. There are no data 
regarding the early changes in the innate immune system or tight junction protein expression 
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that may predispose to pouchitis. The ileal pouch offers a unique opportunity to study the 
development of inflammation in the gut before disease onset and this opportunity may also 
afford new insights into the pathogenesis of gut inflammation in other inflammatory bowel 
diseases. 
5.3 Aims 
 To assess changes in tight junction expression from the ileum and pouch of ulcerative 
colitis patients before and twelve months after closure of ileostomy 
 To assess changes in dendritic cell phenotype from the ileum and pouch of ulcerative 
colitis patients before and twelve months after ileostomy closure 
 To assess cytokine profiles in the ileum and pouch of ulcerative colitis patients before 
and twelve months after ileostomy closure 
5.4 Patient characteristics 
 
 
Ten patients were initially recruited to participate in the study, but only five completed twelve 
months follow up. All patients had a previous history of UC diagnosed clinically, endoscopically 
and histologically. The median age of the five patients was 37 years (range 29-40 years). All of 
the patients had a J pouch and underwent a three stage procedure. None of the patients had 
extra-intestinal manifestations or primary sclerosing cholangitis (PSC). One patient developed 
pouchitis at twelve months. Two further patients developed mild endoscopic and histological 
inflammation but were asymptomatic (Table 5.1) 
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Table 5.1 Patient characteristics 
 
Patient 
No. 
Duration UC 
(years) 
Indication 
for 
colectomy 
EIM/PSC Backwash 
Ileitis 
PDAI at 6 
 
months 
PDAI histology 
score at 6 
months 
PDAI at 12 
 
months 
PDAI 
 
histology 
score at 12 
months 
1 6 ASUC N N 4 2 12 4 
2 10 CRSUC N N 2 2 2 2 
3 5 ASUC N N/K 3 2 7* 4 
4 14 ASUC N N 3 2 6* 3 
5 3 ASUC N N 2 2 2 2 
ASUC- acute severe UC. CRSUC- chronic refractory severe UC. N/K- not known, original histology 
specimen not available. *No clinical symptoms of pouchitis. 
 
 
For all subsequent figures patient 1 at twelve months follow up (PDAI 12) will be marked with the colour 
red. Patients 3 and 4 at twelve months with histological and endoscopic feature of pouchitis but no 
clinical symptoms will be marked with the colour orange. 
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5.5 Altered epithelial tight junction expression in the pouch of ulcerative colitis patients 
following restorative proctocolectomy 
 
 
Mucosal biopsies were taken from the ileum and diverted ileal pouch prior to ileostomy closure 
and during flexible pouchoscopy at six and twelve months following. Biopsies were processed 
and analysed as described (Chapter 2.2.5- 2.2.10 and Chapter 4.6). 
 
 
ZO-1, claudin 1 and claudin 2 expression were assessed over the twelve months following 
ileostomy closure. There were no significant differences in the proportion of epithelial cells 
expressing ZO-1 at six months (89 +-2.4%, χ2=1.2, p=0.7) or at twelve months (90 +-1.9%, 
χ2=0.4, p=0.95) following ileostomy closure compared with the ileum (88 +-3.5%) or diverted 
pouch (90 +-3.6%) prior to closure. There were no significant differences in the median intensity 
ratio of ZO-1 at six months (8.4 +-1.3, χ2=2.1, p=0.4) or at twelve months (4.2 +-0.6, χ2=0.4, 
p=0.8) following ileostomy closure compared with the ileum (6.8 +-2.5) or diverted pouch (5.1 
+-1.3) prior to ileostomy closure (Figure 5.1). 
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Figure 5.1 Epithelial cell expression of ZO-1 in the ileum and diverted pouch of ulcerative colitis patients prior to 
ileostomy closure and at six and twelve months following ileostomy closure. A. Representative single parameter 
histograms of epithelial cell ZO-1 staining. B. Percentage expression and C. Median intensity ratio of epithelial ZO-1 
in the ileum and diverted pouch of ulcerative colitis patients prior to ileostomy closure and at six and twelve 
months following ileostomy closure (n=5). 
 
 
 
There were no significant differences in the proportion of epithelial cells expressing claudin 1 at 
six months (38 +-11%, χ2=0.3, p=0.9) or at twelve months (58 +-10%, χ2=3.6, p=0.2) following 
ileostomy closure compared with the ileum (25 +-14%) or diverted pouch (35 +-15%) prior to 
ileostomy closure. There were no significant differences in the median intensity ratio of claudin 
1 at six months (3.2 +-1.0, χ2=2.4, p=0.3) or at twelve months (2.3 +-0.6, χ2=1.2, p=0.6) 
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following ileostomy closure compared with the ileum (1.3 +-0.6) or diverted pouch (1.7 +-0.8) 
prior to closure (Figure 5.2). 
 
 
Figure 5.2 Epithelial cell expression of claudin 1 in the ileum and diverted pouch of ulcerative colitis patients 
prior to ileostomy closure and at six and twelve months following ileostomy closure. A. Representative single 
parameter histograms of epithelial cell claudin 1 staining. B. Percentage expression and C. Median intensity ratio of 
epithelial claudin 1 in the ileum and diverted pouch of ulcerative colitis patients prior to ileostomy closure and at 
six and twelve months following ileostomy closure (n=5). 
 
 
 
There was a significant increase in the proportion of epithelial cells expressing claudin 2 at six 
months (48+-15%, χ2=6.5, p=0.02) but this was not significant at twelve months (46 +-19%, 
χ2=1.7, p=0.4) following ileostomy closure compared with the ileum (8.6 +-5%) or diverted 
pouch (15 +-10%) prior to ileostomy closure. There were no significant differences in the 
median intensity ratio of claudin 2 at six months (1.6 +-0.5, χ2=2.8, p=0.12) or at twelve months 
184 
 
 
 
 
(0.9 +-0.4, χ2=1.7, p=0.4) following ileostomy closure compared with the ileum (0.6 +-0.4) or 
diverted pouch (1.4 +-0.7) prior to ileostomy closure. 
 
 
The proportion of epithelial cells expressing claudin 2 was elevated in four of the five patients 
at six months following ileostomy closure. Three of these patients had endoscopic and 
histological inflammation of the pouch at twelve months. One patient had an increased 
proportion of epithelial cells expressing claudin 2 at six months and did not develop pouch 
inflammation, but had a low proportion of epithelial cells expressing claudin 2 at 12 months 
(Figure 5.3). 
 
* 
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Figure 5.3 Epithelial cell expression of claudin 2 in the ileum and diverted pouch of ulcerative colitis patients 
prior to ileostomy closure and at six and twelve months following ileostomy closure. A. Representative single 
parameter histograms of epithelial cell claudin 2 staining. B. Percentage expression and C. Median intensity ratio of 
epithelial claudin 2 in the ileum and diverted pouch of ulcerative colitis patients prior to ileostomy closure and at 
six and twelve months following ileostomy closure (n=5). * denotes p values ≤0.05. 
 
 
 
5.6 Altered dendritic cell phenotype in the pouch of ulcerative colitis following restorative 
proctocolectomy 
 
There were no significant differences in the proportion of DC expressing TLR 4 at six months (42 
 
+-3.2%, χ2=5.2, p=0.09) or at twelve months (47 +-7.0%, χ2=3.6, p=0.2) following ileostomy 
closure compared with the ileum (34 +-9.6%) or diverted pouch (18 +-6.4%) prior to ileostomy 
closure. There was no significant change in the proportion of DC expressing TLR 2 at 6 months 
(28 +-5.0%, χ2=1.2, p=0.7) or at twelve months (33 +-11%, χ2=1.4, p=0.5) following ileostomy 
closure compared with the ileum (24 +-7.4%) or diverted pouch (21 +-10%) prior to ileostomy 
closure (Figure 5.4). 
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Figure 5.4 TLR 4 and TLR 2 expression on lamia propria dendritic cells in the ileum and diverted pouch of 
ulcerative colitis patients prior to ileostomy closure and at six and twelve months following ileostomy closure. A 
and B. One parameter histograms representative of TLR 4 and TLR 2 staining cells and C and D. Percentage 
expression of TLR 4 and TLR 2 in the ileum and diverted pouch of ulcerative colitis patients prior to ileostomy 
closure and at six and twelve months following ileostomy closure (n=5). 
 
 
 
There was a significant increase in the proportion of DC expressing β7 at six months (17 +-3.1%, 
χ2=6.6, p=0.02) and at twelve months (37 +-2.2%, χ2=7.6, p≤0.01) following ileostomy closure 
compared with the ileum (8.4 +-4.2%) or diverted pouch (3.4 +-2.0%) prior to ileostomy closure. 
There was a significant increase in the proportion of DC expressing CCR9 at six months (46 +- 
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2.3%, χ2=9.6, p≤0.001) but this was not significant at twelve months (50 +-6.5%, χ2=4.5, p=0.1) 
following ileostomy closure compared with the ileum (41 +-4.1%) or diverted pouch (26 +-6.5%) 
prior to ileostomy closure (Figure 5.5). 
 
 
Figure 5.5 β7 and CCR9 expression on lamina propria dendritic cells in the ileum and diverted pouch of ulcerative 
colitis patients prior to ileostomy closure and at six and twelve months following ileostomy closure. A and B.  
One parameter histograms representative of β7 and CCR9 staining cells and C and D. Percentage expression of β7 
and CCR9 in the ileum and diverted pouch of ulcerative colitis patients prior to ileostomy closure and at six and 
twelve months following ileostomy closure (n=5). * and ** denote p values ≤0.05 and 0.01 respectively. 
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There were no significant differences in the proportion of DC expressing CD40 at six months (59 
 
+-3.3%, χ2=2.8, p=0.4) or at twelve months (75 +-6.6%, χ2=2.8, p=0.4) following ileostomy 
closure compared with the ileum (49 +-7.6%) or diverted pouch (54 +-3.3%) prior to ileostomy 
closure (Figure 5.6). 
 
 
Figure 5.6 CD40 expression on lamina propria dendritic cells in the ileum and diverted pouch of ulcerative colitis 
patients prior to ileostomy closure and at six and twelve months following ileostomy closure. A. One parameter 
histograms representative of CD40 staining cells and B. Percentage expression of CD40 in the ileum and diverted 
pouch of ulcerative colitis patients prior to ileostomy closure and at six and twelve months following ileostomy 
closure (n=5). 
 
 
 
5.7 Increased proinflammatory cytokines in the pouch of ulcerative colitis patients 
following restorative proctocolectomy 
 
 
There were no significant changes in the levels of IL-2 (χ2=1, p=0.7), IL-4 (χ2=2, p=0.4), IL-10 
(χ2=2 p=0.4) or TNF (χ2=4, p=0.1) in the supernatants of mucosal biopsy samples over the 
twelve months following ileostomy closure. There was a significant increase in IL-6 levels at 
twelve months following ileostomy closure (χ2=6.6, p=0.04) (Figure 5.7). 
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Figure 5.7. IL-6 levels in biopsy supernatant of ulcerative colitis patients before and at six and twelve months 
following ileostomy closure. IL-6 levels in supernatants of mucosal biopsies from the ileum prior to ileostomy 
closure and from the pouch at six and twelve months following ileostomy closure (n=4) 
 
 
 
5.8 Discussion 
 
 
This is the first study to longitudinally assess DC characteristics and epithelial cell tight junction 
protein expression following ileostomy closure in UC patients. The increased expression of 
claudin 2 in the pouch of UC patients at six months following ileostomy closure suggests this is 
an early event in the development of inflammation. The proportion of epithelial cells expressing 
claudin 2 was increased at six months in four of the five patients studied. There was no  
evidence of histological inflammation in any of these patients at this time point. Three of these 
patients went on to develop histological inflammation at 12 months post ileostomy closure  
with one meeting criteria for a diagnosis of pouchitis. This could present a mechanism for 
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barrier dysfunction by which UC patients are more susceptible to immune activation by the 
more “colon-like” microbiota following ileostomy closure. 
 
 
Animal models demonstrate epithelial barrier dysfunction to occur in parallel with 
redistribution of DC, elevations in pro-inflammatory cytokines and recruitment of lymphocytes 
that predispose to the early development of inflammation and amplify immune-mediated 
inflammation (Silva et al., 2008, Su et al., 2009). Similarly here, increased claudin 2 expression 
was concurrent with alterations in DC homing marker expression and preceded increased IL-6 
levels, as well as increased TLR4 and CD40 activation marker expression in the patients with 
inflammation of the pouch at 12 months. 
 
 
Changes in DC homing markers in the pouch of UC patients also represent an aberrant response 
to the more colonic microenvironment following RPC. Following ileostomy closure there was an 
increase in the proportion of DC expressing β7 that might be expected with the changes 
towards a more colonic microenvironment. However, CCR9+ DC were also increased with a 
more “small bowel” profile that may be an aberrant response to the altered microenvironment. 
 
 
The levels of IL-6 increased in the biopsy supernatants of pouch samples following ileostomy 
closure. As mentioned previously IL-6 levels are elevated not only in the inflamed, but also the 
non-inflamed pouch of UC patients compared with FAP patients (Gionchetti et al., 1994, Leal et 
al., 2008). IL-6 is produced by many cell types, but the main sources in the intestinal lamina 
propria are dendritic cells and macrophages. IL-6 is a key signal in the transition from the initial 
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innate immune response to infection to a more sustained, adaptive immune response (Naugler 
and Karin, 2008). IL-6 also synergises with intestinal DC and retinoic acid to induce gut specific 
IgA secreting B cells. The increase in IL-6 following ileostomy closure may therefore impact on 
epithelial expression of tight junction proteins (Chapter 4) and the type of immune responses 
following DC activation of lymphocytes. 
 
 
There are several limitations to this study. The number of patients studied is small, reflecting 
the difficulties of such a longitudinal study in clinical practice. Furthermore, the addition of FAP 
patients would aid the differentiation of responses following ileostomy closure that are specific 
to UC patients. Correlation with changes in the microbiota would also be important in 
determining the response to changes in the microbiota as well as analysis of DC function. 
 
 
Nonetheless, this is the first truly longitudinal study of immune characteristics and epithelial 
tight junction protein expression following ileostomy closure and re-introduction of the faecal 
stream. Increased epithelial cell expression of claudin 2 and increased DC gut homing marker 
expression are early changes following ileostomy closure and the introduction of the faecal 
stream. It may not be possible to resolve the “chicken and egg” dilemma as to the primary 
aetiological factor in the development of intestinal inflammation. 
 
 
However, this study demonstrates the potential utility of the ileal pouch as a human model that 
can enhance our understanding of the inter-relationships of key factors in the aetiology of 
inflammatory bowel diseases. Studies of these immunological factors following modification of 
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the microbiota in the context of pouch inflammation may further enhance our understanding of 
the inter-relationships between the microbiota and the gut immune responses. 
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Chapter 6. A pilot study of faecal microbiota transplantation for 
chronic pouchitis 
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6.1 Abstract 
 
 
Introduction: Faecal microbiota transplantation (FMT) is effective in the treatment of recurrent 
Clostridium difficile infection, where resolution of disease is tightly linked to post-FMT changes 
in microbiota diversity and composition. Effects of FMT in inflammatory bowel diseases (IBD) 
remain unclear. We undertook a pilot study to assess the clinical outcome in patients with 
chronic pouchitis after FMT. 
Methods: Eight patients with chronic pouchitis (with a current PDAI ≥7) were treated with FMT 
via nasogastric administration. Clinical activity and faecal coliform antibiotic sensitivities were 
assessed before and four weeks following FMT. 
Results: None of the patients achieved clinical remission and no patients achieved clinical 
response with a PDAI ≤7 at four weeks post FMT. There were no significant changes in pouch 
frequency or Cleveland global quality of life score. Four patients had coliform resistant to 
ciprofloxacin on faecal analysis prior to FMT. Two of these patients demonstrated coliforms 
that had regained sensitivity to ciprofloxacin four weeks following faecal transplantation. 
Conclusions: FMT appears to be safe and acceptable to patients with chronic pouchitis. 
However, in this study a single nasogastric administration of healthy donor stool was not 
clinically effective. Further studies of FMT for chronic pouchitis and other inflammatory bowel 
diseases will need to consider alternative protocols. 
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6.2 Background 
 
 
Antibiotics are the mainstay of treatment for pouchitis. The majority of patients will respond to 
a course of a single agent or combination of antibiotics and remain in remission (Hurst et al., 
1996). Patients who fail to respond to a single antibiotic, or have early relapse, may respond to 
combination therapy with two antibiotics (Abdelrazeq et al., 2005, Gionchetti et al., 1999, 
Mimura et al., 2002, Shen et al., 2007). Around 5-19% (Madiba and Bartolo, 2001, 
Mowschenson et al., 2000) will develop chronic pouchitis. 
 
 
A proportion of patients will go on to suffer from frequent episodes which remain responsive to 
antibiotics, others will require continuous antibiotic or probiotic treatment to maintain a 
remission (Mimura et al., 2004) and a proportion of patients will not respond to antibiotics. 
These patients are difficult to manage and few evidence based treatments are available (Pardi 
and Sandborn, 2006). Long term treatment with antibiotics may lead to the development of 
antibiotic resistance and extended spectrum beta-lactamase-producing (ESBL) bacteria 
(McLaughlin et al., 2010a) rendering patients resistant to antibiotic therapy (McLaughlin et al., 
2009b). 
 
 
Long-term follow-up studies demonstrate that pouchitis accounts for 10% of pouch failures 
(Tulchinsky et al., 2003). The only proven treatment for these individuals is conversion to a 
permanent ileostomy which may hold significant physical and psychological morbidity. New 
therapies that target the pouch microbiota and alter immune responses are needed. Probiotics 
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have shown some promise in the treatment of pouchitis (Gionchetti et al., 2000a, Mimura et 
al., 2004, Gionchetti et al., 2003, Gionchetti et al., 2007) and studies have demonstrated their 
immunoregulatory effects in UC patients who have undergone restorative proctocolectomy 
(Lammers et al., 2005b, Pronio et al., 2008). However, results with probiotics in clinical practice 
are less convincing (Shen et al., 2005a). Other strategies to alter the composition of the pouch 
microbiota are needed. 
 
 
An alternative approach is transplantation of the entire “organ” of the gut microbiota from a 
healthy donor. Faecal microbiota transplantation (FMT) is effective in the treatment of 
recurrent Clostridium difficile infection, where resolution of disease is tightly linked to post-FMT 
changes in microbiota diversity and composition (van Nood et al., 2013). Case reports and small 
case series have suggested positive clinical outcomes following FMT in IBD (Borody et al., 2003, 
Grehan et al., 2010, Borody et al., 1989, Bennet and Brinkman, 1989). However, recent studies 
of FMT in UC did not demonstrate clinical efficacy and suggest variable efficiency of  
colonisation by the donors’ microbiota (Angelberger et al., 2013, Kump et al., 2013). 
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6.3 Aims 
 To conduct a prospective pilot study of faecal microbiota transplantation (FMT) for 
chronic refractory pouchitis. 
6.4 Primary end point 
 
The number of patients in clinical remission (Clinical PDAI 0 or Total PDAI <4) four weeks after 
treatment with faecal microbiota transplantation. 
Secondary end points 
 
 The number of patients to achieve clinical response (reduction in PDAI score ≥3 points 
(Abdelrazeq et al., 2005)) four weeks after treatment with faecal microbiota 
transplantation 
 The number of patients demonstrating changes in pouch faecal bacterial sensitivities 
following faecal microbiota transplantation 
 
 
6.5 FMT Protocol 
 
 
To be included in the study UC patients had an ileal pouch with chronic pouchitis (Chapter 
1.1ii), diagnosed clinically, endoscopically and histologically) with a current pouch disease 
activity index (PDAI) ≥7. Patients were excluded if they had used antibiotics, probiotics, non- 
steroidal medications, steroids or immunosuppressants within 2 weeks of study participation. 
Stool samples were taken prior to study entry to exclude Cryptosporidium, Salmonella spp., 
Shigella spp., Escherichia coli, Campylobacter jejuni, C. difficile toxin, helminths, ova and 
parasites. 
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Healthy donors were nominated by the patients receiving FMT and included relatives, partners 
or an anonymous previously screened donor. Healthy donors were excluded if they had a 
history of gastrointestinal illness, inflammatory bowel disease, bowel cancer, antibiotic or 
probiotic use within the preceding six months, or hospitalisation within three months of study 
participation. Screening of healthy donors included blood tests for full blood count, renal and 
liver function, serology for hepatitis A, B, C, E, CMV, EBV, HTLV I/II, HIV and Treponema 
Pallidum. Three stool samples were taken to exclude Cryptosporidium, Salmonella spp., Shigella 
spp., Escherichia coli, Campylobacter jejuni, C. difficile toxin, helminths, ova and parasites. 
Donor stool was prepared as previously described (27). Stool donors were asked to provide a 
stool sample less than six hours prior to faecal transplantation. Thirty grams of stool was 
homogenised in 50ml of 0.9% saline and filtered through a sterile gauze to produce a faecal- 
saline solution. The night before the procedure the recipient was treated with proton pump 
inhibitor to provide a favourable gastric pH. A nasogastric tube was inserted and the position 
confirmed according to local protocols. Thirty millilitres of the faecal-saline solution was 
administered via the nasogastric tube which was then flushed with 50ml of normal saline 
solution. 
 
 
A flexible pouchoscopy was performed and biopsy and stool samples were collected prior to 
FMT and at four weeks following transplantation. PDAI and Cleveland Global Quality of Life 
Scores (CGQoL) were recorded at each time point. 
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6.6 Patient characteristics 
 
 
Ten patients were recruited to the study. One withdrew prior to faecal transplantation. Another 
patient was diagnosed with adenocarcinoma of the rectal cuff at the screening pouchoscopy 
and so did not proceed to faecal transplantation. Therefore eight patients were studied of 
whom five were female. The median age was 46 years (range 24-63 years). The median number 
of years since RPC was 10 years (range 4-22 years) (Table 6.1). 
 
 
Table 6.1. Patient characteristics 
 
Patient Sex Time since RPC 
(years) 
Pouch type Pre-pouch ileitis Baseline pouch 
frequency 
1 F 6 J Yes 24 
2 F 6 J Yes 20 
3 F 10 J Yes 11 
4 F 22 W Yes 15 
5 M 16 J Yes 9 
6 M 22 W Yes 13 
7 M 4 J Yes 15 
8 F 4 J Yes 20 
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6.7 Clinical outcomes following FMT 
 
 
None of the patients achieved clinical remission following FMT. Two patients (patients 2 and 3) 
achieved a reduction of total PDAI score >3 points at 4 weeks post FMT. However, both patients 
had a total PDAI score >7 (PDAI 9 and 10 respectively) at 4 weeks post FMT. There were no 
significant differences in clinical PDAI (4, range 3-5 vs. 4, range 3-5; p=0.3) (Figure 6.1a), 
endoscopy (5, range 3-6 vs. 4.5 range, 3-6; p=0.6) (Figure 6.1b) or histology sub-scores (2.5, 
range 2-4 vs. 2, range 2-4; p=0.4) (Figure 6.1c) before and four weeks after FMT. 
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Figure 6.1 A. Median Clinical PDAI, B. Endoscopy subscore, C. Histology subscore before and 4 weeks following 
FMT (n=8). 
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There were no significant differences in pouch frequency (15, range 9-24 vs. 15, range 8-25, 
p=1) (Figure 6.2), Total PDAI (11.5, range 10-14 vs. 10.5 range 9-14; p=0.2) (Figure 6.3a) or 
Cleveland Global Quality of Health Score (0.41, range 0.2-0.7 vs. 0.47, range 0.2-0.7; p=0.8) 
(Figure 6.3b) before and four weeks after faecal transplantation. 
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Figure 6.2. Median pouch frequency before and 4 weeks after FMT (n=8). No change in pouch frequency was 
noted 4 weeks after FMT. 
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Figure 6.3 A. Median total PDAI and B. Median Cleveland Global Quality of Life (CGQoL) score before and 4 
weeks after FMT (n=8). 
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6.8 Changes in coliform sensitivities before and after FMT 
 
 
Four patients had faecal sensitivities which demonstrated coliforms that were resistant to 
ciprofloxacin and in three patients stool testing detected ESBL-coliforms. Two of these patients 
demonstrated coliforms that had regained sensitivity to ciprofloxacin four weeks following 
faecal transplantation (Table 6.2). For these patients, regaining sensitivity to ciprofloxacin 
enabled further effective antimicrobial therapy during their ongoing disease management. 
 
Table 6.2. Changes in faecal coliform sensitivities before and four weeks after faecal 
transplantation. 
 
 
Patient Pre-faecal transplant Post-faecal transplant 
 ESBL coliform Ciprofloxacin 
sensitive coliform 
ESBL coliform Ciprofloxacin 
sensitive coliform 
1 No Yes No Yes 
2 No No No No 
3 Yes No No Yes 
4 No Yes No Yes 
5 Yes No No Yes 
6 Yes No Yes No 
7 No Yes No Yes 
8 No Yes No Yes 
 
 
 
 
6.9 Adverse Events 
 
There were no major adverse events following FMT. Three patients reported adverse effects 
including nausea (n=3); vomiting (n=1); bloating (n=2); fever (n=1). All adverse events were 
transient, lasting less than 24 hours. 
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6.10 Discussion 
 
This was the first study of FMT for chronic pouchitis. In this study FMT was not effective in 
achieving either clinical response or remission for patients with chronic pouchitis. No 
improvement in any parameter was seen at four weeks following FMT. Two patients (patients 2 
and 3) achieved a clinical response with a reduction of total PDAI score ≥3 points at 4 weeks 
post FMT. However, both patients still had a total PDAI score ≥7 at 4 weeks post FMT. Two of 
the four patients (patients 3 and 5) demonstrating resistant coliform in stool samples prior to 
FMT, regained sensitivity to ciprofloxacin at four weeks following FMT, enabling further efficacy 
of antibiotic therapy. Regaining sensitivity to antimicrobials may enable further effective 
antimicrobial therapy in this group of unresponsive patients. This study demonstrates that 
patients with chronic inflammatory bowel disease are willing to undergo the treatment and  
that FMT is safe and well tolerated although side effects were noted as have been previously 
documented in other reports of FMT (Silverman et al., 2010, van Nood et al., 2013). 
Previous reports of FMT for IBD report the use of more frequent faecal infusions as well as 
rectal or colonic administration. However, in this study FMT was performed via nasogastric 
tube in accordance with previously reported efficacious protocols for Clostridium difficile (Aas 
et al., 2003, MacConnachie et al., 2009). This was due to the potential difficulties this group of 
patients have in retaining enemas as well as the need to standardise the administration of the 
faecal-saline solution. 
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Previous case reports of FMT for IBD also include pre-treatment with antibiotics and 5 ASA, 
steroids or immunosuppressant medication. However, animal studies demonstrate that 
antibiotics are not necessary to establish engraftment of exogenous microbiota (Manichanh et 
al., 2010). The use of other medications for IBD concurrently with FMT raise the question of the 
efficacy of FMT in the treatment of active disease or the maintenance of remission once 
induced by other medications. The patients included in this study had longstanding severe 
inflammation and may represent a refractory spectrum of disease. 
 
 
It remains to be seen whether FMT is effective in induction of remission for chronic active IBD. 
There is only limited data regarding the efficacy of probiotics for the induction of remission of 
colitis and pouchitis. The vast majority of data suggesting efficacy of probiotics in UC or 
pouchitis are in the context of quiescent disease for the prevention of onset or maintenance of 
remission.  The timing of interventions altering the microbiota may be relevant in the efficacy 
of this strategy in changing the course of IBD. 
 
 
FMT appears to be safe and acceptable to patients with chronic pouchitis. However, in this 
study a single nasogastric administration of healthy donor stool was not clinically effective. 
Further controlled studies of FMT for chronic pouchitis and other inflammatory bowel diseases 
will need to consider alternative protocols including combined upper and lower gastrointestinal 
administration as well as repeated infusions. Studies will need to ascertain the role of pre- 
treatment antibiotics, probiotics, bowel lavage and proton pump inhibition in FMT. 
Furthermore, studies including selection of patients with less chronic and refractory disease or 
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patients conventionally induced into remission are necessary. Understanding the effect of FMT 
on the microbiota in pouchitis will enhance our understanding of the immunotherapeutic 
potential of FMT in IBD. 
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Chapter 7. The microbiological effects of faecal microbiota 
transplantation in chronic pouchitis 
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7.1 Abstract 
 
Introduction: The efficacy of faecal microbiota transplantation (FMT) in the treatment of 
Clostridium difficile infection is tightly linked to changes in microbiota diversity and 
composition. Effects of FMT on recipient microbiota in inflammatory bowel diseases (IBD) 
remain unclear. We undertook a pilot study to assess the effects of FMT on microbiota 
composition in patients with chronic pouchitis. 
Methods: Eight patients with chronic pouchitis (with a current PDAI ≥7) were treated with FMT 
via nasogastric administration. Changes in pouch faecal and mucosal microbiota were assessed 
by 16S rRNA gene pyrosequencing before and four weeks after FMT. 
Results: There was significant inter-individual variation in microbiota content, in both the 
donors and pouch patients. Significant taxonomic differences were found between healthy 
donors and patients with pouchitis. Following FMT, there were no overall changes in bacterial 
richness or diversity of the faecal or mucosal microbiota. However, post FMT there were 
variable shifts in faecal and mucosal microbiota composition and changes in proportional 
abundance of species suggestive of a “healthier” pouch microbiota. 
Conclusions: FMT via a single nasogastric administration in patients with chronic pouchitis 
resulted in variable changes in microbiota composition and did not alter the diversity of the 
pouch microbiota. Further modifications in the methodology of FMT may be required to impact 
on the microbiota for patients with IBD. 
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7.2 Background 
 
 
A significant body of clinical and microbiological evidence has accumulated to suggest a 
dysbiosis of the pouch microbiota is likely to be important in the aetiology of this inflammatory 
disease process. Studies of the pouch microbiota have reached conflicting conclusions 
regarding differences in the abundance of particular species and phylotypes present in 
pouchitis or whether there is an increased or reduced diversity of the pouch microbiota. 
Predominantly studies find a reduced diversity of the microbiota in pouchitis with increased 
proportion of Proteobacteria and reduced Bacteroidetes (Mizoguchi et al., 2013, Tannock et al., 
2012, McLaughlin et al., 2010b). 
 
 
Several studies have assessed changes in the pouch microbiota following interventions of either 
antibiotic or probiotic therapy (Gosselink et al., 2004a, Kuisma et al., 2003, Gionchetti et al., 
2000b) with limited success in achieving overall change in the composition of the microbiota 
(see Chapter 1.3v, Table 1.4). 
 
 
Faecal microbiota transplantation may be a means of altering the composition of the  
microbiota as a whole. Animal and human studies have demonstrated the effective and durable 
transfer of donor microbiota using faecal transplantation for Clostridium difficile infection 
(Manichanh et al., 2010, Lawley et al., 2012, Grehan et al., 2010, van Nood et al., 2013). These 
studies demonstrate FMT to increase bacterial diversity and particularly replenish Bacteroidetes 
and Clostridia and reduce the proportions of Proteobacteria (van Nood et al., 2013, Tvede and 
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Rask-Madsen, 1989). Two recent studies have assessed the microbiota following FMT in IBD. 
Faecal microbiota transplantation reduced the relative abundance of Proteobacteria and 
increased Bacteroidetes and at family level the most prominent relative changes were a 
decrease in Enterobacteriaceae and Enterococcaceae and a relative increase in Bacteroidaceae. 
Abundant bacteria from donors established in some of the recipients, but the efficiency and 
stability of donor microbiota colonization varied greatly (Angelberger et al., 2013, Kump et al., 
2013). No previous studies have assessed the pouch microbiota following FMT. 
7.3 Aims 
 To assess the faecal and mucosal microbiota in patients with active chronic pouchitis 
before and four weeks after FMT 
7.4 Methods 
 
FMT was undertaken as described in Chapter 6.5. Stool and biopsies were collected for 
microbiological analysis before and four weeks following FMT. Biopsies (n=2) for  
microbiological assessment were immediately washed in phosphate buffered saline (PBS) and 
snap frozen in liquid nitrogen and stored at -80◦C. 2ml of stool for microbiological and  
metabolic assessment was mixed with 8ml of PBS, vortexed and centrifuged at 250g for 1 
minute to exclude large particulate matter. Aliquots (1:10) were stored in RNA later (Ambion) at 
-80◦C. DNA extraction, PCR and 16S rRNA gene sequencing and analysis were performed as 
 
described in Chapter 2.2.13-16. 
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7.5 Results 
 
 
A total of 156963 sequences were generated with an average of 3982 reads per sample (range 
391-12592). Samples with less than 250 reads were excluded from analysis (n=4). Most 
sequences were related to phyla Firmicutes (57%), Bacteroidetes (26%), Proteobacteria (14.5%) 
and Actinobacteria (1.6%). A total of 105 bacterial families were detected in samples, sixteen of 
these accounting for more than 90% of operational taxonomic units (OTUs) in the whole 
dataset. Good’s coverage (an estimate of completeness of species sampling) at 391 reads per 
sample was greater than 92% for all sample groups (overall median for all samples was 95.9%, 
range 87.9 to 99.7%). 
7.6 Donor and patient samples at baseline 
 
 
There was significant inter-individual variation in microbiota content, in both the donors and 
pouch patients. Despite this, some general trends were observed. At the phylum level, prior to 
FMT, pouchitis patient stool and biopsy samples were characterised by a lower proportion of 
Bacteroidetes (stool, p=0.05; biopsies, p=0.0003) and a higher proportion of Proteobacteria 
(stool, p=0.02; biopsies, p=0.04) compared with donor stool samples. Patient mucosal samples 
also had a higher proportional abundance of Firmicutes (p=0.009) compared with donor stool 
samples (Figure 7.1). 
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Figure 7.1 Percentage of sequences identified from the four predominant bacterial phyla in donor and patient 
samples at baseline. Percentage of total sequences from the predominant bacterial phyla in donor stool (n=8), 
patient stool pre FMT (n=7) and patient mucosal samples pre FMT (n=8). * and ** denote p values ≤0.05 and 0.01 
respectively. 
 
 
 
At the family level, patient stool and biopsies prior to FMT were characterised by a lower 
proportion of Ruminococcaceae (stool, p=0.0003; biopsies, p=0.01) and higher 
Enterobacteriaceae (stool, p=0.0003; biopsies, p=0.0003). Patient mucosal samples prior to FMT 
also demonstrated higher proportional abundances of Lachnospiraceae (p=0.004), and 
Clostridiaceae (p=0.02) (Figure 7.2). 
 
 
At genus level analysis both patient stool and mucosal samples prior to FMT demonstrated 
reduced proportions of Faecalibacterium (p=0.003) and increased proportions of Escherichia- 
shigella (p=0.001) compared with donor stool samples (Table 7.1). 
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Patient stool prior to FMT was characterised by low phylotype richness (observed OTU diversity 
p=0.001; Chao 1 p=0.0003) and diversity (Shannon diversity index p=0.001; Simpson diversity 
index p=0.02) compared with donor stool samples. However, patient mucosal samples prior to 
FMT demonstrated no differences in richness (observed OTU diversity p=0.9; Chao 1 p=0.6) or 
diversity (Shannon diversity index p=0.9; Simpson diversity index p=0.8) compared with donor 
stool (Figure 7.3). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2 Percentage of sequences identified from the bacterial families of >1% total abundance in donor and patient samples at 
baseline. Percentage of total sequences from the predominant bacterial families in donor stool (n=8), patient stool pre FMT (n=7) 
and patient mucosal samples pre FMT (n=8).   * and ** denote p values ≤0.05 
2
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Table 7.1 Analysis of genera from donor and patient samples at baseline 
 
Genus Donor stool 
(%) 
Patient stool baseline 
(%) 
p-value Patient mucosa baseline 
(%) 
p-value 
Bacteroides 19.3 +- 5.6 16.6 +- 7.8 0.4 10.7 +-2.4 0.2 
Escherichia_Shigella 0.06 +- 0.02 22.0 +-8.3 0.001** 7.3 +-2.8 0.001** 
Prevotella 9.3 +-6.3 0.07 +-0.03 0.9 0.93 +-0.3 0.3 
Lachnospiracea_incertae_s 
edis 
4.6+-0.6 10.6 +- 3.5 0.3 11.7 +-3.6 0.009** 
Clostridium_sensu_stricto 0.45 +-0.1 11.1 +-4.1 0.2 9.9 +-3.5 0.02* 
Lactobacillus 1.6 +- 1.4 2.7 +- 2.4 0.6 1.9 +- 1.6 0.9 
Faecalibacterium 10.9 +-2.1 1.4 +-0.9 0.003** 4.6 +-1.7 0.03* 
Blautia 2.5 +-0.4 5.0 +-2.3 0.7 7.2 +- 2.3 0.2 
Clostridium_XI 1.8 +-0.5 6.8 +-3.9 0.9 7.8 +-1.6 0.001** 
unclassified 
Lachnospiraceae 
4.6 +-0.8 2.8 +-1.0 0.2 6.7 +-0.9 0.1 
Sutterella 2.0 +-0.5 0.2 +-0.2 0.004** 1.0 +-0.5 0.1 
Anaerostipes 2.6 +-0.3 3.6 +-2.5 0.2 2.7 +-0.7 0.6 
Clostridium_XVIII 1.5 +-0.4 2.2 +-1.4 0.2 1.2 +-0.4 0.3 
Alistipes 5.7 +-1.5 0.2 +-0.1 0.003** 0.9 +-0.2 0.03* 
Streptococcus 1.3 +-0.4 0.2 +-0.1 0.04* 1.3 +-0.4 0.8 
Clostridium_XlVa 0.9 +-0.4 1.4 +-0.9 0.3 1.8 +-0.5 0.2 
Barnesiella 2.8 +-0.5 0.1 +-0.1 0.001** 1.1 +-0.7 0.02* 
Subdoligranulum 3.0 +-0.7 0.04 +-0.0 0.0003** 1.0 +-0.5 0.04* 
Roseburia 1.0 +-0.2 2.4+-2.3 0.03* 2.7 +-2.0 0.6 
Percentage of sequences identified from genera of >1% total abundance in donor and patient samples at 
baseline. Percentage of total sequences from the predominant bacterial genera in donor stool (n=8), patient stool 
pre FMT (n=7) and patient mucosal samples pre FMT (n=8).   * and ** denote p values ≤0.05 and 0.01 respectively. 
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Figure 7.3 Phylotype richness and diversity in donor and patient samples A. Comparison of the number of 
operational taxonomic units (OTUs) observed. B. Chao estimate of total OTU number. C. Shannon diversity index. 
D. Simpson Diversity index. donor stool (n=8), patient stool pre FMT (n=7), patient mucosal samples pre FMT (n=8), 
patient stool post FMT (n=8), patient mucosal samples post FMT (n=5). * and ** denote p values ≤0.05 and 0.01 
respectively. 
A C 
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7.7 Changes in microbiota composition post faecal transplantation 
 
There were no overall changes in bacterial richness or diversity of the faecal or mucosal 
microbiota post FMT (Figure 7.3). However, Non-metric multidimensional scaling (NMDS) 
analysis using the Bray Curtis calculator, which measures dissimilarity in microbial community 
structure between samples by comparing overlapping OTU membership and their relative 
abundances, indicated a shift in both the stool and mucosal microbiota towards a composition 
with greater similarity to donor stool following FMT (Figure 7.4). Analysis of molecular variance 
(AMOVA) using the Yue and Clayton calculator, which also takes into account OTU membership 
and relative abundances when comparing bacterial community structures also suggested less 
difference between recipient and donor microbiota compositions following FMT (Donor vs. 
recipient faeces pre FMT p=0.005; Donor vs. recipient faeces post FMT p=0.034; Donor vs. 
recipient biopsy pre FMT p=0.003; Donor vs. recipient biopsy post FMT p=0.174). 
 
 
Despite a high degree of inter-individual variation, assessment by metastats revealed an overall 
significant reduction in proportional abundance of Escherichia coli/Shigella spp. (p=0.005) and 
Ruminococcus gnavus (p=0.01) in patients post FMT, and an increase in relative abundance of 
Sutterella stercoricanis (p=0.003) and Dorea longicatena (p=0.01) as well as a trend towards 
increased proportional abundance of Faecalibacterium prauznitzii (p=0.09). 
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Figure 7.4 (Created by Dr A Walker) Principal coordinate analysis for donor and patient samples pre and post 
FMT. Principle coordinate analysis of donor stool (x) and patient stool pre FMT (open squares) and post FMT (filled 
squares) and patient mucosal samples pre FMT (open circles) and post FMT (filled circles) for each patient and 
donor. Oval shows distinct clustering of healthy donor faecal microbiota sample profiles in comparison to the 
pouchitis patient samples, arrows indicate directional shifts in patient samples post FMT. 
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There were no significant changes at phylum level in either the stool or mucosal microbiota 
post FMT (Figure 7.5). 
 
 
Figure 7.5 Percentage of sequences identified from the four predominant bacterial phyla in patient samples pre 
and post FMT. Percentage of total sequences from the predominant bacterial phyla in patient stool pre FMT (n=7) 
and patient stool post FMT (n=8); patient mucosal samples pre FMT (n=8) and patient mucosal samples post FMT 
(n=5). 
 
At family level analysis there was a significant increase in the proportion of Suterellaceae in 
both stool and mucosal samples post FMT (p=0.02) as well as a significant reduction in the 
proportion of Clostridiaceae (p=0.03) in mucosal samples post FMT (Figure 7.6 and Figure 7.7). 
At genus level, the proportion of Suterella was significantly increased post FMT in both stool 
and mucosal samples (p=0.02). There was a trend towards increased Faecalibacterium in stool 
(p=0.07), but not in mucosal (p=0.4) samples post FMT. There was a significant reduction in the 
proportion of Echerischia-shigella in stool (p=0.03), but not in mucosal (p=0.6) samples post 
FMT (Table 7.2). 
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Table 7.2 Analysis of genera from patient stool and mucosal samples pre and post FMT 
 
Genus Patient stool 
baseline (%) 
Patient stool 
post FMT (%) 
p-value Patient 
mucosa 
baseline (%) 
Patient 
mucosa post 
FMT (%) 
p-value 
Bacteroides 16.6 +- 7.8 20.7 +-6.2 1 10.7 +-2.4 11.9 +-3.2 0.9 
Escherichia_Shigella 22.0 +-8.3 4.5 +-2.6 0.03* 7.3 +-2.8 3.2 +-1.1 0.6 
Prevotella 0.07 +-0.03 6.2 +-5.7 0.3 0.93 +-0.3 7.5 +_5.4 0.5 
Lachnospiracea_incertae_s 
edis 
10.6 +- 3.5 4.0 +-1.4 0.3 11.7 +-3.6 9.2 +-2.5 0.9 
Clostridium_sensu_stricto 11.1 +-4.1 6.5 +-5.0 0.3 9.9 +-3.5 2.9 +-0.8 0.2 
Lactobacillus 2.7 +- 2.4 6.4 +-6.2 1 1.9 +- 1.6 7.2 +-7.0 0.9 
Faecalibacterium 1.4 +-0.9 5.2 +-2.4 0.07† 4.6 +-1.7 6.1 +-1.3 0.4 
Blautia 5.0 +-2.3 2.3 +-0.8 0.2 7.2 +- 2.3 5.0 +-1.6 0.3 
Clostridium_XI 6.8 +-3.9 5.2 +-2.6 0.9 7.8 +-1.6 5.2 +-1.6 0.3 
unclassified 
Lachnospiraceae 
2.8 +-1.0 2.0 +-0.6 0.5 6.7 +-0.9 5.6 +-1.5 0.3 
Sutterella 0.2 +-0.2 9.7 +-3.7 0.02* 1.0 +-0.5 2.7 +-0.8 0.02* 
Anaerostipes 3.6 +-2.5 1.4 +-0.7 0.7 2.7 +-0.7 3.6 +-1.2 0.5 
Clostridium_XVIII 2.2 +-1.4 3.4 +-1.7 0.6 1.2 +-0.4 3.5 +-1.8 0.3 
Alistipes 0.2 +-0.1 0.2+-0.2 0.4 0.9 +-0.2 1.3 +-0.5 0.7 
Streptococcus 0.2 +-0.1 4.6 +-2.6 0.3 1.3 +-0.4 2.6 +-1.3 0.9 
Clostridium_XlVa 1.4 +-0.9 1.4+-0.8 0.6 1.8 +-0.5 2.9+-0.9 0.5 
Barnesiella 0.1 +-0.1 0.7+-0. 0.8 1.1 +-0.7 1.2 +-0.6 0.9 
Subdoligranulum 0.04 +-0.0 0.5 +-0.3 0.6 1.0 +-0.5 1.2 +-0.4 0.6 
Roseburia 2.4+-2.3 0.2 +-0.1 0.4 2.7 +-2.0 0.8 +-0.2 0.9 
 
 
Percentage of sequences identified from genera of >1% total abundance in patient samples at baseline. Percentage of total 
sequences from the predominant bacterial genera in patient stool pre FMT (n=7) and post FMT (n-8) and patient mucosal 
samples pre FMT (n=8) and post FMT (n=5).   * denotes p values ≤0.05. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.6 Percentage of sequences identified from the four predominant bacterial phyla in patient samples pre and post 
FMT. Percentage of total sequences from the predominant bacterial families in patient stool pre FMT (n=7) and patient stool 
post FMT (n=8).   * denotes p values ≤0.05. 
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Figure 7.7 Percentage of sequences identified from the bacterial families of >1% total abundance in patient mucosal 
samples pre and post FMT. Percentage of total sequences from the predominant bacterial families in patient mucosal 
samples  pre FMT (n=8) and patient mucosal sampels  post FMT (n=5).   * denotes p values ≤0.05. 
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7.8 Inter-individual variation 
 
 
The significant inter-individual variation of the baseline faecal and mucosal microbiota was also 
reflected in the varying responses following FMT by each of the recipient patients (Figures 7.4 
and 7.8). Broadly, Patients 2 and 3 showed a shift in their faecal and mucosal microbiota 
towards that of their respective donor’s stool following FMT. Patient 5 showed a shift in the 
faecal and mucosal microbiota post FMT, although this shift was not towards a similar 
microbiota as Donor 5. Patients 1 and 4 showed a slight shift in the composition of their faecal 
microbiota, but not of their mucosal microbiota. Patients 6, 7 and 8 showed no shift in either 
stool or mucosal microbiota following FMT. There was an increased proportion of 
Ruminococcaceae with a concomitant reduction in the proportion of Enterobacteriaceae in the 
samples post FMT in patients 2, 3, 4 and 5. 
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Figure 7.8 Individual patient/donor combination analysis pre and post FMT (created by Dr A 
Walker) 
 
 
 
 
 
 
 
A 
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Figure 7.8. A. Family-level compositional analysis, and Bray-Curtis NMDS plots for each patient/donor 
combination. Key: X=donor; empty square=faeces pre; filled square=faeces post; empty circle=biopsy pre; filled 
circle=biopsy post. B. Bray Curtis dendrogram showing overall comparison between samples. This illustrates how 
some samples (e.g. from Patient 2) come to resemble the donor’s microbiota following FMT, while others (e.g. 
Patient 7) remain distinct from the donor’s microbiota following FMT. 
B 
225 
 
 
 
 
7.9 Discussion 
 
 
Studies of FMT for IBD are rare and restricted to case reports and small case series. Only two 
studies recently published have assessed the changes in the microbiota following FMT in the 
context of UC in a total of eleven patients (Kump et al., 2013, Angelberger et al., 2013). This is 
the first study to assess the microbiological effects of FMT in chronic pouchitis. 
 
 
In this study there were no major overall shifts in the composition of the patients’ microbiota at 
four weeks following FMT. There were no changes in either faecal or mucosal microbiota 
diversity at four weeks following FMT. However, there was some shift in the composition of the 
microbiota, with specific changes in the abundance of some species suggestive of a “healthier” 
pouch microbiota. 
 
 
A number of studies have documented the association between increased Proteobacteria, 
specifically Escherichia, in IBD (Giaffer et al., 1992, Pilarczyk-Zurek et al., 2013, Gosselink et al., 
2004b). It is unclear whether this finding is causative or secondary to inflammation. However, it 
is of interest that post FMT, Escherichia were significantly less proportionally abundant in the 
patients’ stools. Other post FMT microbiota changes also suggested a shift towards a healthier 
bacterial composition. The mucolytic bacterium Ruminococcus gnavus, which was significantly 
reduced in proportional abundance following FMT, is increased in the epithelium of UC and CD 
patients (Png et al., 2010). Clostridiaceae, also reduced following FMT, are associated with 
pouch inflammation (37). Furthermore, potentially beneficial bacterial groups were increased in 
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proportional abundance following FMT. For example, Faecalibacterium prauznitzii is reduced in 
colitis patients (Sokol et al., 2009) and has anti-inflammatory properties , Dorea has been 
associated with non-inflammatory pouch outcomes (Mizoguchi et al., 2013) and a recent study 
associated increased abundance of Sutterella with pouch health (Mizoguchi et al., 2013). 
 
 
There were also significant inter-individual differences with some patients demonstrating a  
shift in the microbiota either towards that of their donor or a merged composition of recipient 
and donor microbiota. However, patients 2 and 3 (who showed some response following FMT, 
see Chapter 6) showed a shift in their faecal and mucosal microbiota towards that of their 
respective donor’s stool following FMT (although no stool sample was available for analysis for 
patient 3 prior to FMT and close similarity of the microbiota in this sample cannot be ruled out). 
However, although patients 2 and 3 demonstrated some changes towards a “healthy” pouch 
following FMT on family and genus level analysis, these changes were neither consistent, nor 
entirely restricted to these patients. 
 
 
As expected, the patients’ faecal and mucosal microbiota differed greatly from healthy donors’ 
faecal microbiota. This difference may in part be due to the comparison of pouch and colonic 
samples. Nonetheless, the baseline pouch samples demonstrated findings in keeping with a 
dysbiosis as (previously found in IBD and specifically pouchitis) that may be attributable to the 
inflammatory state and underlying disease (Angelberger et al., 2013, Kump et al., 2013, 
Mizoguchi et al., 2013, Tannock et al., 2012, McLaughlin et al., 2010b, Scarpa et al., 2011a). 
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The diversity of the pouch microbiota was reduced in the faecal samples, but not in the 
mucosal samples at baseline. This is an unexpected finding, but may represent the severity and 
longevity of the refractory inflammation in the mucosa of the patients included in this study. 
The chronic refractory exposure to inflammation may have enabled the residual mucosal 
microbiota  to create a niche with reasonable diversity, whilst the high pouch frequency in 
these patients may have counteracted the stability of the faecal microbiota. Previous studies 
have suggested a higher richness of the mucosal microbiota than the faecal microbiota. Higher 
phylotype richness (‘‘biodiversity’’), enhances the robustness and stability of an ecosystem and 
might be an intrinsic safeguard against perturbations (Lawley and Walker, 2013). Consequently, 
oosmotic diarrhoea also has a greater impact on the diversity of the faecal compared with 
mucosal microbiota (Gorkiewicz et al., 2013). Patients with milder or quiescent disease may 
therefore be more amenable to durable alteration of the microbiota with FMT. 
 
 
There are several possible explanations for the lack of significant engraftment of the donors’ 
microbiota to the recipients. The protocol of FMT used in this study consisted of a single 
nasogastric administration without pre-treatment with antibiotics or bowel lavage. This 
protocol is effective for Clostridium difficile infection (Aas et al., 2003, MacConnachie et al., 
2009). However, more recently evidence has suggested greater efficacy with nasoduodenal 
administration (van Nood et al., 2013) and repeated infusions have been suggested for the use 
of FMT in chronic intestinal inflammation (Borody and Khoruts, 2012) although this has been 
demonstrated only in small case series to date. No human data exist regarding the benefit of 
prior antibiotics in FMT. One study in rats suggested this was not beneficial for engraftment of 
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the transplanted microbiota and instead led to a merging of antibiotic effects and transplant 
microbiota (Manichanh et al., 2010). 
 
 
A study of FMT in mice showed that successful alteration of the recipient’s microbiota 
depended on the donor microbiota being both phylogenetically diverse and distinct from that  
of the recipient (Lawley et al., 2012). Donors were not selected for their microbiota 
compatibility and indeed relatives and household contacts were used in some cases. Relatives 
of patients with IBD have been shown to have alterations in their microbiota distinguishing 
them from other “healthy” donors (Joossens et al., 2011). Donors’ microbiota were dissimilar to 
recipients and were significantly more diverse than recipients’ faecal microbiota, but not 
mucosal microbiota. However, donor microbiota may not be applicable to the niche of the UC 
pouch and perhaps FAP RPC or UC RPC patients without a history of pouchitis would be a more 
appropriate donor in this context. 
 
The two recent studies of FMT in UC demonstrate a transient shift in the recipients’ microbiota 
following FMT. Sampling at week four in this study may have missed some of the changes in the 
microbiota that occurred following FMT. This effect may be more exaggerated in pouch 
patients where frequency and bowel transit are increased. Finally, the patient group included in 
this study may be responsible for the lack of success of FMT engraftment. The patients included 
in the study had severe, refractory chronic disease with high pouch frequency. This in itself may 
have reduced the chances of successful transplantation due to their frequency and the 
likelihood of a well-established microbiota in the presence of chronic inflammation. 
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Future studies of the effects of FMT on the microbiota in inflammatory bowel diseases will 
need to address a number of questions in addition to those raised in Chapter 6: 
1. Which donors are most appropriate microbiologically? 
 
2. Does engraftment of particular species or a complex community altering microbiota diversity 
lead to functional efficacy of FMT? 
3. Does alteration of the microbiota with FMT result in significant functional change of the 
microbiota? 
4. What are the immunological consequences of FMT? 
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Chapter 8. The mucosal immunological effects of faecal microbiota 
transplantation in chronic pouchitis 
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8.1 Abstract 
 
Introduction: Studies of the immune responses to modification of the microbiota in 
inflammatory bowel diseases may enhance our understanding of these diseases. Probiotics 
alter immune responses and epithelial barrier function in IBD. To date no previous studies in 
humans with IBD have assessed the immunological effects of faecal microbiota transplantation 
(FMT). We aimed to assess alterations of mucosal dendritic cell and tight junction protein 
expression following FMT in patients with chronic pouchitis. 
Methods: Eight patients with chronic pouchitis (with a current PDAI ≥7) were treated with FMT 
via nasogastric administration. Mucosal biopsy samples were taken before and four weeks after 
FMT. Epithelial cells and lamina propria DC were isolated from biopsy tissue and epithelial cell 
expression of ZO-1, claudin 1, claudin 2 and DC expression of TLR 2 and 4, CCR9, β7 and CD40 
were measured by multicolour flow cytometry. Ongoing production of cytokines by dendritic 
cells were assessed following incubation with and without monensin and cytokine levels in 
biopsy supernatants were assessed by multiplex analysis . 
Results: There were no significant changes in dendritic cell expression of TLRs, homing markers, 
activation markers or cytokine production following FMT. There were no significant changes in 
epithelial cell tight junction protein expression or cytokine levels in whole biopsy supernatants 
following FMT. 
Conclusions: FMT via a single nasogastric administration in patients with chronic pouchitis did 
not result in immunological response. Further studies that include assessment of the 
functionality of the microbiota post FMT in conjunction with immunological assessment are 
required. 
232 
 
 
 
 
8.2 Background 
 
 
Probiotics alter the innate and adaptive immune responses in IBD (Hart et al., 2004b, Ng et al., 
2009b). Probiotics also alter epithelial barrier function and the expression and distribution of 
epithelial tight junctions (Ng et al., 2009b, Mennigen et al., 2009, Madsen et al., 2001, 
Karczewski et al., 2010, Persborn et al., 2013). Studies of the immune effects of probiotics in 
IBD are predominately in vitro, ex-vivo or in animal models. Few studies demonstrate the 
immune effects of probiotic administration in vivo in UC and pouchitis patients. 
 
 
Crohn’s disease and UC patients treated with a probiotic yoghurt containing L. rhamnosus GR-1 
(GR-1) and L. reuteri RC-14 (RC-14) demonstrated expansion of CD4+CD25high cell population 
with a decrease in serum IL-12 concentration and a decreased percentage of TNF-α and IL-12- 
producing monocytes and myeloid DC. Colonic myeloid DC of UC patients treated with VSL#3 
down regulated TLR2 expression and increased IL-10 production whilst decreasing IL-12p40 
production (Ng et al., 2010b). 
 
 
Ulcerative colitis patients treated with VSL#3 prophylactically following RPC have lower mucosal 
mRNA expression levels of interleukin-1beta, interleukin-8, and interferon-gamma compared 
with placebo treated patients (Lammers et al., 2005b). Patients with active pouchitis where 
remission was induced with combination antibiotics and maintained with VSL#3 for nine  
months demonstrated additional immune effects to VSL#3 beyond those seen following 
antibiotic induced remission with reductions in tissue TNFα and IL-1α and increased IL-10 as 
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well as reduced matrix metalloproteases (Ulisse et al., 2001). In another study of VSL#3 
treatment of non-inflamed ileal pouch patients a significant increase in mucosal CD4+CD25high 
cells as well as increased Foxp3 mRNA expression was found after treatment compared with 
baseline (Pronio et al., 2008). 
 
 
To date no previous studies in humans have assessed the immunological effects of faecal 
microbiota transplantation (FMT). In a recent study in a mouse model of Clostridium difficile, 
high levels of expression of pro-inflammatory genes were suppressed following FMT (Lawley et 
al., 2012). Transplantation of the microbiota as an “organ” rather than specific strains or 
combinations of bacteria may have significant effects on the immune responses in 
inflammatory bowel diseases. 
8.3 Aims 
 To assess dendritic cell phenotype and cytokine production in patients with active 
chronic pouchitis before and after FMT 
 To assess cytokine levels in biopsy supernatants of patients with active chronic pouchitis 
before and after FMT 
 To assess epithelial tight junction protein expression in patients with active chronic 
pouchitis before and after FMT 
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8.4 Methods 
 
FMT was undertaken as described in Chapter 6.5. Biopsies were taken for immunological 
assessments before and four weeks after FMT. Biopsies were processed and analysed as 
described (Chapter 2.2.5- 2.2.10 and Chapter 4.6). 
 
 
8.5 Dendritic cell phenotype before and after FMT 
 
 
There were no significant changes after FMT in DC expression of TLR 4 (46 +- 6.5% vs. 34 +- 7%, 
p=0.2) or TLR 2 (43 +-5.4% vs. 49 +-8.8%, p=0.3) (Figure 8.1). There were no significant changes 
in DC expression of homing markers β7 (40 +-7.6% vs. 32 +-4.5%, p=0.4) or CCR 9 (39 +-5.2 vs. 
40 +-3.5%, p=0.8) before and after FMT (Figure 8.2) or expression of activation marker CD40 (81 
+-2.9% vs. 76 +- 2.8%, p=0.3) (Figure 8.3). 
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Figure 8.1 TLR 4 and TLR 2 expression on HLA DR+ lineage negative cells in pouch tissue in patients with active 
chronic pouchitis pre and post FMT. A, B and C. One parameter histograms representative of TLR 4 and TLR 2 
(n=8) staining pre and post FMT. D, E and F. Percentage expression of TLR 4 and TLR 2 pre and post FMT. 
B E 
A Pre D 
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Figure 8.2 β7 and CCR9 expression on HLA DR+ lineage negative cells in pouch tissue in patients with active 
chronic pouchitis pre and post FMT. A and B. One parameter histograms representative of β7 and CCR9 staining 
pre (n=8) and post (n=8) FMT. C and D. Percentage expression of β7 and CCR9 pre and post FMT. 
 
 
Figure 8.3 CD40 expression on HLA DR+ lineage negative cells in pouch tissue in patients with active chronic 
pouchitis pre and post FMT. A and B. One parameter histograms representative of CD40 staining pre (n=8) and 
post (n=8) FMT. C and D. Percentage expression of CD40 pre and post FMT. 
A B 
A C 
B D 
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8.4 Ongoing production of cytokines in dendritic cells before and after FMT 
 
 
For a functional assessment of DC before and after FMT, ongoing intracellular production of 
cytokines in DC was assessed as described previously (Chapter 2.2.6) in the absence of 
exogenous stimulation. Levels of IL-12, IL-10, IL-17 and IL-4 production were assessed. There 
were no significant changes in ongoing production of cytokines in DC before and after FMT. 
There were no changes in IL-12 (-14 +-8.7% vs. 12 +-12.6%, p=0.3), IL-10 (0 +-11% vs. 7 +-5%, 
p=0.5), IL-17 (27 +-13% vs. 14 +-7%, p=0.5) or IL-4 production (17 +-7% vs. 34 +-17%, p=0.4) 
 
(Figure 8.4). 
 
 
 
Figure 8.4 Percentage expression of ongoing production of cytokine in dendritic cells from pouch tissue of 
patients with active chronic pouchitis pre (n=5) and post FMT (n=5) of A. IL-12; B. IL-10; C. IL-17; D. IL-4. 
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8.5 Cytokine levels in biopsy supernatants of patients with active chronic pouchitis before 
and after FMT 
 
 
No changes were demonstrated in either DC phenotype or function following FMT. In order to 
assess whether other aspects of the mucosal response were altered following FMT, cytokine 
levels of biopsy supernatants were assessed before and after FMT. There were no significant 
changes in any of the cytokine levels assessed following FMT: IL-2 (12.2 +-0.98 pg.ml-1 vs. 11.8 
+-0.6 pg.ml-1, p=0.8); IL-4 (13.5 +-1.1 pg.ml-1 vs. 12.3 +-0.3 pg.ml-1, p=0.3); IL-6 (1325+-750 pg.ml- 
 
1 vs. 1666 +-946 pg.ml-1, p=0.4); IL-10 (10.4+-0.8 pg.ml-1 vs. 14.1 +-2.43 pg.ml-1, p=0.1); TNF (12.0 
 
+-1.5 pg.ml-1 vs. 15.5 +-2.5 pg.ml-1, p=0.3) (Figure 8.5). 
 
 
 
Figure 8.5 Cytokine levels in biopsy supernatants of pouch biopsies of patients with active chronic pouchitis 
before (n=8) and after (n=8) FMT.  A. IL-2; B. IL-4; C. IL-6; D. IL-10; E. TNF. 
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8.6 Epithelial tight junction protein expression before and after FMT 
 
 
There were no significant changes in tight junction expression before and after FMT. There 
were no changes in the median intensity ratio of epithelial expression of ZO-1 (2.9 +-0.4 vs. 3.4 
+-0.7, p=0.4) or Claudin 1 (1.3 +-0.3 vs. 1.2 +-0.6, p=0.9) or the percentage epithelial cell 
 
expression of Claudin 2 (19 +-11% vs. 40 +-13%, p=0.3) (Figure 8.6). 
 
 
 
Figure 8.6 Epithelial tight junction expression from pouch tissue of patients with active chronic pouchitis pre 
(n=5) and post (n=5) FMT. A. Median intensity ratio of epithelial expression of ZO-1 and B. claudin 1. C. Percentage 
epithelial cell expression of claudin 2. 
 
 
 
8.7 Discussion 
 
 
This is the first study to assess the immunological outcomes following FMT in humans. There 
were no changes in DC phenotype or cytokine production following FMT. Neither were there 
any alterations in cytokine levels in the biopsy supernatants or in tight junction protein 
expression. 
Despite the potentially beneficial shifts in the microbiota post FMT as described in Chapter 7 no 
immunological response was seen. The changes in composition of the microbiota reflect 
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alterations in relative abundance rather than absolute abundance and may therefore not be 
reflected by immunological responses. Furthermore, abundant molecular functions are not 
necessarily provided by abundant species (Arumugam et al., 2011) and core metabolic  
functions may be shared between bacteria, promoting stability in metabolic function, and 
maintaining homeostasis. Consequently, the changes in the microbiota that were demonstrated 
post FMT might not lead to significant metabolic and subsequently immunological changes. 
 
 
The patients included in the study had severe, refractory chronic disease. The immune effects 
of bacteria may also depend on the local microenvironment in which they are acting and the 
integrity of the epithelial monolayer (Tsilingiri et al., 2012). Loss of epithelial barrier integrity 
with increased translocation of otherwise non-pathogenic, non-invasive bacteria may worsen 
inflammation (Tsilingiri et al., 2012). FMT in this group of patients may therefore have 
deleterious rather than positive clinical and immunological outcomes. 
 
 
Despite a large body of evidence suggesting the microbiota drives gut inflammation, it is 
uncertain whether dysbiosis itself causes IBD or if it represents an epiphenomenon. In addition, 
whether the absolute or relative abundance of particular species or the overall complexities of 
the microbial ecosystem are predominantly responsible for host immune responses to the 
microbiota is not known. Future studies will need to assess these issues as well as the 
functional aspects of the microbiota. 
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Chapter 9. General discussion and future work 
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9.1 General discussion 
 
 
The ileal pouch provides a unique human model for studying IBD pathogenesis. The first part of 
the thesis focuses on characterising lamina propria dendritic cell phenotype and epithelial cell 
tight junction expression in the UC pouch and pouchitis. This is the first study to identify and 
characterise DC in the ileal pouch mucosa of UC and FAP patients. The focus of the work here is 
more descriptive than mechanistic. However, before moving forward into the mechanisms 
responsible for the development of pouchitis we must first understand its natural evolution. 
 
 
An aberrant DC phenotype was identified in the non-inflamed ileal tissue of UC patients 
undergoing RPC. In the ileum of UC patients compared with healthy controls there was 
abnormal expression of gut homing markers and reduced expression of activation marker CD40. 
Further analysis revealed expansion of the plasmacytoid DC subset in UC patients. However, the 
aberrant gut homing marker expression in UC patients was not only a consequence of the 
relative expansion of pDC, but a genuine reduction of DC expressing β7 on myeloid DC. This 
suggests abnormalities of the innate immune response in the ileum of UC patients prior to RPC 
that may lead to a susceptibility to inflammation following restoration of the microbiota with 
ileostomy closure. Aberrant expression of gut homing markers was also noted in the non- 
inflamed pouch of UC patients compared with FAP patients. Changes in DC homing markers in 
the ileal pouch of UC patients are likely to represent an aberrant response to the altered 
microenvironment following RPC. 
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The findings regarding DC phenotype in the ileum and the non-inflamed pouch of UC patients 
suggest that aberrant DC characteristics, in particular aberrant homing marker expression, in  
UC patients may play a critical role in the colitogenic susceptibility following RPC for UC. We 
speculate that prior to the onset of inflammation, the aberrant homing profile and expansion of 
pDC in UC patients may lead to a loss of gut homing marker imprinted lymphocytes and 
reduced activation of tolerogenic T cell responses to the colonic microenvironment in the 
functioning pouch. Furthermore inappropriate recruitment of DC to the lamina propria may 
lead to a mis-shaping of the microbiota in UC patients and increased levels of microbial 
interaction at the epithelium. We also identified differences in DC expression of gut homing 
markers as well as TLRs and activation markers between the inflamed and non inflamed ileal 
pouch in UC patients and FAP patients. These findings suggest DC play a critical role in the 
maintenance of inflammation with increased homing of activated DC to the inflamed pouch in 
response to microbial signals. 
 
 
The aberrant immune responses to the microbiota depend on interactions at the epithelium. 
We demonstrated the development of a methodology using flow cytometry to quantitatively 
assess tight junction protein expression on epithelial cells. We identified abnormalities in pouch 
epithelial TJPs in UC patients with an increase in expression of the “pore forming” TJP, claudin 
2. Furthermore, we demonstrated differences in the expression of claudin 2 in acute pouchitis 
and of ZO-1 and claudin 1 in chronic pouchitis. We suggest that increased epithelial expression 
of claudin 2 is an early event in the development of inflammation which could present a 
mechanism by which UC patients are more susceptible to microbial signalling compared with 
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FAP patients. However, the findings of altered tight junction expression may be secondary to 
the elevation in inflammatory cytokines that were demonstrated in both acute and chronic 
pouchitis. 
 
 
The temporal inter-relationships between defective barrier function, abnormal immune 
responses and the microbiota are not known. To determine the aetiological role of these 
factors, longitudinal studies of patients prior to disease onset are needed. These are not 
feasible in Crohn’s disease or UC, but the pouch offers a unique opportunity for such 
investigation. We undertook the first study to longitudinally assess DC characteristics and 
epithelial cell tight junction protein expression following ileostomy closure (with reintroduction 
of the faecal stream) in UC patients. 
 
 
The increased expression of claudin 2 in in the ileal pouch of UC patients at six months 
following ileostomy closure suggested this is an early event in the development of 
inflammation. Changes in DC homing markers in the pouch of UC patients also represent an 
aberrant response to the more colonic microenvironment following RPC. This could present a 
mechanism for barrier dysfunction by which UC patients are more susceptible to immune 
activation by the more “colon-like” microbiota following ileostomy closure. 
 
 
The second part of the thesis focuses on an in vivo study of faecal microbiota transplantation 
(FMT) in patients with chronic pouchitis. A significant body of evidence suggests a dysbiosis of 
the pouch microbiota is likely to be important in the aetiology of pouchitis. No previous studies 
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have assessed the effects of FMT in pouchitis or the immunological effects of FMT in humans or 
in the context of IBD. 
 
 
FMT was safe and acceptable to patients with chronic pouchitis. However, in this study a single 
nasogastric administration of healthy donor stool was not clinically effective. There were no 
changes in either faecal or mucosal microbiota diversity at four weeks following FMT. However, 
there was some shift in the composition of the microbiota, with specific changes in the 
abundance of some species suggestive of a “healthier” pouch microbiota. There were also 
significant inter-individual differences between patients. There were no changes in dendritic 
cell phenotype or cytokine production following FMT. Neither were there any alterations in 
cytokine levels in the biopsy supernatants or in tight junction protein expression. This most 
likely is a consequence of the lack of overall changes in the microbiota of the recipients. 
However, may also be due to the severe refractory nature of the inflammatory response in the 
patients studied. 
 
 
This study did not elucidate the key changes in the microbiota necessary for resolution of pouch 
inflammation. However, these data stimulate a number of questions regarding the role of FMT 
in IBD and the likelihood of successful engraftment of donor microbiota in the context of 
chronic mucosal inflammation: 
1. What is the most appropriate protocol regarding route of administration and frequency of 
infusions as well as the need for pre-treatment antibiotics, probiotics, bowel lavage and proton 
pump inhibition? 
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2. Which donors are most appropriate both by relationship to the recipient and 
microbiologically? 
3. In which patient group will FMT be most effective- acute or chronic active disease or once 
remission has been induced by standard therapies 
4. Whether engraftment of particular species or a complex community altering microbiota 
diversity is necessary for functional efficacy? 
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9.2 Future work 
 
 
Data presented in the first part of this thesis characterise an aberrant dendritic cell phenotype 
in the development and maintenance of pouch inflammation. There are small numbers of 
patients in these studies and larger cohorts of UC and FAP patients following RPC are necessary. 
Further studies are also necessary to characterise the role of DC subsets, particularly 
plasmacytoid DC, CCR9+ and CD103+ DC in these patient groups. Furthermore, future studies 
are needed to assess the functional outcomes of the findings presented in this thesis. 
 
 
The relative expression of CCR9 and β7 on lamina propria DC may determine a gradient of their 
preferential homing to the small or large bowel reflecting the gradient in the composition of 
the microbiota between the small and large bowel. Further studies, designed to assess the 
relative co-expression of β7 and CCR9 on tissue DC in the ileum, non-inflamed and inflamed 
pouch of UC patients are necessary. Furthermore, transwell migration studies are required to 
assess the migratory affinity of β7CCR9+ DC to their respective ligands depending on their 
relative proportions found in different patient groups as well as the effects of biopsy 
supernatants from the different patient groups. 
 
 
In addition, future studies should assess the functional consequences of the DC phenotype in 
the UC ileum and normal ileum and in UC patients with and without pouchitis and FAP patients. 
Mixed leucocyte reaction experiments are needed to ascertain differences in T cell responses as 
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a consequence of the DC phenotypes demonstrated by this data. B cell properties and IgA levels 
should also be assessed in future studies. 
 
 
We demonstrated the development of a methodology using flow cytometry to quantitatively 
assess tight junction protein expression on epithelial cells. In the process of this methodological 
development novel findings regarding expression of tight junctions were noted on blood 
dendritic cells and further studies of tight junction protein expression in peripheral blood 
dendritic cells should be undertaken in health and in IBD. 
 
 
The distribution and co-localisation of tight junction proteins are likely to be critical with regard 
to their effects on barrier function and measures of epithelial barrier function were not 
assessed here. Further studies using immunohistochemistry in addition to quantitative analyses 
are necessary to assess tight junction protein distribution. Further assessment with electron 
microscopy to assess structural alterations of the apical junctions and assessment of trans- 
epithelial electrical resistance would contribute to characterisation of the changes in barrier 
function resulting from the altered tight junction protein expression demonstrated by our data. 
Clinical data pairing tight junction protein expression with intestinal permeability using 
lactulose-rhamnose tests in patients are also required. 
 
 
The unique opportunity afforded by the pouch to assess the temporal inter-relationships 
between defective barrier function, abnormal immune responses and the microbiota require 
further study with functional assessments and correlation with data regarding the microbiota 
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using molecular techniques. This work also requires comparative study to a cohort of FAP 
patients undergoing RPC. 
 
 
Treatment with VSL#3 immediately following ileostomy closure is effective in the prevention of 
the onset of acute pouchitis (Gionchetti et al., 2003). Further work assessing changes in barrier 
function and immune responses as a consequence of probiotic therapy post ileostomy closure 
should be undertaken to assess the critical factors in development of pouchitis. In addition, 
larger and longer term studies are necessary to establish molecular markers that may be 
predictive of poor outcome when assessed either prior to ileostomy closure or at six months 
post ileostomy closure to enable the identification and early management of at risk patients. 
 
 
The data regarding the study of FMT raise a number of questions that should be addressed in 
future studies. The optimal protocol of FMT in inflammatory bowel disease requires further 
definition as well as the group of patients or phase of disease in which this therapy is likely to 
be most effective. Increasing data suggest that strategies to alter the microbiota in IBD may be 
most effective in quiescent disease. Future studies should consider the role of FMT in 
“resetting” the colitogenic potential of patients’ microbiota following induction of remission 
and resolution of the inflammatory responses. 
 
 
Donor microbiota used in this study may not be applicable to the niche of the UC pouch and 
perhaps FAP RPC or UC RPC patients without a history of pouchitis would be a more 
appropriate donor in this context. This option may raise considerable ethical and medical 
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concerns as the long-term sequelae of FMT are unknown and protocols to date ensure only 
healthy individuals are recruited as donors. 
 
 
Therefore as a preliminary study, in vitro work to assess the immunological effects of bacterial 
and mucos 
al supernatants from FAP and UC patients without pouchitis are needed to assess their 
potential as donors as well as the luminal micro-environmental factors that may differentiate 
these patients immunologically. Further in vitro and animal work is also necessary to assess the 
immunological effects of defined mixtures of specific bacteria that are most likely to re-
establish a health-associated microbiota as has been suggested for Clostridium difficile (Lawley 
et al., 2012). 
 
 
Throughout this thesis we have stated the importance of the interactions between the 
intestinal microbiota and host immune responses in health and disease. Inflammatory bowel 
diseases are considered to be due to an inappropriate inter-relationship between the immune 
responses and intestinal microbiota and studies of the aetiology of these diseases enhance our 
knowledge of host-microbiota relationships. The ileal pouch offers a unique opportunity to 
study the inter-relationships between the gut microbiota, epithelial barrier and host immune 
responses from before the onset of disease and serves as a human model that significantly 
enhances our understanding of inflammatory bowel diseases in general. Further studies of the 
ileal pouch will most likely lead to a greater understanding of host immune-microbiota 
interactions and opportunities to manipulate these relationships for the prevention and 
treatment of pouchitis and other inflammatory bowel diseases. 
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